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ABSTRACT 
The osteogenic and chondrogenic lineages derived from mesenchymal stem 
cells (MSCs) are of immense biomedical importance especially in the area of 
regenerative therapy for numerous degenerative bone diseases and developmental 
defects. The coordinated expression of key transcription factors (eg. Pax, Runx, Sox 
etc.) orchestrate the commitment of the MSCs towards the chondro-osteogenic 
lineage. However, much remains to be learned about the regulatory relationships 
between these transcription factors (TFs) controlling embryonic skeletal 
development. 
Immense research has been carried out to elucidate the roles of the Sox and 
the Runx family of TFs which are master regulators in the chondro-osteogenic 
pathway. Yet, less attention has been conferred upon other early acting TFs like 
Pax1 and Pax9 which are critical in patterning and differentiation of the sclerotomal 
cells that give rise to the vertebral bodies and intervertebral discs of the axial 
skeleton. Using mice as the experimental model, gene-targeting strategies and 
current genomic technologies were employed to identify, for the first time, the target 
genes of Pax1 and Pax9, in a cell-type specific manner.  
Pax1 and Pax9 were knocked-out by the insertion of EGFP in their exons, in 
order to enrich for Pax1 and Pax9 cell lineages. For a WT comparison, EGFP was 
co-expressed with Pax1 using the F2A-peptide strategy. Besides, Pax1 and Pax9 
proteins were successfully endogenously tagged with hemagglutinin (HA) epitope for 
use in TF mapping and other protein-related studies.  
Using FACS, highly enriched populations of Pax1- and Pax9-specific cells 
were used on microarrays. Firstly, genes enriched in Pax1-specific cells at E12.5 and 
E13.5 stages were identified. Subsequently, the target genes of Pax1 and Pax9 were 
	   ix	  
discovered from the various knock-outs (Pax1-/-, Pax1-/-Pax9+/- & Pax1-/-Pax9-/-). The 
use of 3-allele and 4-allele knock-outs enabled the identification of Pax1 and Pax9 
regulated genes that were masked in the Pax1-/- embryos by the functional 
redundancy between Pax1 and Pax9.  
In parallel, TF mapping performed on the wild-type embryos helped to 
distinguish the direct and indirect targets of Pax1 and Pax9. From this, the molecular 
functions of Pax1 and Pax9 could be delineated. Pax1 and Pax9 appear to have a 
role in regulating the early functions of intervertebral disc morphogenesis, i.e. cell 
proliferation, cell adhesion, cell motion, condensation, ECM organization and 
cartilage development.  Also, a novel link between the Pax genes and Sox5 has been 
identified. Moreover, the Pax genes regulate several of the genes that are known to 
be regulated by the Sox trio (Sox5/Sox6/Sox9). While the Pax genes are not master 
regulators of chondrogenesis, they probably play accessory roles by assisting the 
Sox genes in initiating the early expression of chondrogenic genes. Once the 
chondroblasts mature into chondrocytes, these Pax genes are down-regulated in the 
chondrocytes possibly by a negative feed-back mechanism.  
In conclusion, this genome-wide, non-hypothesis driven study has provided a 
better understanding on the roles of Pax1 and Pax9 and helped to formulate more 
hypotheses regarding their molecular functions. The data and the numerous mouse 
lines generated in this study also serve as an invaluable resource to construct the 
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CHAPTER 1 – INTRODUCTION 
1.1 Gene regulation – the central dogma, revised. 
The sequencing of human genome to a “finished-grade” by 2004 has 
provoked an explosion of sequencing technologies over the past decade [1]. The 
burgeoning sequencing technologies have enabled us to probe the eukaryotic DNA 
and RNA sequences in greater depth and at a single base resolution [2]. This has 
revealed the unprecedented complexities of the genome architecture, whereby gene 
regulation is not really modular as once thought, but involves an intricate 
orchestration of protein molecules (transcription factor, TFs; co-factors; chromatin 
modifiers; transcription machinery complex) and RNAs (long non-coding RNAs, 
lncRNAs;  lincRNAs; retrotransposon-derived RNAs; micro RNAs, miRNA etc) acting 
on segments of DNA (cis- & trans-regulatory elements, CREs/TREs and promoter) 
[3, 4].  
The central dogma of genetics described a “gene” as a segment of DNA that 
could be transcribed into mRNA and then translated into a protein. Everything else 
was deemed to be “junk” DNA. However, in the past decade significant evidence has 
emerged to prove the importance of such “junk” DNA which do produce either non-
coding RNAs or function as cis-regulatory elements, all of which are paramount to 
genetic regulation. Indeed, organismal complexity arises not just because of the 
increase in protein diversity (from alternative splicing of transcripts), but also because 
of the increased level of genomic regulation by the trans-acting factors (TFs and non-
coding RNAs). For instance, while only ~3% of the protein-coding genes encompass 
TFs in a simple, unicellular eukaryote like Saccharomyces cerevisiae, in the more 
complex multicellular nematode C.elegans it is about ~5%, and in the much more 
complex mouse and humans, it is about ~10% [5]. Moreover, the percentage of non-
protein-coding DNA in humans is ~98%; a drastic difference from that of a prokaryote 
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which is only ~12% [6]. The non-protein-coding DNA could encode non-coding RNAs 
(long RNAs, miRNAs etc) which function as trans-acting factors, or serve as cis-
regulatory elements for TF binding. Indeed, the repetitive sequences in the human 
genome, mainly derived from transposable elements, have been shown to 
encompass TF binding sites (cis-elements) [7-9]. Transposable elements possessing 
TF binding motif precursor sequence, once integrated into the genome, could evolve 
into novel, species-specific TF binding sites [7-9]. Thus, the coding and non-coding 
components of the genome contribute to colossal numbers of permutations and 
combinations of trans-acting factors interacting with the cis-elements that presumably 
give rise to organismal complexity [6]. With that realization, it is evident that the 
genome is an efficiently organized information system and nothing is really “junk”. 
This shift in the paradigm of gene regulation has completely transformed our 
interpretation of the genetic landscape and hence, our approach to unravelling its 
three-dimensional architecture. 
1.2 The conceptual framework – the GRN 
In a multicellular organism, the individual cell types are determined by 
differential gene expression. Such spatio-temporally regulated expression of a 
combination of genes, is called the “gene battery” [3, 10]. As a single gene can have 
multiple cis-regulatory elements (CREs) and a particular CRE can be bound by 
several TFs, to regulate the expression of that gene in a specific tissue and time. 
Thus, it is the trans-acting factors like the TFs, which bind to a subset of these CREs, 
and miRNAs1 which regulate gene expression at post-transcriptional level, that will 
determine the composition of the gene battery. While non-coding RNAs are a recent 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 miRNA mediate repression at post-transcriptional level by binding to the target 
transcripts at the 3ʼUTR and inhibiting its translation or reducing its stability. The 
mode of miRNA action is different from that of the TFs, which have the ability to 
activate a gene as well. 
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discovery whose regulatory functions are constantly being updated, the TFs have 
long taken the center-stage in our pursuit of understanding gene regulation. Genome-
wide techniques such as microarray and ChIP-chip, and two-hybrid (yeast and 
mammalian) paved the way to examine gene expression patterns, protein-DNA  and 
protein-protein interactions in a systematic fashion [5, 11]. Such complex 
interconnections of the TFs (with their interactors) with their CREs, and the causal 
links of the trans-acting factors with their target genes, can be mapped into a 
comprehensive conceptual framework – the gene regulatory network (GRN). 
The transcriptional network regulates the expression of this “gene battery” 
and determines the differentiation program of stem cells into specific lineages. The 
composition of activated and repressed genes by a combination of TFs would in turn 
control the various signalling pathways to execute the specification, commitment and 
differentiation of the precursors to a particular lineage. Dysregulation of such 
transcriptional regulatory programs can give rise to diseases owing to aberrant 
behaviour of cells (eg. cancer, diabetes, congenital diseases and developmental 
defects) [12].  
Modelling complex gene regulation as a network map presents numerous 
advantages. GRNs will enable us to interrogate the network motifs within, which may  
assist us in understanding the mechanisms of regulation of a specific biological 
process. For example, feed-forward loops result in a gene to be expressed quickly, 
while feed-back/ auto-regulatory loops either reinforce or further reduce the 
expression of a gene. Such observed patterns can then be coupled with the known 
functions of the process-in-question to comprehend that biological process. 
Moreover, such network maps allow formulation of hypotheses to be made which can 
be further tested experimentally. We can also predict the outcome of various 
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perturbations to the network, and thus design appropriate therapies (eg. regenerative 
therapies, tissue engineering, multi-target drugs) for numerous diseases [5, 12].  
GRNs are composed of nodes and edges, whereby the nodes are the 
biological molecules (DNA, protein, miRNA etc) while the edges represent the 
functional association between them (eg. activation or repression) [5]. Thus, 
construction of GRNs for any process requires four key data sets: (1) the protein-
DNA interaction, (2) protein-protein interaction, (3) the causal links between the TFs / 
miRNAs and their target genes and (4) spatio-temporal expression of genes [13]. 
Genome-wide in vitro or in vivo data for each of these components can be acquired 
via a myriad of techniques, which are summarized in Table 1.   
Table1: Data sets required for the construction of a GRN and techniques that 
can be used to acquire those data. 




PBM, Y1H, B1H, SELEX, 
luciferase-based PDI 
mapping, microfluidics-
based PBM, luciferase 






Y2H, M2H, co-IP (small 
scale), affinity purification 
(small scale), mass 
spectrometry (small scale) 
co-IP (small scale), 
affinity purification 
(small scale), mass 
spectrometry (small 
scale) 
3 Causal links 
between TFs/ 






- In situ hybridization, 
RT-qPCR 
PBM- protein binding microarray; Y1H – yeast one hybrid; B1H – bacterial one 
hybrid; SELEX - systematic evolution of ligands by exponential enrichment; PDI – 
protein-DNA interaction; ChIP – chromatin immunoprecipitation; EMSA – 
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electrophoretic mobility shift assay; Y2H – yeast two hybrid; M2H – mammalian two 
hybrid; co-IP – co-immunoprecipitation. 
Evidently, constructing a GRN for even a single process requires a vast 
amount of data, and acquiring that is a daunting task. Indeed such a task need not be 
handled independently since it is time-consuming, labour-intensive and simply very 
expensive.  Researchers world-wide have been generating genome-wide data sets 
which can be integrated to eventually generate the GRN. For instance, GRNs have 
been constructed for (and are constantly being updated) endomesoderm 
specification of the sea urchin [14, 15], dorsal-ventral patterning of Drosophila [16, 
17], vulva development [18] and neuron cell type specification in Caenorhabditis 
elegans [19] and mesendoderm development in Xenopus [20, 21]. These networks 
were not constructed overnight but took decades of data collection and required the 
effort of numerous independent labs. Also, with the complexities of gene regulation, 
such networks have a long way to attain completion. Nonetheless, data collection is 
the first-most obligatory step for modelling such networks. 
1.3  Bone development  
Embryonic bone formation is a tightly regulated process that can occur 
through endochondral ossification or intramembranous ossification [22]. Most of the 
bones of the axial and appendicular skeleton and some craniofacial bones are 
formed by endochondral ossification. In this process, three major cell types are 
involved: the chondrocytes, osteoblasts and osteocytes, which are all derived from a 
common precursor, the msenchymal stem cell (MSC). The MSCs first form a 
condensation which is mostly complete by embryonic day (E) 10.5 [23]. These cells 
produce extracellular matrix (ECM) composed of collagen type I. The cells within the 
condensations then differentiate into chondrocytes and secrete ECM components 
rich in collagen type II and aggrecan. The peripheral cells of the condensation, 
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however, form the perichondrium and continue to secrete collagen type I instead. 
The cartilage condensation thus formed, acts as a template of the future bone. The 
chondrocytes of the cartilage subsequently become hypertrophic, secrete ECM 
composed of collagen type X, then undergo terminal differentiation and eventually die 
through apoptosis. In parallel, the perichondrial cells differentiate into osteoblasts 
upon Indian hedgehog (Ihh) signal induction from the pre-hypertrophic cells, thus 
forming the periosteum [23]. Meanwhile, the ECM in the immediate vicinity around 
the hypertrophic chondrocytes is degraded by matrix metalloproteinases (MMPs) and 
a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) family of 
enzymes [24]. This is followed by an invasion of blood vessels through a vascular 
endothelial growth factor (VEGF)-dependent pathway, which imports the osteoblast 
precursors, osteoclasts and bone marrow cells to the center of the cartilaginous 
template. While the osteoclasts play a critical role in bone resorption, the 
differentiating osteoblasts then replace the remnant cartilaginous template with bone. 
The mineralization of this cartilage matrix occurs through the deposition of 
hydroxyapatite [24]. 
Contrary to endochondral ossification, the intramembranous ossification 
process does not involve a cartilage intermediate. The MSCs differentiate directly 
into osteoblasts. These osteoblasts secrete a fibrillar, non-calcified ECM called 
osteoid, which in turn become mineralized to form the bone. This process forms parts 
of the skull bones (eg. the frontal and parietal bones of the neurocranium (skull roof)) 
and lateral parts of the clavicles [25]. 
1.3.1 Key players in skeletogenesis 
 Although both ossification mechanisms of embryonic bone development are 
distinct, cells in the majority of skeletal elements are derived from a common 
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precursor - the MSCs. As with other differentiation pathways, the restriction of MSCs 
towards the chondro-osteogenic lineage in skeletal development involves the 
coordinated and sequential expression of key TFs (e.g. Bapx1 (Nkx3.2), Pax1, Pax9, 
Runx2, Runx3, Osterix, Sox9, Sox5, Sox6 etc.) and the involvement of various 
hormones (growth and thyroid hormone) and local secreted factors (Ihh, PTHrP, 
BMP, Wnt, FGFs) [24]. The various TFs involved in the chondro-osteogenic pathway 
are depicted in a schematic diagram in Figure 1. 
Of these, Sox9 (SRY-box containing gene 9) is the master regulator of 
chondrogenesis while Runx2 is the master gene for osteogenesis. Sox9 is known to 
activate numerous chondrogenic markers like Acan (aggrecan), Col2a1 (collagen, 
type II, alpha 1), as well as Sox5 (SRY-box containing gene 5) and Sox6 (SRY-box 
containing gene 6) TFs which are important for chondrocyte differentiation. It plays 
essential functions in promoting chondrocyte proliferation while inhibiting its 
hypertrophy. Moreover, loss-of-function mutations of Sox9 gives rise to Campomelic 
dysplasia, which is a form of skeletal dysplasia, resulting in abnormalities of the 
head, neck and long bones and is often lethal [23, 26, 27]. 
Runx2 (runt related transcription factor 2), on the other hand, is essential for 
osteogenesis as Runx2-/- mouse mutants completely lack osteoblasts in all the 
skeletal elements. Runx2 also regulates the expression of osteoblast-specific 
hormone, Osteocalcin and osteoblast-specific TF, Osterix. Besides, it also plays dual 
roles in chondrocytes; when expressed transiently in the pre-hypertrophic 
chondrocytes it promotes hypertrophy, whereas its constitutive expression in the 
perichondrium inhibits both chondrocyte proliferation and hypertrophy [28].   
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Figure 1: Transcription factors involved in the commitment of the 
mesenchymal stem cells in the chondro-osteogenic pathway. Positive regulation 
and positively acting factors are shown in green, negative regulation and negatively 
acting factors are shown in red. Reference for lineage commitment figure - Current 
Opinion in Genetics & Development 2009, 19:437–443 [25]. 
 
1.4 Vertebral Column Structure and Development 
An important skeletal structure and the defining framework of all vertebrates, 
is the vertebral column, which confers support, flexibility and protects the spinal cord 
and crucial spinal nerves of the body. It constitutes metamerically arranged vertebral 
bodies linked together by intervertebral discs (IVDs) [29]. The IVD is an 
indispensable aspect of the vertebral design, withstanding biomechanical forces and 
conferring tensile strength. It also provides flexibility in motion to an otherwise rigid 
spine [30]. The mature IVD is a multi-component fibro-cartilaginous structure, with 
each component possessing distinct biochemical properties so as to execute their 
different biomechanical functions. The central nucleus pulposus of the IVD is semi-
fluidic and acts as a shock absorber. The circular annulus fibrosus, which encases 
the nucleus pulposus, functions to withstand the compressive forces acting on the 
spine. It also endures tension and holds the nucleus pulposus in the center during 
compression. Rostrally and caudally positioned to the annulus fibrosus are the 
cartilaginous end plates which are composed of hyaline cartilage and connect the 
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adjacent bony vertebrae to the annulus fibrosus. These components thus function 
together to transmit and evenly distribute the body weight and load from physical 
activity [29]. 
1.4.1 Embryonic axial skeletogenesis and its genetic regulation 
Axial skeletogenesis is a multi-step process beginning with somitogenesis 
and the paraxial mesoderm that is located adjacent to the neural tube [31]. Spherical 
balls of cells – the somites, “bud off” from the unsegmented mesoderm in a periodic 
manner. The Notch signalling pathway is instrumental in this segmentation process 
and Paraxis is required to form the metameric blocks of epithelial somites [32-34]. 
The cells within the somites become specified to different fates depending on the 
multiple extracellular signals they are exposed to from the surrounding tissues. Of 
these, Wnt signals from the dorsal neural tube and surface ectoderm, BMP signals 
from the dorsal neural tube or lateral plate mesoderm and Sonic Hedgehog (Shh) 
signals from the notochord and the floor plate (of neural tube) all play critical and 
antagonistic roles [35-37]. The Shh morphogen, by antagonizing Wnt signals, 
induces the ventral somites to a sclerotomal fate by activating the expression of 
Paired-box 1 (Pax1), Paired-box 9 (Pax9) and Mesenchyme forkhead-1 (Mfh1) [35, 
38-41]. The proliferative function of Shh is thus believed to be mediated by the 
Pax1/Pax9 and Mfh1 [41]. Also, maintenance of a BMP-reduced zone in the ventral 
somite by BMP antagonists – Noggin (Nog) and Gremlin (Grem1), is required for this 
sclerotomal specification [42-45]. Early exposure of the somites to BMP signals 
renders them to a lateral mesoderm fate, while a late exposure to specified 
sclerotomal cells (after exposure to Shh) promotes a chondrogenic fate [37, 46]. 
Thus, both Shh and Nog have the potential to induce Pax1 expression in the ventral 
somites, through potentially parallel pathways. Pax1 expression is detected, although 
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at diminished levels, in the Shh-/- embryos and Nog is able to induce Pax1 expression 
even in the absence of Hh signalling [42, 47].  
The ventro-medial cells of the somites proliferate and then de-epithelialize to 
become mesenchymal sclerotomal cells [31]. These sclerotomal cells then migrate to 
surround the notochord and form the mesenchymal prevertebrae. The sclerotomal 
cells in the immediate vicinity of the notochord give rise to the vertebral bodies and 
IVDs, while the lateral portions form the proximal parts of ribs, vertebral pedicles and 
laminae of the neural arch of the spine [48, 49]. The prevertebrae forms a segmented 
condensed and less condensed regions along the anterior-posterior (A/P) axis of the 
embryo at around E12.5. The former gives rise to the IVD anlagen while the latter 
develops into vertebral bodies [50].  
Thus, with respect to vertebral column development, both IVD (annulus 
fibrosus) and vertebral bodies are derived from a specified pool of sclerotomal cells 
[48], while the nucleus pulposus is derived from the notochord [30]. Despite a shared 
cellular ancestry, the vertebral body and IVD fates are acquired through different 
underlying molecular mechanisms. Moreover, in the embryonic stages, the annulus 
fibrosus is composed of two portions - a cartilaginous inner annulus and a fibrous 
outer annulus. The genetic pathway leading to a vertebral fate has been well-studied, 
however there is a dearth of information regarding the molecular pathway leading to 
an annulus fibrosus fate.  
While Shh, Nog and Grem1 clearly play a role in sclerotome specification, 
Pax1, Pax9 and Mfh1 are essential in sclerotome maintenance by regulating their 
numbers. Indeed, Pax1 and Mfh1 are known to genetically interact as the Pax1-/-
Mfh1-/- double-null mutants showed a reduced cell proliferation [41]. The fact that 
Mfh1 expression was unaffected in the Meox1-/-Meox2-/- (Mesenchyme homeobox 1 
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and 2) mutants, but Pax1 expression (Pax9 to a lesser extent) was reduced, 
indicates a potential parallel pathway in sclerotome maintenance by the Pax1/Pax9 
and Mfh1 [51].  
1.4.1.1 Vertebral body fate determination 
The subsequent differentiation of the sclerotome into chondroblasts in the 
vertebral bodies requires Meox1/Meox2, Nkx3.2/Nkx3.1 and Sox9.  
Sox9 is a well-known master regulator of chondrogenesis [52]. Nkx3.2 (a.k.a 
Bapx1, bagpipe homeobox gene 1 homolog) also appears to be essential based on 
the observation that the pre-chondroblasts failed to differentiate into chondrocytes in 
the vertebral bodies of the Bapx1-/- mutants [53]. This was accompanied by a loss of 
Sox9, Col2a1 and fibroblast growth factor receptor 3 (Fgfr3) expression in the 
vertebral anlagen, all of which are chondrogenic differentiation markers [53]. At the 
same time, the ability of Sox9 to drive Bapx1 expression in vitro, by binding to its 
promoter, indicates a potential positive-regulatory loop between Sox9 and Bapx1[54]. 
Indeed, Sox9 and Bapx1 were able to induce each others expression in chick explant 
cultures when over-expressed [54, 55].  
Meox1 and Meox2 are not needed for sclerotome specification but they act 
upstream of Pax1, Pax9 and Bapx1. In the Meox1-/-Meox2-/- mutants, Pax1, Pax9 and 
Bapx1 expression was lost in the sclerotome but not Mfh1 [51]. Furthermore, both 
Meox1 and Pax1 (Pax9 to a smaller extent) have been shown to bind to the promoter 
of Bapx1 and transactivate its expression in vitro [56, 57]. Also, Meox1 
transactivation of Bapx1 expression was enhanced in the presence of Pax1 and/or 
Pax9  [56]. Indeed, Pax1 and Meox1 are known to interact at protein-level in vitro 
[58], and their binding sites in the promoter of Bapx1 are adjacent to each other [56, 
57]. This indicates a potential genetic hierarchy whereby Meox1 is upstream of Pax1, 
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which is in turn upstream of Bapx1. However, in wild-types, Bapx1 expression is 
maintained in the chondrogenic cells of the vertebral bodies, while Pax1 and Pax9 
expression are down-regulated. This led to the hypothesis that Pax1/Pax9 may be 
required for the initiation of Bapx1 but not for its maintenance at later stages [57]. 
Sox9, which is expressed in the chondrogenic cells may be involved in its 
maintenance. It is postulated that the Shh induced positive regulatory loop between 
Sox9 and Bapx1 is subsequently maintained by BMP signals [55]. 
Thus, the current hypothesis is that Pax1/Pax9 and Mfh1 are needed to 
expand the sclerotome population to a sufficient density, upon which Sox9 and 
Bapx1 can then confer a chondrogenic potential, whereby the BMP signal is able to 
differentiate these competent cells to their chondrogenic fates.  
1.4.1.2 Annulus fibrosus (IVD) fate determination  
Mfh1 and TGF-beta signalling are known to be important players in annulus 
fibrosus fate determination,. The annulus fibrosus structure was reduced / abnormal 
in the Mfh1-/- and Tgfbr2 conditional KO (in Col2a1-expressing cells) mutants [59, 
60]. Moreover, gene expression profiling analysis of the IVD anlagen from Tgfbr2 
conditional KO mutants showed the mutant gene expression profile more closely 
resembled a wild-type vertebral body profile than the wild-type IVD. The authors had 
also observed a similar phenotype whereby the boundary between the vertebral body 
and IVD was not maintained. Moreover, Fibromodulin (Fmod, an IVD marker) and 
several other IVD markers were found to be regulated by TGF-beta signalling. Thus, 
TGF-beta signalling is required for annulus fibrosus differentiation and potentially 
prevents inappropriate chondrocyte differentiation in the IVD region [60, 61]. 
 Owing to the tissue-specific expression of Pax1 and Pax9 in the IVD anlagen 
and the complete absence of the IVD structures in the Pax1-/-Pax9-/- double-null 
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mutants indicates their potential role in IVD formation [62, 63]. It is not clear if it is 
simply a patterning and cell maintenance role, or if these genes are also essential in 
the differentiation of the sclerotome cells to an annulus fibrosus fate (fibrosus tissue). 
Whether Pax1 or Pax9 act as competence factors in sclerotome cells for their further 
differentiation into the annulus fibrosus by other signals (eg. TGF-beta signalling), is 
unknown. Also, Sox5/Sox6 also appear to be important in annulus fibrosus 
differentiation since they are known to induce Fmod expression just like TGF-beta 
signalling. How exactly the Pax and Sox genes come into play in the IVD formation 
remains unknown.  
Thus, a considerable amount of research has been carried out to reveal the 
numerous TFs involved in the general chondro-osteogenic pathway. Yet, little is 
known about the regulatory relationships between the TFs orchestrating the 
embryonic skeleton development. Moreover, the focus has largely been on the 
ossification processes in general, without much attention given to the annulus 
fibrosus fate determination, which forms an indispensable part of the vertebral 
column.  
In this study, the main focus is on the Pax1 and Pax9 genes which are 
essential for axial skeletogenesis, especially for IVD formation. Some of the known 
characteristics and functions of these two Pax genes are discussed in the following 
section. 
1.5 The Pax genes 
The Pax gene family was initially identified through similarity to the “paired-
box” in the Drosophila gene gooseberry and paired [64-66]. This Pax family 
constitutes a group of nine genes (Pax1-Pax9) encoding TFs with the highly 
conserved DNA-binding domain, the paired-box (of 128-amino acids). Genes within 
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the family are further divided into subfamilies based on their sequence similarity, the 
combination of domains they possessed: paired-domain containing two helix-turn-
helix (HTH) motifs [67], paired-type homeodomain (full or truncated) and octapeptide 
motif (HSVSNILG) [68]; and their overlapping domains of expression [65]. 
Of these Pax1 and Pax9 belong to the same subfamily, essential for the early 
stages of axial skeleton formation. Moreover, Pax1 and Pax9 are the only Pax genes 
that are expressed in the sclerotomal cells [69]. They contain only the paired-domain 
and the octapeptide motif, and share a high protein sequence similarity of 79%, 
diverging mainly at their C-terminal ends. Within the paired-domain they differ in only 
3 amino acids, at positions 82, 89 and 93, which belong to the C-terminal half of the 
paired box [50]. They also share similar expression domains, especially in the 
pharyngeal pouch endoderm, sclerotome and later in the intervertebral disc anlagen 
[50].  
The Shh morphogen emanating from the notochord and the floor plate (of the 
neural tube) induces the expression of Pax1 transcripts at E8.5 in the ventro-medial 
deepithelializing somites to specify their sclerotomal fates [35, 39, 40]. Pax9 
expression in the sclerotome is also mediated by notochordal signals [50]. It is 
believed Pax1 and Mfh1 mediate the proliferative functions of Shh [39, 41]. As 
mentioned earlier, besides Shh, Nog is also able to induce Pax1 expression in the 
somites [42]. Other factors which are not known to independently induce the 
expression of Pax1 or Pax9, but regulate their expression in the somite are 
Pbx1/Pbx2 (TALE homeodomain TFs) and Meox1/Meox2 TFs [51, 70]. In the Pbx1-/-
Pbx2-/- mutants and Meox1-/-Meox2-/- mutants Pax1 and Pax9 expression is 
diminished in the somites / sclerotome. Moreover, the effect of Pbx1/Pbx2 and 
Meox1/Meox2 is greater on the Pax1 than Pax9 [51, 70]. This indicates the presence 
of an alternative mechanism by which Pax9 is induced in the sclerotome.  
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1.5.1 Spatio-temporal expression patterns of Pax1 and Pax9  
Pax1 expression begins in the deepithelializing somites at E8.5, while 
detectable levels of Pax9 expression begin a little later at E9.0. Subsequently in the 
metameric condensing sclerotome, Pax1 is initially expressed in both rostral and 
caudal segments while Pax9 is restricted to the caudal half. Subsequently both Pax1 
and Pax9 become restricted to the caudal half of the condensing cells of the 
intervertebral disc anlagen by E12.5. While Pax1 expression is stronger in the medial 
portion of the IVD anlagen, Pax9 expression is stronger in the lateral portion. Pax1 
remains strongly expressed in the intervertebral disc and the perichondrium of the 
vertebral bodies till E14.5, after which it declines with only the annulus fibrosus cells 
of the intervertebral disc expressing it in the post-natal mice. Similarly, Pax9 is still 
expressed weakly in the E14.5 intervertebral discs, but by E16.5 its expression is no 
longer detectable in the vertebral column [50, 63, 71].  
Beyond the axial skeleton, Pax1 and Pax9 are also expressed in the 
craniofacial mesenchyme, foregut, appendicular skeleton, pharyngeal arch and its 
derivatives (maxillary and mandibular arches, thymus, parathyroid glands, 
ultimobranchial bodies). Both Pax genes are expressed in the foregut at E8.5, the 
pharyngeal pouches at E9.5, anterior proximal limb buds at around E10.0 to E11.5 
and thymus anlagen at E12.5 [50, 72, 73]. However the domains of expression in 
these sites are not always exactly overlapping. For instance, Pax9 expression in the 
anterior proximal limb buds is adjacent to the Pax1 domains of expression [50]. 
Moreover, Pax9 also has its own unique sites of expression such as in the 
ultimobranchial bodies (pharyngeal arch derivative), hindgut, ventral tail 
mesenchyme, salivary glands, squamous epithelia of esophagus, tongue and tooth 
mesenchyme, while Pax1 expression in the sternum at E13.0 has not been 
mentioned for Pax9 [50, 73, 74]. Of these, the nasal, palatal and teeth mesenchyme 
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are neural-crest derived cells. Notably, the craniofacial bones, nasal & palatal bones, 
are mainly formed by intramembranous ossification without a cartilaginous 
intermediate [75]. The detailed list of all the expression sites, the stages during which 
the expression begins/ reported to be expressed at, and the corresponding 
references are shown in Table 2.  
Table 2: Pax1 and Pax9 region of expression 
Site of expression Pax1 Ref Pax9 Ref 
Somite (ventro-medial) E8.5 [71] 
 
E9.0 [50] 
 Sclerotome E8.5  E9.5 
Axial skeleton: IVD anlagen E12.5 E12.5 
Perichondria lining VB, 
pedicles and proximal ribs 
E12.5 E12.5 
Rib intercostal mesenchyme E13.5 E12.5 [50, 
74] 
IVD: AF ~E15.5 onwards ~E15.5 to E16.5 
(subsequently 
expression is lost) 
Ventral tail mesenchyme Not expressed NIL E9.5  
Anterior proximal fore limb 
bud 
E10.0 [76] E11.5 
Anterior proximal hind limb 
bud 
E10.5 E11.5 
Hindlimb knee joint E12.5 E12.5 [50] 
Hindlimb tarsal E12.5 E12.5 [74] 
Between digits E12.5 Not mentioned NIL 
Sternum  E13.0 [73] Not mentioned 
1st arch branchial pouch E9.5 [50, 
72] 
E9.5 [50] 
2nd arch branchial pouch E9.5 E9.5 
3rd arch branchial pouch E9.5 (weak) E9.5 
4th arch branchial pouch E10.5 E9.5 
Parathyroid glands Not mentioned NIL E12.0 [74] 
Thymus epithelium E12.5  [72] E12.0 
Ultimobranchial bodies Not mentioned NIL E12.0 
Nasal process E11.5 [50] E10.5 [50] 
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Wolffian ridge E11.5 Not expressed NIL 




Not expressed E13.5 [74, 
75] 
Tongue epithelium Not expressed E11.5 [50] 
Foregut  E8.5 [72] E8.5 
Middle ear (tympanic ring) Not mentioned NIL E13.5 [74] 
Teeth mesenchyme Not expressed E10.0 [74] 
Hindgut Not expressed E9.5 [50] 
 
1.5.2 Functions of Pax1 and Pax9  
The role of Pax1 in axial and appendicular skeletogenesis was initially 
identified through spontaneous mouse mutants the undulated (un) [77], Undulated 
short-tail (Uns) [78], undulated-extensive (unex) [79] and undulated intermediate (un-i) 
[80] which consisted of either point mutations or deletions in Pax1 or deletion of its 
entire locus [68, 71, 73]. Targeted disruption of Pax1 subsequently helped to clarify 
the structures Pax1 was genuinely essential for - the vertebral bodies, intervertebral 
disc, scapula, sternum and pelvic girdle [73]. The Pax1+/- were externally similar to 
wild-type mice, viable and fertile, but with mild abnormalities of certain skeletal 
elements like the first two cervical vertebrae (atlas-axis), lumbar vertebrae and 
sternum, but with an overall penetrance of only 88%. The authors had attributed the 
lack of 100% penetrance of such skeletal defects to a genetic background effect [73]. 
The Pax1-/- mice, however, were smaller than wild-type and exhibited a shortened, 
kinked-tail phenotype but were still viable and fertile. They possessed more severe 
defects in the vertebral column, scapula, sternum and tail. The first two cervical 
vertebrae (atlas-axis) were inappropriately fused; pedicles were fused to the ventral 
ossification centres of their respective vertebrae from the thoracic segment onwards 
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till the caudal region; loss of the acromion process of the shoulder girdle; and 
inappropriate ossification of some of the intersternebra. The lumbar segments 
exhibited more severe defects with split vertebrae accompanied by the loss of IVD 
structures and formation of ventral rod-like cartilage structure [73].   
Surprisingly, targeted inactivation of Pax9 does not result in any vertebral 
column abnormalities, but shows limb, craniofacial, teeth and thymus defects. 
Although the Pax9 heterozygotes were perfectly normal, resembling a wild-type, the 
Pax9-/- mutants possessed numerous defects and die post-natally. They showed lack 
of pharyngeal arch derivatives - thymus, parathyroid glands and ultimobranchial 
bodies; absence of all teeth (molars & incisors), palatal processes of mandible and 
maxilla, cleft secondary palate (neural-crest derived structures), displayed preaxial 
polydactyly of both fore- and hind-limbs and tympanic ring was hypoplastic (inner 
ear). However, there were no vertebral column defects observed. The Pax9-/- mice 
die shortly after birth exhibiting difficulties in respiration and a bloated abdomen [74, 
75].  
Notably, the facial and dentition defects are unique to Pax9 and were not 
found in Pax1-/-, which corroborates with the distinct expression sites of Pax9 in these 
neural-crest derived structures. Although defects in the thymus were not reported by 
the authors for the Pax1-targeted null mice, thymus size reduction has been reported 
for the Pax1 spontaneous mouse mutants [72].  
Since both Pax1 and Pax9 belonged to the same sub-family, and there was 
an absence of vertebral column defects in the Pax9-/- mice, it was hypothesized that 
both Pax genes may have redundant roles in axial skeletogenesis. This prompted the 
generation of multiple allele knock-outs through the inter-mating of Pax1+/- and 
Pax9+/- mutants.  
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 An analysis of the various Pax1/Pax9 mutants revealed the synergistic roles 
played by Pax1 and Pax9 in the vertebral column. Conforming to their redundant 
roles, a clear gene-dosage effect was observed; with the loss of more alleles of 
Pax1/Pax9, the vertebral column malformations were more severe. Furthermore, in 
the vertebral column, while Pax9 could only partially compensate for the loss of 
Pax1, Pax9 deficiency was fully rescued by Pax1. The most severe axial skeleton 
defect was seen in the Pax1-/-Pax9-/- (double-null) mutants, whereby there was a 
complete loss of vertebral bodies and IVDs, deformed proximal parts of the ribs and 
the mice died post-natally. These axial skeleton defects were more drastic than those 
seen in the single-null mutants, thus demonstrating the synergistic functions of Pax1 
and Pax9 [62, 73, 74].   
In the double-null mutants, besides the vertebral column, malformations in the 
other organs / structures were exclusive to the loss of either Pax1 or Pax9. The 
preaxial polydactyly, cleft secondary palate and lack of ultimobranchial bodies (4th 
pharyngeal arch derivative) seen in the double-null mutant was also seen in Pax9-/- 
mice. Likewise, defects in the scapula seen in the Pax1-/- mice were also observed in 
the double-null mutants. Abnormalities of the thymus glands, however, were not 
reported in the study owing to their primary focus being the axial skeleton [62, 73, 
74]. All the phenotypes of the Pax1 and Pax9 targeted mutants are summarized in 
Table 3. 
 Thus, it was hypothesized that Pax1 and Pax9 are not needed for sclerotome 
formation per se, but are imperative to maintain the proliferative capacity of the 
sclerotomal cells, enough for a critical size of mesenchymal condensation to form, 
upon which endochondral ossification can successfully take place. Indeed, the vital 
role of Pax1 in controlling cell proliferation is apparent through its genetic interaction 
with another TF - Mfh1. Also expressed in the sclerotome, Mfh1 has been shown to 
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synergize with Pax1 to regulate the mitotic activity of sclerotomal cells [41]. Similarly, 
several other Pax genes like Pax5 and Pax6 are well-known to regulate proliferation 
of B cells and diencephalic precursor cells respectively [81, 82]. Therefore, the Pax 
genes in general may possess a conserved role of regulating cell proliferation.  
While proliferation might be an early role of the Pax1/Pax9, they evidently 
have a late function in IVD development. Therefore, other hypotheses are that these 
two Pax genes may regulate other processes or factors essential for the 
condensation process, such as cell shape, cell size, cell adhesion and junction, and 
ECM production and degradation [62, 71]. Also, as mentioned earlier, Pax1 and Pax9 
have been shown, in vitro, to directly bind to the promoter and trans-activate Bapx1, 
another TF known to be critical for the proper differentiation of prechondroblast into 
chondrocytes in axial skeletogenesis [53, 57]. This led to the hypothesis that both 
Pax genes may have roles in early chondrogenesis and that they are crucial for the 
early stages of axial skeleton formation.  
Currently, besides Bapx1 as one of the potential early targets, other down-
stream targets of Pax1 and Pax9 are not known. Therefore, identification of the target 
genes of Pax1 and Pax9 during early stages of sclerotome differentiation and their 
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Table 3: Summary of Pax1 and Pax9 targeted mouse mutant phenotypes 
Pax 
Mutants 
Phenotype Survival & 
references 
Pax1+/- - Mild defects in axial skeleton: 
§ Fused atlas-axis (C1 & C2 cervical vertebrae) 
§ Lumbar vertebrae 
§ Sternum 




Pax1-/- More severe defects in axial skeleton: 
- Fused atlas-axis (C1 & C2 cervical vertebrae) 
- Lumbar vertebrae – VBs & IVDs 
- Sternum 
- Scapula (Pectoral girdle - acromion) 
- Pelvic girdle 
- Tail à short & strongly kinked 
- Lack derivatives of 3rd & 4th pharyngeal pouches 
(thymus, parathyroid glands) 




Pax9+/- No axial skeleton defects; Mice are phenotypically normal Viable & 
fertile [74] 
Pax9-/- - Cleft secondary palate 
- Absence of teeth (incisors & molars) 
- Absent palatal processes of premaxilla & coronoid 
process of the mandible 
- Hypoplastic tympanic ring (ear) 
- Preaxial polydactyly (ectopic cartilage formation) of 
fore- & hind-limbs 
- Lack derivatives of 3rd & 4th pharyngeal pouches 
(thymus, parathyroid glands) 
- Distended abdomen at birth; no feeding 
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Pax1-/-
Pax9-/- 
- No vertebral bodies or IVDs 
- Missing: 
§ Proximal parts of most ribs,  
§ all skeletal elements of tail, 
§ connection between sacrum & pelvic girdle  







1.5.2.1 Pleiotropic roles of Pax1 and Pax9. 
Similar to several other TFs, Pax1 and Pax9 have pleiotrophic roles, in that 
they are important for the development of other structures besides the vertebral 
column. Pax1 is also necessary for scapula, pelvic girdle and thymus development. 
Although the thymus was not investigated by the authors in the Pax1-targeted null 
mutants, analysis of Pax1 undulated mutants (un, unex and uns) had revealed a 
reduction in the size of thymus and also altered maturation of thymocytes. 
Similarly, Pax9 is critical for digit, teeth, craniofacial bones (mandible and 
maxilla), thymus and parathyroid gland development, as seen from the defects in all 
of these structures in the Pax9-/- mutants (Table 3).  
Thus, these TFs expression sites correlate with their roles in numerous 
organs / structures. Evidently, the developmental pathways must be different for the 
various structures, and it is highly likely that they regulate such distinct organ 
development through cooperation with varied partners in the different tissues.  
1.5.3 Pax1/ Pax9 related defects in humans 
The importance of Pax1 and Pax9 can also be perceived through the 
emergence of vertebral column anomalies in humans, associated with the 
counterpart human PAX1 and PAX9 genes. Skeletal defects such as Jarcho-Levine 
syndrome [83], Klippel-Feil syndrome [84] and kyphoscoliosis or variants of such 
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vertebral segmentation [85, 86] defects have been associated with the PAX1 and 
PAX9.  
In brief, Jarcho-Levine syndrome is a lethal, autosomal recessive 
developmental disorder, comprising a variety of vertebral and rib deformities. The 
associated phenotypes include a “crab-like” thoracic spine and ribs, fused vertebrae 
or ribs, kyphoscoliosis and short stature, which may occur in conjunction with 
cardiovascular disorder, renal defects or neural tube anomalies. The axial skeleton 
phenotypes similar to that of Pax1/Pax9 compound mice mutants have been 
identified in human foetuses suffering from the Jarcho-Levine syndrome [62, 83]. A 
significant decrease in the PAX1 and PAX9 proteins were detected in the vertebral 
column of the autopsied foetuses. Morphologically, the thoracic and lumbar vertebrae 
were defective with fusions and irregular shape [83].  
Thus, Pax1 and Pax9 have conserved roles in axial skeletogenesis in mouse 
and humans. Moreover, the high similarity of the paired-domain sequence between 
murine and human Pax genes indicates the suitability of the mouse as a model 
system to study such developmental disorders. 
 
1.6 Research Aims, Strategy and Significance 
1.6.1 Objective 
With the ultimate objective of putting together a comprehensive and accurate 
gene regulatory network (GRN) of the embryonic chondro-osteogenic pathway, this 
study is specifically centered on unravelling a portion of this GRN by experimenting 
on two of the genes, Pax1 and Pax9. The objective of this study is to identify the 
target genes of Pax1 and Pax9 in the IVD, using traditional gene-targeting strategies 
(loss-of-function study) and current genomic technologies (microarray and chromatin 
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immunoprecipitation-sequencing (ChIP-SEQ)). The information derived from these 
genome-wide techniques can then be linked to the existing chondro-osteogenic 
pathway, and thus help in the construction of the GRN. From that, we also aim to 
understand the roles of Pax1 and Pax9 in IVD development and decipher how they 




1. The target genes of Pax1 in the early stages of IVD development, in a cell-
type specific manner. 
2. The common set of Pax1 and Pax9 targets that cannot be picked up in the 
single-null mutants due to the redundant roles of these paralogous genes. 
3. The corresponding direct binding targets of Pax1 and Pax9 in the IVD 
development. 





(I) Generate Pax1 and Pax9 WT and knock-out (KO) mouse-lines for use in gene 
expression profiling and TF mapping studies to identifying the target genes of Pax1 
and Pax9 
A traditional transgenic approach was adopted to KO these two genes in the 
mouse using BAC templates and gene targeting in mouse embryonic stem cells 
(mESCs) cells by homologous recombination. Pax1 and Pax9 were knocked-out 
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(KO) by insertion of EGFP in order to enrich for Pax1 and Pax9 cell lineages (using 
Fluorescence-Activated Cell Sorting, FACS) specifically from the vertebral column, 
which were subsequently used for gene expression profiling profiling. Also, for 
comparison with WT cells, EGFP was co-expressed with Pax1 via the IRES or F2A 
peptide concatenating strategies. This way, cells producing WT Pax1 and EGFP from 
the Pax1 locus were enriched from the vertebral column using FACS, and 
subsequently used on microarrays for gene expression analyses. 
For ChIP-Seq, there are only two ChIP-grade antibodies available (for Pax1 
and Pax9 each) commercially at the moment. To overcome potential cross-reactivity 
issues with these commercial antibodies, the Pax1 and Pax9 proteins were 
endogenously tagged with hemagglutinin (HA) epitope in mice. These mouse lines 
were generated as an alternative in case the gene-specific antibodies were not 
sensitive and specific enough. Moreover, the HA epitope was chosen as several 
commercial ChIP-grade HA-antibodies are available.  
(II) Specific Aim 1: Identify targets regulated by Pax1 in the early stages of IVD 
development 
Gene expression profiling profiling of Pax1 (Pax1E/E vs Pax1-/-) was performed 
on cells sorted by FACS from E12.5 and E13.5 vertebral column, stages when the 
IVD anlagen is being formed. 
(III) Specific Aim 2: Find the common set of Pax1 and Pax9 targets that cannot be 
picked up in the single-null mutant owing to the redundant roles of these paralogous 
genes 
In the presence of Pax1, Pax9+/- and Pax9-/- show no vertebral defects, 
probably because of compensation by Pax1 in the vertebral column. Therefore, it is 
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unlikely that any significant number of Pax9 regulated genes in the axial skeleton will 
be picked up in the array comparison of WT vs Pax9-/-. However, the Pax1-/-Pax9+/- 
(three allele knock-out) and Pax1-/-Pax9-/- (double-null) mice exhibit a progressively 
more severe phenotype of the vertebral column than the single-null mutants, 
indicating an obvious gene-dosage and redundant effects of these two genes in axial 
skeleton formation.  
Hence, to identify the target genes of Pax9 that were obscured by Pax1 owing 
to the redundant roles, the Pax1-/-Pax9+/+ vs Pax1-/-Pax9-/- and Pax1-/-Pax9+/- vs Pax1-
/-Pax9-/- mutants were analyzed. This helped to identify the genes regulated by 2 
copies and 1 copy of Pax9 in the absence of Pax1. Moreover, the double-null (Pax1-/-
Pax9-/-) vs WT enabled the identification of the whole array of target genes of Pax1 
and Pax9 that were obscured by their redundancy.  
In the double-null embryos, the first signs of abnormalities in cell proliferation 
and apoptosis of sclerotomal cells and an arrest of chondrogenesis was observed at 
E12.5, so the gene expression profiling was performed at E12.5.  
A potential rate-limiting step in this specific aim was to obtain sufficient cells 
for gene expression profiling, as the chances of getting a Pax1/Pax9 double-null 
embryo from mating the Pax1+/-Pax9+/- (double heterozygotes) is 1 in 16 (based on 
the Mendellian ratio of inheritance). As the triple allele mutants do not survive (Pax1-/-
Pax9+/- undergoes early postnatal lethality; Pax1+/-Pax9-/- also undergo postnatal 
lethality), they could not be used for mating. 
(IV) Specific Aim 3: Identify the direct binding targets of Pax1 and Pax9 in the early 
stages of IVD development  
	   27	  
To distinguish the direct from the indirect targets of Pax1 and Pax9, ChIP-Seq 
was performed on E12.5 and E13.5 CD1 WT mouse embryonic tissues (enriched 
only for the vertebral column) using commercial anti-Pax1 and anti-Pax9 antibodies, 
with input chromatin as background control. By overlapping the TF mapping data and 
gene expression profiling data (WT vs Pax1-/-Pax9-/-), the direct and indirect targets of 
Pax1 and Pax9 were distinguished. 
To overcome potential cross-reactivity issues with commercial antibodies 
against Pax1 and Pax9, and also because there are only two ChIP-grade antibodies 
available (for each gene-product) commercially at the moment, these two genes were 
also endogenously tagged with hemagglutinin (HA) epitope sequence in mice. This 
was meant to serve as an alternative if those Pax-specific antibodies were not 
sensitive and specific enough. Moreover, HA epitope was chosen as there are 
several commercial ChIP-grade HA-antibodies available.  
(V) Specific Aim 4: Potential link between Pax1 and Pax9 and the other TFs in the 
chondro-osteogenic pathway 
The list of direct and indirect targets of Pax1 and Pax9 identified through the 
gene expression profiling and TF mapping studies were further scrutinized manually 
to identify any of the known TFs involved in the chondro-osteogenic pathway. This 
served as the link between the Pax1/Pax9 TFs and the other TFs in the chondro-
osteogenic pathway. Furthermore, literature search and existing gene expression 
data for other TFs (eg. Sox5, Sox6, Sox9) in the chondro-osteogenic pathway 
(generated by other researchers in the lab via the same strategies for the same 
embryonic stages and tissue) were mined for elucidating the relationship between the 
Pax1/Pax9 and the other TFs.  
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1.6.3 Significance 
Mesenchymal stem cells (MSCs) are multi-potent progenitor cells that 
possess the ability to differentiate into osteoblasts, chondrocytes, myocytes, 
adipocytes, tendon cells, fibroblasts or neuronal cells [87]. Understanding the 
mechanisms by which these multi-potent stem cells differentiate into specific lineages 
is essential for therapeutic applications in the area of regenerative medicine, such as 
reprogramming of patient-specific somatic cells or tissue engineering. The chondro-
osteogenic lineage is of immense biomedical importance as it gives rise to most of 
the skeletal components of the body such as the axial, appendicular and some parts 
of craniofacial bones. Comprehending how the MSCs are patterned and become 
committed into chondrocytes or osteoblasts to form the skeleton will also shed light 
on the basis for congenital diseases/ syndromes and degenerative disorders of the 
bone like Klippel-Feil syndrome, Jarcho-Levine syndrome, spondylocostal 
dysostosis, Campomelic dysplasia, osteopenia, osteoporosis, arthritis, intervertebral 
disc degeneration and osteoporosis pseudoglioma (OPPG). 
More importantly, identification of the target genes of Pax1 and Pax9 will help 
to illuminate the early events of regulation involved in the commitment of MSCs 
towards the annulus fibrosus fate in the IVD. Furthermore, by elucidating the network 
of chondro-osteogenic cell, we can also predict the outcome of various perturbations 
to the system. This would enable us to design better and more appropriate therapies 
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CHAPTER 2 – MATERIALS AND METHODS  
2.1 BAC Modification and Subcloning 
C57BL/6J mouse strain-derived bacterial artificial chromosomes (BAC) clones 
RP24-88N2 and RP24-211J10 containing the Pax1 (mouse chromosome 2) and 
Pax9 (mouse chromosome 12) gene loci respectively, were obtained from the 
BACPAC Resources Centre at Childrenʼs Hospital Oakland Research Institute 
(CHORI). BAC clones were confirmed by polymerase chain reaction (PCR) and 
sequencing before proceeding with gene manipulation. All the primers for BAC 
screening, modification and subcloning were designed using the Primer 3 (v. 0.4.0) 
web-based software (http://frodo.wi.mit.edu/primer3/). Genetic modifications of the 
clones were performed using the Gene Bridges Quick and Easy BAC Modification kit 
(Cat #K001) through the Red/ET recombineering technology, according to the 
manufacturerʼs protocol (Figures 2- 5). Briefly, appropriate 50 bp homology arms 
flanking the cassettes (F2A-EGFP-FRT-PGKgb2-Neo-FRT; HA3-TGA-loxP-PGKgb2-
Neo-loxP) were added via PCR. pRed/ET plasmids were first transformed into the 
E.coli strain DH10B containing the required BAC clone with selection by 
chloramphenicol (12.5 μg/mL) and tetracycline (3 μg/mL) antibiotics. The cassettes 
were subsequently transformed into the E.coli containing the pRed/ET plasmids. 
Colonies with successful homologous recombination were selected by their 
resistance to chloramphenicol (12.5 μg/mL) and kanamycin (20 μg/mL) antibiotics 
and screened by colony PCR. Positive clones were further screened for errors such 
as point mutations or deletions by sequencing the PCR products of the inserted 
cassette with multiple overlapping primer sets. Mutation-free, successfully modified 
BAC clones were subcloned into a minimal vector using the Gene Bridges Quick and 
Easy BAC Subcloning kit (Cat # K003) using the same Red/ET recombineering 
technology as per the manufacturerʼs protocol (Figure 5). Grabbing arms were 
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chosen in a repeat-free region, with a short arm of at least 1.5kb and a long arm of at 
least 7kb. A PmeI restriction site was added at one end of the grabbing arms to 
facilitate plasmid linearization for electroporation later. The selection of the positive 
recombinants (subclones) was performed with kanamycin (20 μg/mL) and ampicillin 
(100 μg/mL) antibiotics and screened by colony PCR. Clones were further confirmed 
for absence of errors by sequencing the PCR products of the modified region with 
multiple overlapping primer sets. Mutation-free subclones were linearized with PmeI 
















Figure 2: Map of the Red/ET expression plasmid pSC101-BAD-gbaAtet. 
Transformation of E.coli hosts with this plasmid is selected for by acquisition of 
tetracycline resistance at 30oC. Expression of the Red/ET recombination proteins is 
induced by L-arabinose activation of the BAD promoter at 37oC. Picture adapted from 
Gene Bridges Quick and Easy BAC Modifi cation Kit By Red®/ET® Recombination 
Version 2.4   (February 2005) technical protocol. 
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Figure 3: Illustration of the principle for modifying bacterial artificial 
chromosomes (BACs). Left: Cassettes with selectable marker gene are first 
synthesized using appropriate primers with homology arms by polymerase chain 
reaction (PCR). Middle: PCR product (cassette) is electroporated into host E.coli cells 
containing the BAC (vector) to be modified. Right: The BAC is thus modified by 
Red/ET mediated recombination. Sm - selectable marker; the small blue arrow -
prokaryotic promoter. Picture adapted from Gene Bridges Quick and Easy BAC 











Figure 4: Mutagenesis strategy for inserting the cassette-of-interest into a 
bacterial artificial chromosome (BAC).1: Red/ET expression plasmid is first 
electroporated into the DH10B E.coli strain containing the BAC-of-interest. 2: 
Cassette with a selectable marker gene is then electroporated into cells containing 
the Red/ET plasmid. 3: Presence of selectable markers allows the identification of 
colonies with modified BAC. Picture adapted from Gene Bridges Quick and Easy 
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Figure 5: BAC subcloning by recombineering technology. Left: Primers with 
homology to region-of-interest for subcloning is synthesized first. Using the plasmid 
template provided in the kit for the minimal vector containing the ampicillin selection 
marker, PCR products are generated. Middle: Red/ET expression plasmid is first 
electroporated into the clones with modified BAC. The PCR products for subcloning 
are then electroporated into the cells. Right: Through homologous recombination, the 
region-of-interest is subcloned into the minimal vector which contains the ampicillin 
selectable marker. Presence of selectable markers (ampicillin + kanamycin) allows 
the identification of colonies with modified BAC that have been successfully 
subcloned. Picture adapted from Gene Bridges Quick and Easy BAC subcloning Kit 
By Red®/ET® Recombination Version 2.4 (February 2005) technical protocol. Hm – 
homology arm; RS – restriction site; Amp – ampicilin. 
 
2.2 Homologous Recombination in Mouse ES Cells 
 
2.2.1 ES Cell Culture  
 
Either the R1 (derived from 129X1 x 129S1 strain) or the V6.4 (hybrid 
C57BL/6J x 129) mouse ES cells (p17 - p20) were used for gene targeting of the 
different constructs. All the mouse ES cells were grown on gelatinized plates (0.1%) 
containing irradiated mouse primary embryonic fibroblast (PEF). Cells were grown in 
ES media (ESM) composed of DMEM supplemented with 15% heat-inactivated ES 
grade fetal bovine serum (FBS) (Gibco, Invitrogen), 0.1 mM β-mercaptoethanol, 4 
mM L-glutamine, 1 mM sodium pyruvate, 40 ug/mL gentamicin, and 500 U/mL LIF 
(ESGRO, Chemicon) at 37°C in 5% CO2. Fresh media was added on alternate days 
and cells were passaged with 0.05% trypsin (Gibco, Invitrogen) every 3 days. 
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2.2.2 Electroporation of ES Cells 
 
Mouse ES cells were passaged 24 hrs before electroporation. For 
electroporation, cells were trypsinized (0.05% trypsin for 3 min at 37oC), washed with 
ESM (3 min, 1000 rpm, RT) and counted using a haemocytometer. 5 million or 10 
million cells, for R1 and V6.4 cells respectively, were used per electroporation. Cells 
were resuspended in 500 uL of ESM with 10 ug of linearized subclone (targeting 
vector) or without any DNA for negative control. Cell were then electroporated using 
an electroporation cuvette (Biorad, 1 mm gap) at 125 μFarads, 0.4 kVolts. 
Electroporated cells were allowed to rest for 10 min at RT before being split equally 
into six 10 cm gelatinized tissue culture dishes containing DR4 feeder (Neomycin 
resistant). Cells were grown overnight in ESM before selecting for successfully 
recombined clones by G418 selection. A range of G418 concentrations were used for 
the selection process: 150 ug/mL, 200 ug/mL, 250 ug/mL, 300 ug/mL, 350 ug/mL and 
400 ug/mL. Negative controls were selected at only two concentrations: 150 ug/mL 
and 400 ug/mL. 
 
2.2.3 ES Cell Colony Picking 
G418 selection of positive recombinants was carried out for 8-10 days. 
Negative control plates contained no colonies by the end of the 8th day of G418 
selection. 192 colonies that survived the selection from DNA-electroporated plates 
were picked into two 96-well gelatinized plates containing irradiated PEFs. Colonies 
were allowed to grow overnight in ESM before trypsinization and being split into two 
96-well replicate plates. Cells were allowed to recover for 2 days in ESM before 
being split again. One 96-well plate was split into two fresh 96-well plates with 
irradiated PEFs and grown to 80% confluency before being frozen down at -150oC; 
the other replicate was split into 24-well plates for subsequent DNA extraction. 
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Colonies were then pre-screened by PCR, followed by Southern blotting using the 
appropriate external and internal DIG-labelled probes. 
 
2.2.4 ES Cell Cryopreservation 
ES cells in 96-well plates were frozen down using freshly prepared, filtered, 
freezing medium (70% DMEM, 20% FBS and 10% DMSO). ESM was first removed 
from the wells and replaced with 70 uL of freezing medium. Plates were sealed with 
cling wrap and aluminium foil, and placed in a Styrofoam box for freezing in -80oC 
overnight before further storage at -150oC. Positive clones identified from pre-
screening by PCR or Southern blotting were thawed at 37oC, expanded, trypsinized 
and washed with ESM before resuspension in 500 uL of freezing medium in cryo-
vials. The cryo-vials were then placed in freezing containers (Invitrogen; allows a 
drop in temperature at a rate of 1oC per min) and frozen slowly at -80oC overnight 
before further storage at -150oC. 
 
2.3 ES Cell Clone Screening  
2.3.1 Genomic DNA Extraction 
ES cells and mouse tail tips were digested with Proteinase K (Sigma; at a 
final concentration of 0.5 mg/mL in PK digestion buffer (PKDB)) overnight with 
agitation at 37oC and 57oC respectively. Phenol: Chloroform extraction of genomic 
DNA was performed using MaXtract High Density tubes (Qiagen; Cat.#129046. 
Equal volume of phenol: chloroform: isoamyl alcohol (pH7.9) (Ambion; Cat# AM9732) 
was added to the digested sample and vortexed for 30 seconds before spinning 
down at 13200 rpm for 5 min to separate the organic and aqueous phases. The 
DNA-containing aqueous layer was decanted into a fresh 1.5 ml microcentrifuge tube 
and was precipitated with twice the volume of 100% ethanol and subsequently 
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washed with 70% ethanol. DNA pellet was air-dried before re-suspension in sterile 







TRIS- tris(hydroxymethyl)aminomethane ; EDTA- Ethylenediaminetetraacetic 
acid; SDS- Sodium dodecyl sulfate ; NaCl – sodium chloride 
 
2.3.2 Southern Blotting 
§ Southern Probe Design  
Vector NTI software (from Invitrogen) was used to identify the appropriate 
homology arms on the wild-type (WT) and modified allele to be used for Southern 
blot screening. Corresponding restriction sites were also identified for each construct. 
In brief, short (at least 1.5 kb long) and long homology arms (at least 7 kb long) were 
chosen in a repeat-free region. The UCSC genome browser was used to identify 
repeat regions (http://genome.ucsc.edu/cgi-bin/hgGateway). External and internal 
Southern probes (of 400 bp – 1000 bp long) were designed to be outside or inside 
the homology arms respectively, but within the selected restriction sites (Figures 7-
14). External Southern probes were utilized to identify the clones that had been 
successfully recombined, while internal probes were designed to differentiate clones 
with random integration of the cassettes as well. Primer 3 (v. 0.4.0) web-based 
software (http://frodo.wi.mit.edu/primer3/) was used to design the primers for 
synthesizing the external and internal probes.  
 
§ DIG-labelled Probe Synthesis 
PK Digestion Buffer (PKDB) 
Final concentration Reagents 
50 mM   TRIS, pH 7.0-8.0 
5 mM    EDTA 
1%    SDS 
0.2M  NaCl 
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Southern DIG-labelled probes were synthesized by PCR the PCR DIG Probe 
Synthesis kit (Roche, Cat #1636090). The kit allows the addition of non-radioactive 
digoxygenin (DIG) by incorporating DIG-dUTP into the nucleotide sequence during 
the PCR. The PCR products were column purified using QIAGEN PCR purification kit 
(Cat #28106) and eluted using sterile water. Probe concentration was quantitated 
using Nanodrop Spectrophotometer and the quality was assessed by gel 
electrophoresis. Probes were stored at -20°C. 
 
§ DNA digestion and transfer 
Phenol: chloroform purified genomic DNA from the ES colonies were digested 
with the appropriate restriction enzymes for 16 hrs. The digested DNA (10 - 12 ug) 
was resolved on 0.8% TAE agarose gels (without ethidium bromide) slowly at a 
constant voltage of 25 V for 12 - 14 hrs. The gels were then stained with ethidium 
bromide (10 ug/mL) for 15 - 30 min and imaged under UV light (SYNGENE gel Bio 
Imaging System). The gels were subsequently denatured using 0.5 M NaOH with 
gentle agitation for 2 x 30 minutes. For DNA bands of more than 12 kb, depurination 
with 0.25 M HCl was performed for 10 min before proceeding with NaOH 
denaturation. Stacking of the gel for Southern blotting by capillary force was done as 
shown in Figure 6.  The gel was watered with 0.5 M NaOH every 1 hr before sealing 
with cling wrap for overnight transfer.  
 
Figure 6: Illustration of stacking of the agarose gel for Southern blotting. The 
denatured gel is placed on a stack of C-fold towels with two sheets of Whatman 3 
MM filter paper and a single positively charged nylon membrane.  
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§ Hybridisation and Washing 
After the overnight transfer, the nylon membrane was washed in 5X SSC for 
10 min and placed in a roller bottle containing pre-warmed DIG Easy Hyb buffer 
(Roche, Cat #1603558; 10 mL/100 cm2) for pre-hybridization at 42°C for 4 hrs. The 
DIG-labelled probes (external or internal probes) were denatured at 99°C for 3 min 
and quick-chilled on ice for 1 min before being added to pre-warmed DIG Easy Hyb 
buffer at a final concentration of 25 ng/mL. The membrane was hybridized overnight 
at 42°C in a rotating oven. After hybridization, the nylon membrane was washed once 
at RT (RT) for 10 min (2X SSC, 0.1% SDS), then twice at 60°C for 15 min each in a 
pre-warmed higher stringency wash buffer (0.5X SSC, 0.1% SDS) with vigorous 
agitation, followed by a brief rinse in 1X MABT. 
 
§ Blocking and Detection 
The membrane was next blocked with 1% Blocking buffer (Roche Blocking 
Reagent, Catalog #11096176001; 1g/100mL of 1X MAB) for 30 min. The membrane 
was then incubated for 30 min at RT with alkaline-phosphatase (AP)-conjugated anti-
DIG antibody (Roche, Catalog #11093274910) at a 1:10,000 dilution in 1% Blocking 
buffer with gentle agitation. Unbound antibody was washed off with 1X MABT for 15 
min twice at RT with vigorous agitation. The membrane was rinsed briefly in 
detection buffer (0.1 M Tris-HCl, pH9.5 and 0.1 M NaCl) and incubated with CDP- 
Star chemiluminescent AP substrate (1 mL/100 cm2;  Roche Cat #12041677001) at 
RT for 5 min. The membrane was then warmed at 37°C for 10 min before signal 
detection on an X-ray film. The film was generally exposed for 1 hr in order to detect 
a reasonable signal. 
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§ Stripping and Re-probing 
Once probed with the external probe, the nylon membrane was stripped and 
re-probed with the internal probe. For stripping, the membrane was rinsed with 
deionized water for 1 min at RT, followed by washing at 37oC for 2 x 15 min in pre-
warmed stripping buffer (0.2 M NaCl/ 0.1% SDS) with vigorous agitation. The 
membrane was then washed with 2X SSC before pre-hybridization and hybridization 







Maleic acid buffer with Tween (MABT) 1x 





2.4 Generation of Transgenic Mice 
2.4.1 Ethics statement 
All the animal procedures were performed according to the Singapore 
A*STAR Biopolis Biological Resource Center (BRC) Institutional Animal Care and 
Use Committee (IACUC) guidelines. The IACUC protocols were reviewed and 
approved by the aforementioned committee before any animal procedures were 
undertaken for this study (IACUC Protocol No: 110689 and 110648). 
 
2.4.2 Microinjection of ES Cells 
Correctly targeted ES cell clones (without secondary random intergration) 
where thawed from cryo-vials, washed with ESM and cultured for 2 days before 
being passaged 24 hrs prior to microinjection. On the morning of microinjection, cells 
Maleic acid buffer (MAB) 10x 
Final concentration Reagents 
0.2 M   Maleic acid 
0.3 M   NaCl 
Adjust pH to 7.5 with NaOH  NaOH pellets 
	   39	  
were trypsinized, washed with PBS and resuspended in M2 medium. In each 2- to 8-
cell stage mouse embryos harvested from C57BL/6J mice, about 8-10 ES cells were 
microinjected [88]. On the same day, 6-10 microinjected embryos per oviduct were 
re-implanted in CD-1 pseudopregnant mice. This method of microinjection allowed 
the generation of high percentage germline transmitting chimeras. All the ES cell 
microinjections, mouse maintenance and embryo harvesting were performed by Dr 
Petra Kraus. 
2.4.3 Breeding and Genotyping of Transgenic Mice 
The male chimeras, identified by coat-colour, were crossed with female 
C57BL/6J mice to obtain heterozygous transgenic mice. Homozygous mice were 
subsequently generated by mating the heterozygotes. Mice were weaned at 3 weeks 
after birth and ear-tagged for identification purposes. The genotypes of the mice were 
determined by PCR of genomic DNA extracted from mouse tail tips. 
 
2.5 Fluorescence – Activated Cell Sorting (FACS) 
2.5.1 Dissociation of Mouse Embryonic Tissue into Single Cells 
For Pax1, both heterozygous and homozygous null mutants are viable and 
fertile. Hence, the Pax1-/- embryos were easily obtained by intermating the 
homozygotes. The Pax1+/- embryos were obtained by mating the Pax1-/- mice with 
CD-1 WT mice. The embryos were first staged based on the M.H. Kaufmann, Theiler 
morphological criteria and confirmed for the presence of enhanced green fluorescent 
protein (EGFP) by viewing under the fluorescence microscope (LEICA M205 FA 
microscope). The Pax1 WT tagged with EGFP (Pax1+/EGFP) embryos were obtained 
by mating the Pax1EGFP/EGFP  with CD-1 WT mice. The vertebral column which showed 
EGFP expression was dissected from the E12.5 or E13.5 mouse embryos in cold 
Leibovitzʼs L-15 Medium (Invitrogen, Catalog #21083027). The dissected tissue was 
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dissociated manually by pipetting up and down in freshly prepared and sterile filtered 
(Millipore, 0.2 µm filter disc) dissociation buffer (DB). The dissociated suspension 
was passed through a 100 um strainer placed on a 50 mL Falcon tube containing an 
equal volume of 20% FBS in Leibovitz medium (sterile filtered) in order to stop the 
enzymatic activity. Any clumps of tissue left on the strainer was aspirated with a 
wide-bored 1 mL pipette tip and dissociate again in more DB and passed through the 
same 100 um strainer and collected in the same 50 mL Falcon tube. This step was 
repeated until no clumps of tissue were observed on the strainer. The filtrate was 
then pelleted at 2000 rpm for 5 min in a 4°C centrifuge. The supernatant was 
discarded and the pellet was resuspended in the filtered, pre-warmed (to 37oC) 
resuspension buffer (RB). For every vertebral column tissue from a single embryo 
(E12.5 or E13.5), 400 uL of RB was used. The cell suspension was passed through a 
40 um strainer and aliquoted into a 5 mL polystyrene tube. In parallel, vertebral 
column tissue from a CD-1 WT or a littermate WT embryo of the same embyonic 
stage was dissociated to be used as the gating control for GFP detection threshold. 
The cells were then sorted by FACSAria flow cytometer (BD Biosciences) and 
collected into a 1.5 mL microcentrifuge tube containing 500 uL of 20% FBS. Sorted 
cells were pelleted at 1,400 rcf for 10 min in a 4°C tabletop centrifuge, resuspended 
in Trizol (Invitrogen Cat#15596-018; 100,000 cells / mL of Trizol), incubated for 5 min 
at RT and stored at -80°C. Cells can be stored in Trizol for a maximum of 6 months in 







Dissociation buffer (DB) 
Final concentration Reagents 
-   Lebovitz L-15 medium 
100 U/mL   Collagenase I (Sigma) 
100 U/mL Collagenase II (Sigma) 
50 U/mL Dnase 
0.05% Trypsin 







2.6 Microarray Analysis of Gene Expression 
2.6.1 RNA Extraction  
Sorted cells that had been stored in -80°C were thawed on ice before total 
RNA extraction was carried out using Trizol followed by column purification with the 
QIAGEN RNeasy Micro kit (Cat # 74004). Briefly, 0.2 mL of chloroform was added 
per 1 mL of Trizol and transferred to a 2 mL MaXtract High Density tube (Qiagen; 
Cat. #129046). After a 15 sec vigorous shaking by hand and incubation at RT for 3 
min, the tube was centrifuged at 15,800 rcf for 15 min at  4°C in a table-top 
centrifuge. The aqueous layer was then transferred to fresh RNase-free 1.5 mL 
microcentrifuge tube and precipitated with an equal volume of freshly prepared 70% 
ethanol (about 60% of the initial volume of Trizol sample). Precipitated sample was 
then passed through RNeasy MinElute column (Qiagen) and centrifuged at RT for 30 
sec at 10,000 rpm. The column was washed with 350 ul wash buffer RW1 before on-
column DNase treatment was done using 80 uL of 1U/uL DNaseI in buffer (QIAGEN 
#79254) for 15 minutes at RT. The column was washed with 350 uL buffer RW1, 500 
uL RPE and then 500 uL 80% ethanol (made fresh). Thereafter, the column was 
spun dry at 13,200 rpm for 5 min at RT, and incubated in 14 uL of RNase-free for 1 
min before elution at 13,200 rpm for 1 min in a fresh 1.5 mL centrifuge tube. RNA 
samples were quantified and checked for their integrity using Agilent RNA Pico 6000 
Resuspension buffer (RB) 
Final concentration Reagents 
2 %  FBS 
2  uM  EDTA (pH 8.0) 
25 mM HEPES-KOH (pH 7.5) 
50% AccumaxTM 
- Lebovitz L-15 medium 
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Chip (#5067-1513) and Agilent 2100 Bioanalyzer software according to the 
manufacturerʼs protocol. RNA was stored at -80°C until further use. 
2.6.2 RNA Amplification and Biotin Labelling 
Purified RNA samples with RIN value of at least 7.0 were chosen for 
subsequent processing. RNA samples were amplified using the NuGEN Ovation™ 
RNA Amplification V2 kit (Cat # 3100-12) and biotin-labeled with NuGEN Encore™ 
BiotinIL Module kit (Cat # 4210-48) according to the manufacturerʼs protocol. 2 ng of 
total RNA was used to synthesize the single-stranded cDNA with a single round of 
linear PCR amplification using SPIA amplification system. The microgram amounts of 
cDNA that was prepared this way was purified using QIAGEN PCR purification 
columns as per manufacturerʼs instructions. cDNA samples were quantified using the 
Nanodrop spectrophotometer before 3 ug of cDNA was used for biotin-labeling using 
the NuGEN Encore™ BiotinIL Module kit. Labeled cDNA were then purified using 
QIAGEN PCR purification columns and quantified by Nanodrop and stored in -20oC 
until further use.  
 
2.6.3 Hybridization on Illumina Mouse WG-6 BeadChip  
Biotin-labelled cDNA was used for gene expression analysis using the 
Illumina MouseWG-6 Expression BeadChip (Cat #BD-201-0202). Hybridization, 
washing and signal development were performed according to manufcaturerʼs 
protocol provided in the Illumina MouseWG-6 Expression BeadChip kit. For each 
sample, 1.5 ug of cDNA was resuspended in 10 uL of nuclease-free water. The 
sample was incubated at RT for 10 min before 20 uL of GEX-HYB (prewarmed to 
58°C and cooled  to RT) was added and heated at 65 °C for 5 min. Hybridization 
chamber and gaskets were assembled and 200 uL of GEX-HCB was added to the 
humidifying buffer reservoirs. The 30 uL of warmed biotin-labeled cDNA was briefly 
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vortexed, centrifuged at 13,200 rpm for 1 min and cooled to RT before being loaded 
onto the microarray chip. Biological replicates for each genotype were loaded in a 
randomized manner on multiple chips. The loaded BeadChips were placed 
horizontally inside the hybridization chamber and sealed. The chamber was placed in 
the pre-warmed hybridization oven and incubated for 18 hours at 48°C according to 
the recommendations by the NuGEN Ovation™ RNA Amplification V2 kit owing to 
the use of less stable cDNA/DNA pairs compared to the usual cRNA/DNA pairs. 
Meantime, the 1X High-Temp wash buffer (500 mL) was prewarmed overnight at 
55°C.  
The following day, coverseals of the hybridized BeadChips were carefully 
removed in the Wash E1BC solution.  Beadchips were incubated in the 1X High 
Temp wash buffer at 58°C for 10 minutes, followed by washing in the E1BC solution 
for 5 min, 100% ethanol for 10 min and E1BC solution for 2 min. Blocking with the 
Block E1 buffer for 10 min at RT was then performed. Next, Streptavidin-Cy3 
labelling was carried out in the dark (2 uL of Streptavidin-Cy3 in 2 ml of Block E1 
buffer) for 10 min. Beadchips were then washed in E1BC solution for 5 min, spun dry 
at 275 rcf for 4 min and finally scanned with the Illumina® BeadArray Reader on the 
same day. 
 
2.6.4 Gene Expression Analysis using GeneSpring GX 11.0 
Illumina® BeadStudio software was used to extract the raw image data from 
the scanned beadchips. The gene expression data was exported as sample probe 
profiles in a GeneSpring GX 11.0 compatible text file format, with background 
subtraction but no normalization. The text file was then imported into GeneSpring GX 
11.0 for further gene expression analysis.  
 
	   44	  
For E12.5 and E13.5 Pax1-null vs WT & GFP(+) vs GFP(-) comparisons 
Criteria for flagging entities were chosen as follows: “present” – detection p-
value > 0.8;  “absent” – detection p-value < 0.6; and “marginal” – values in between 
“present” and “absent”. Negative raw values were set to a minimum threshold of 1.0 
and a 75% percentile shift. The entities were filtered by flags, including only those 
that fell in the “present” and “marginal” categories in at least one out of total number 
of samples. A gene-level analysis was performed and the entities were further filtered 
by raw expression data, including those that were between 20-100th percentile in at 
least one out of the total number of samples. WT B1 (E12.5) biological replicate was 
found to be an outlier and hence removed from further analyses. Pair-wise 
comparison was made with unpaired Studentʼs t-test for Pax1+/E (WT) vs Pax1-/- for 
E12.5 and E13.5 samples. For GFP(+) vs GFP(-) comparisons, one-way ANOVA 
statistical testing was performed since it involved the comparison of more than one 
pair of samples (GFP(-) vs WT, Pax1+/- and Pax1-/-). Multiple testing correction was 
performed on the p-values with the Benjamini Hochberg False Discovery Rate (B-H 
FDR) and all entities with p-value < 0.05 and a fold change of ≥ 1.5 were defined as 
significant.   
For multiple allele KO study (Pax1-/-Pax9+/- and Pax1-/-Pax9-/-): 
For the Pax1-/-Pax9+/- and Pax1-/-Pax9-/- embryos, only 1.1 ug of biotin-labelled 
cDNA could be produced for each biological replicate from the extracted RNA. This 
was still within the recommended amount of cDNA for hybridization on Illumina Chips 
(750 ng -1.5 ug). Owing to time and fiscal constraints new Pax1+/E (WT) and Pax1-/- 
samples could not be collected. Hence, the cDNA of WT (Pax1+/E) and Pax1-/- left-
over from the biological replicates used in the prior analysis (E12.5 Pax1-/- vs WT) 
were biotin-labelled and used in the new microarray chips alongside the multiple-
allele KOs, at a constant cDNA amount of 1.1 ug for each sample (3 biological 
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replicates each). Since the Pax1+/E  (WT) and Pax1-/- samples were stored in the 
cDNA form at -20oC for only a short period, degradation should be minimal.  
The raw intensity data from the new microarray analysis (E12.5 Pax1+/E, 
Pax1-/-, Pax1-/-Pax9+/- and Pax1-/-Pax9-/- - at 1.1ug) and old microarray analysis 
(E12.5 Pax1+/E, Pax1+/- and Pax1-/-) were loaded onto GeneSpring GX 11.0 software 
and quantile normalized. The quantile normalization method successfully mitigated 
any batch effect and differences owing to the DNA amount used, with any difference 
between the new and old batch to be defined by just ~19% in the Principal 
Component Analysis (PCA). Also, combining both data sets improved the statistical 
strength of the WT and Pax1-/- samples (from 3 biological replicates to 8 biological 
replicates) and hence the accuracy of the results. WT B1 (E12.5) biological replicate 
was an outlier and was removed from all further analyses. 
Again, all entities were filtered by flags (including only those that fell in the 
“present” and “marginal” categories). A gene-level analysis was performed and the 
entities were filtered by expression (including only those that were between 20-100th 
percentile in at least one out of the total number of samples). Multiple pair-wise 
comparisons were made with Welch, one-way ANOVA (unequal variance) statistical 
testing, with Benjamini Hochberg False Discovery Rate (B-H FDR) multiple testing 
correction on the p-values. All entities with p-value < 0.05 and a fold change of ≥ 1.5 
were defined as significant.   
Functional annotation clustering was performed on the microarray results 




	   46	  
2.7 Chromatin Immunoprecipitation – Sequencing (ChIP-Seq) 
2.7.1 Tissue Harvesting and Cross-linking 
The vertebral column tissues were dissected from staged (based on M.H. 
Kaufmann, Theiler morphological criteria) E12.5 and E13.5 CD-1 WT mouse 
embryos (about 50 embryos) in ice-cold Leibovitz medium. The dissected tissues 
were pelleted at 1,100g for 5 min at 40C and resuspended in 10 mL of ice-cold 
1xPBS. Tissues were then homogenized using a pre-chilled 15 mL Douncer. Tissues 
were then washed once with ice-cold 1xPBS and pelleted at 1,100g for 5 min at 40C. 
Pellet was weighed and resuspended in 10x volume of 1x PBS at RT. One-tenth the 
volume of cross-linking buffer (11% Formaldehyde) was added to the resuspended 
cell suspension and incubated for 10 min on a nutator at RT. Cross-linking was 
stopped by adding one-tenth the volume of 2.5 M of Glycine solution. Cross-linked 
tissue was then pelleted and washed once with ice-cold 1x PBS at 1,100g for 5 min 
at 40C. Cell suspension was homogenized again on the Douncer before one more 
wash in ice-cold 1xPBS. Cells were then pelleted, weighed and snap frozen in liquid 
nitrogen before being stored at -80oC until futher use. Cross-linked tissue samples 
can be stored for up to 6 months in -80oC. 
 
 
2.7.2  Binding of Antibodies to Magnetic Beads 
Antibodies of interest (Pax1: SC-25407X (M116X) or Pax9: SC-25410X (H-95 
X)) were conjugated to magnetic Dynabeads® Protein G (Invitrogen; Cat. 100.04D).  
Cross-linking buffer (11% formaldehyde) 
Final concentration Reagents 
100 mM   NaCl 
50 mM Hepes-KOH (pH7.5) 
1 mM EDTA (pH 8.0) 
0.5 mM EGTA (pH 8.0) 
11% Formaldehyde 
- Water 
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100 uL of dynabeads were used per immunoprecipitation reaction (IP). The beads 
were washed thrice in 1 mL of pre-chilled blocking solution (0.5% BSA) and 
incubated with 5 µg of rabbit IgG (ab46540) in 250 uL of   blocking solution and 
rotated 360o   for 6 hrs at 4oC  for use in the pre-clearing step later. In parallel, another 
set of tubes were set up for antibody conjugation with 10 ug of the Pax1 or Pax9 
antibodies for 7 - 24 hrs in a similar manner. Lysis of cross-linked cells and 
sonication of the chromatin was performed during the bead conjugation process.  
 
2.7.3  Cell Lysis, Sonication, Pre-clearing and Chromatin Immunoprecipitation 
• Cell lysis 
The cross-linked samples that were stored in -80oC were thawed on ice and 
resuspended in 10x the volume of pellet in lysis buffer 1 (LB1; with protease 
inhibitors; Roche #11697498001) and nutated for 10 min at 40C. Cell debris was 
cleared by centrifuging the samples at 1,350 g for 5 minutes at 40C. Samples were 
then resuspended in lysis buffer 2 (LB2; with protease inhibitors) at an equal volume 
as LB1 and incubated for 10 min at RT. Cell nuclei were obtained by pelleting the 
sample at 1,350 g for 5 minutes at 40C. Nuclei pellet was weighed again and 
chromatin was obtained by lysing the nuclei with 10x the volume of lysis buffer 3 
(LB3; with protease inhibitors).  
 
• Chromatin Sonication 
The nuclear lysates were sonicated in a 15 mL bacterial culture tube with 1 
mL of glass beads (BioSpec Products; #11079105)  per 2-3 mL of lysate using 
Branson Digital Sonifier® in the cold room. Samples were kept on ice throughout the 
sonication process (sonication condition: ON: 15sec; OFF/REST: 30 sec; 20 cycles; 
amplitude: 40%; total effective sonication = 5min; total time = 15min). The chromatin 
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was sheared to a size range of 100-500bp, and transferred to a 2 mL microcentrifuge 
tube. Triton X-100 was added to a final concentration of 1% and samples were spun 
at 13200 rpm for 10 min at 4oC to remove any debris. The chromatin concentration 


















The sheared chromatin ( 2 mg per IP) was precleared in a pre-washed, IgG-
conjugated beads for 1 hr at 4˚C, rotating at 360°. The volume was kept constant for 
all IP reactions at 2 mL by topping up with LB3 containing 1% Triton X-100. From the 
pre-cleared sample, 1% of the volume was reserved as input and stored at -80oC 
until the de-crosslinking step. 
Lysis buffer 1 (LB1) + 1x Protease inhibitors 
Final Concentration Reagents 
50 mM Hepes-KOH, pH 7.5 
140 mM NaCl 
1 mM EDTA 
10% Glycerol  
0.50% Igepal CA630 
0.25% Triton X-100  
-  Water 
Lysis buffer 2 (LB2) + 1x Protease inhibitors 
Final Concentration Reagents 
10 mM Tris-HCl, pH 8.0 
200 mM NaCl 
1 mM EDTA 
0.5 mM EGTA 
- Water 
Lysis buffer 3 (LB3) + 1x Protease inhibitors 
Final Concentration Reagents 
10 mM Tris-HCl, pH 8.0 
100 mM NaCl 
1 mM EDTA 
0.5 mM EGTA 
0.10% Na-Deoxycholate 
0.50% SDS 
 - Water 
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• Chromatin immunoprecipitation (IP) 
The pre-cleared supernatant was transferred to tubes containing the pre-washed 
antibody-conjugated beads. Samples were then rotated 360° overnight at 4˚C for 
immunoprecipitation.  
 
2.7.4  Wash, Elution and Reverse Cross-link 
 After the overnight IP, the beads were washed with 1 mL of wash buffer for 5 
min at 4°C with 360° rotation.  The beads were then magnetized, supernatant was 
discarded, and the wash was repeated 6 more times. Next, the beads were washed 
once with 1 mL of TE buffer in the same way. The IP chromatin was eluted from the 
beads by incubation at 65°C for 30 min in 210 uL of elution buffer with vigorous 
agitation at 1,400 rpm. The eluate (supernatant) was then de-crosslinked overnight at 
65°C. The 1% of input pre-cleared chromatin that was reserved earlier was also de-













Wash Buffer + 1x Protease inhibitors 
Final 
Concentration Reagents 
50 mM Hepes-KOH, pH 7.6 
500 mM LiCl 
1 mM EDTA 
1% NP-40 
0.70% Na-Deoxycholate 
 - Water 
TE buffer 
Final Concentration Reagents 
10mM  TRIS pH8.0 
1mM EDTA, pH8.0 
50mM  NaCl 
 - Water 






2.7.5  ChIP DNA Clean Up 
 To the de-crosslinked samples (including the input sample), 200 uL of TE 
buffer and RNase A (final concentration of 0.2 ug/mL) were added and incubated for 
2 hrs at 37oC to remove all RNA.  Samples were then incubated for another 2 hrs 
with Proteinase K (final concentration of 0.2 ug/mL) at 55°C to remove all protein. 
The samples were then transferred to MaXtract High Density tubes (QIAGEN 
Cat.#129046) and an equal volume of phenol: chloroform: isoamyl alcohol (pH 7.9) 
was added and vigorously agitated for 30 sec. The organic and aqueous phases 
were thus separated by centrifugation at 15,800 rcf for 5 min at RT. The aqueous 
layer was decanted into fresh 1.5 mL microcentrifuge tubes and NaCl (final 
concentration of 200 mM) and glycogen (30 ug) were added per sample. 
Precipitation of the samples was carried out with 800 uL of 100% ethanol for 30 min 
at -80°C. Thereafter, samples were spun at 13200 rpm for 10 min at 4°C, and the 
pellet was washed with 80% ethanol. The pellets were air-dried and resuspended in 
30 uL of 10mM Tris-HCl, pH 8.0 each. The purified DNA was quantitated using 
Nanodrop spectrophotometer. 
 
 2.7.6  ChIP-Seq DNA Library Preparation 
The quantitated DNA from IP was used for library construction suitable for 
Illuminaʼs Solexa Sequencer cluster amplification and sequencing platform. Library 
was prepared according to the in-house protocol using the NEBNext® ChIP-Seq 
Elution buffer 
Final Concentration Reagents 
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
1% SDS 
 - Water 
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Sample Prep Reagent kit (#E6200S). Briefly, 15ng of ChIP DNA fragments were end-
repaired and adenosine ʻAʼ base overhang was added at the 3ʼ end of the fragments. 
Illuminaʼs universal adaptors were added to the ends of the fragments, and amplified 
by PCR using adaptor-specific primers. The PCR-products were then size selected 
on a 2% agarose gel and gel purified using QIAGEN gel purification kit (Cat #28704).  
Samples were eluted with 20 uL of EB buffer. The ChIP DNA libraries were checked 
for their quantity and quality using Agilent Bioanalyzer DNA 1000 chip kit (Cat #5067-
1504). From the sequencing results peak calling, binding site distribution and motif 
analyses were performed by Sun Wenjie and Hu Xiaoming from our collaboratorʼs (Dr 
Shyam Prabhakar) lab. 
 
2.8 Embryo Processing for Histology 
Freshly dissected mouse embryos from the uterine horn were rinsed with cold 
Lebovitz medium and fixed overnight at 4°C in 4% paraformaldehyde (PFA) in PBS 
(DEPC-treated). The following day, embryos were washed with 1xPBS (DEPC-
treated) for 10 min at RT and dehydrated through an ethanol gradient of 50% 
ethanol/ PBS and 70% ethanol/ PBS for 15 min each at RT. Embryos were then 
processed in an automated tissue processor (Leica TP 1020), embedded in paraffin 
and sectioned to 10 uM thickness using the microtome (Leica RM 2165). 
Tissue processing program 
Reagents Time 
70% Ethanol 30 min 
95% Ethanol 15 min 
95% Ethanol 15 min 
100% Ethanol 1 hr 
100% Ethanol 2 hrs 
100% Ethanol 2 hrs 
HistoclearTM  (National diagnostics; #HS-200) 30 min 
HistoclearTM 30 min 
HistoclearTM 30 min 
Paraffin (with vacuum) 2 hrs 20 min 
Paraffin (with vacuum) 3 hrs 
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2.9 Section In-Situ Hybridization (SISH) 
§ RNA Probe Synthesis 
The DIG-labelled RNA probes for sectioned-in-situ hybridization were 
prepared using the DIG RNA labelling kit (Roche, Cat.#11 175 025 910) according to 
manufacturerʼs protocol. All the cDNA clones used as templates for the probe 
synthesis were purchased from Open BioSystems. After in vitro transcription, the 
reaction was stopped with EDTA (final concentration of 0.04 M) and purified using 
QUICK spin columns Sephadex G-50 (Roche cat #11274015001). The purified 
samples were then precipitated with NaOAc, pH 5.5 (final concentration of 0.3 M) 
and 100% ethanol (2.5x the total volume of reaction). The samples were precipitated 
in -20oC for 30 min before pelleting at 13,200 rpm for 10 min at 4oC and washing 
once with 70% ethanol (RNase-free). RNA probe pellets were air-dried and 
resuspended in 30 uL RNase-free water. The integrity of the probes was checked by 
resolving on a 0.8% agarose gel and then samples were quantified using the 
Nanodrop spectrophotometer. 
 
§ Section Pre-treatment, Pre-hybridization and Hybridization 
The paraffin embedded mouse embryos were sectioned (10 uM thickeness) 
onto polysine-coated slides and air-dried before use. The slides were de-waxed 
using the HistoclearTM (20 min) and rehydrated through an ethanol gradient of 5 min 
each (100%, 90%, 70% and 30% ethanol) before washing twice with 1xPBS (DEPC-
treated). The tissues were post-fixed in 4% PFA at RT for 20 min, washed again in 1x 
PBS, before proteinase K digestion (final concentration of 10 ug/mL in 0.1 M Tris, pH 
7.5) for 10 min at RT. The slides were washed in 1x PBS and fixed again for 10 min 
in 4% PFA at RT. Following post-fixing the slides washed and allowed to pre-
hybridize in the pre-hybridization buffer at 67oC for 2-3 hrs before an overnight 
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hybridization with the appropriate DIG-labelled RNA probes (concentration ranging 
from 50 – 1000 ng/mL based on transcript abundance) at 67oC.  
 
§ Post-hybridization Washes and Probing with anti-DIG Antibody 
Following the overnight hybridization, the slides were washed in pre-warmed 
Solution 1 thrice, for 30 min each, at the same temperature as hybridization (67oC). 
The slides were further washed in TNT buffer thrice for 5 min each at RT, once in 
TNT:Solution 2 (1:1 mixture) for 5 min at RT and finally in pre-warmed Solution 2, 
thrice for 30 min each, at 63oC (4oC less than the hybridization temperature). 
Thereafter, the slides were washed thrice in MABT for 5 min each before blocking 
with 2% blocking solution for 2 – 3 hrs at RT and incubation overnight with alkaline 
phosphatase (AP)-conjugated anti-DIG antibody (1 in 2000 dilution in 2% blocking 






Final Concentration Reagents 
50% Formamide (Roche; Cat#11814310001) 
5X  SSC (1st Base) 
1X 50X Denhardtʼs (5g Ficoll, 5g BSA and 5g 
Polyvinylpyrrolidine in 500 mL of RNase-free 
water) 
0.1 % Tween20 
0.1 mg/mL Yeast tRNA (Ambion; Cat# AM7118) 
0.05 mg/mL Heparin 
- RNase-free water 
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Solution 1 
Final Concentration Reagents 
50% Formamide 
5X SSC (pH 4.5 or 7) 
1% SDS 












§  Post-Antibody Washes and Colour Development 
The following day, the slides were washed with MABT thrice for 10 min each 
at RT and washed thrice more for 1 hr each. The slides were then washed with 
freshly prepared NTMT solution thrice for 10 min each before colour development 
with NBT/BCIPsubstrate (Roche; Cat#11681451001; 200 uL of stock diluted in 10 mL 
of 0.1 M Tris-HCl, pH9.5 and 0.1 M NaCl). The slides were incubated in the dark at 
RT until the desired intensity of colour had developed. The slides were then washed 
in 1xPBS, twice for 10 min each, before they were mounted with an aqueous-based 
mounting medium, glycerol gelatin (SIGMA cat # 128K6296). All sections were 




Final Concentration Reagents 
10 mM Tris HCl pH 7.5 
0.5 M  NaCl 
0.1% Tween20 
- RNase-free water 
Solution 2 
Final Concentration Reagents 
50% Formamide 
2X SSC (pH 4.5 or 7) 
0.2% SDS 
- RNase-free water 







2.10 Immunohistochemistry (IHC) 
Similar to SISH, the paraffin sections on the polysine-coated slides were de-
waxed using the HistoclearTM (20 min) and rehydrated through an ethanol gradient of 
5 min each (100%, 95%, 90% and 70% ethanol).  Antigen retrieval was performed in 
0.01 M sodium citrate buffer (pH 6.0) at 121oC for 15 min. After cooling the slides for 
3 hrs, the slides were washed twice with 1x PBS before marking the required 
sections with an immuno-pen. The slides were next incubated with 0.6% hydrogen 
peroxide for 20 min at RT (protected from light) and washed twice with 1x PBST 
(0.2% tween-20) for 5 min each. Blocking of non-specific binding sites were carried 
out with blocking serum provided in the Vectastain® ABC kit (Vector Laboratories; cat 
# PK-4002) for 30 min at RT and then with 2% BSA/ 5% sheep serum in PBS for 
another 30 min at RT. Thereafter, the slides were incubated overnight with the 
primary antibodies (dilutions: Pax1: SC-25407X (M116X) – 1:200; Pax9: SC-25410X 
(H-95 X) – 1:200; GFP: SC-9996 (B-2) - 1:50; HA epitope: AP09230PU-N, 1:200) at 
4oC. 
The following day, the slides were allowed to incubate in the primary antibody 
at RT for another 1 hr before washing in 1xPBST (0.1% Tween20) thrice for 5 min 
each. The slides were then incubated with the appropriate secondary antibodies 
(biotinylated bovine anti-rabbit IgG-B – SC-2363 - 1:400; horse anti-mouse IgG – 









- RNase-free water 
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Meantime, the A+B complex was prepared by mixing reagents A and B (1:100 
dilution) provided in the Vectastain® ABC kit and incubated at 4oC for 1 hr. The slides 
were then washed thrice with 1xPBST (0.1% Tween20) before incubation for 1 hr 
with the A+B complex at RT. Thereafter, the slides were washed extensively thrice 
with 1xPBST (0.1% Tween20), 5 min each, 1xPBS for 10 min and 1x TBS for another 
10min. Colour development was then carried out with DAB substrate (BD 
Biosciences PharmigenTM DAB substrate kit, cat # 550880) at RT, until the desired 
signal/noise ratio was obtained. The slides were next washed in running tap water for 
5 min before they were mounted with aqueous-based mounting medium (glycerol-
gelatin). All the sections were imaged with Zeiss Axio Imager Z1. 
 
2.11 Alcian Blue staining  
The paraffin mouse sections were de-waxed in HistoclearTM (20 min) and re-
hydrated through ethanol gradient (100%, 90%, 70% and 50% ethanol/PBS) for 3 
min each.  The slides were washed for 5 min in 1xPBS before a brief rinse in tap 
water and incubation in alcian blue staining solution for 30 min at RT before washing 








Alcian Blue staining solution 
Final Concentration Reagents 
1% Alcian Blue 8GX (SIGMA – A3157-10G) 
3% Acetic acid 
- Water 
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CHAPTER 3 – RESULTS AND DISCUSSIONS 
3. Generation of Transgenic Mouse Lines  
3.1. Construct Design Strategy 
To perform an in vivo study using the mouse as model system, there was a 
requirement to generate the appropriate transgenic mouse lines via gene targeting 
technique. Since the principal objective of this study was to perform a cell-type 
specific gene expression analysis to identify the target genes of Pax1 and Pax9, 
enrichment of specific populations of cells had to be performed. This evidently called 
for the co-expression of the TF-of-interest with a reporter protein as that would 
enable us to isolate very pure populations of cells through Fluorescence Assisted 
Cell Sorting (FACS). In this study, EGFP was the primary choice as the reporter 
protein owing to its highly photostable nature and it is also known to be one of the 
brightest fluorescent proteins [89].  
Traditionally, to disrupt a gene or to tag it with a reporter protein, the reporter 
protein (eg. EGFP) is simply inserted into the exon of the gene or at the end of the 
last exon (in frame), before the stop codon. This however leads to the production of 
fusion proteins. The drawback with such a strategy is that fusion proteins may 
become misfolded, resulting in a lower level of EGFP fluorescence expression or an 
absolute lack of EGFP fluorescence and a non-functional gene product. This paved 
the way for the use of bi- or poly-cistronic constructs whereby multiple ORFs can be 
concatenated to co-express multiple proteins from a single promoter, without the 
production of fusion proteins. The viral internal ribosome entry site (IRES) sequence 
and 2A oligopeptide sequences (commonly the F2A peptide) are currently the 
popular choices in generating polycistronic vectors [90]. Both of the elements 
function by different mechanisms.  
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When the IRES element is inserted between two open reading frames 
(ORFs), the translation of the first ORF is initiated by a cap-dependent mechanism, 
whereas the second one occurs by a cap-independent mechanism [91]. On the other 
hand, the 2A peptides are self-cleaving, which function by a “ribosomal skipping” 
mechanism. In brief, a 24 amino acid long 2A peptide sequence is inserted between 
two ORFs (consensus motif of 2A peptide: DxExNPG↓P- (↓) represents the position 
of ʻskippingʼ). The ribosome begins translation by a cap-dependent mechanism but 
when it reaches the motif sequence, it fails to form the peptide bond between the 
glycine (G) and proline (P) residues, then continues to translate the second ORF. 
This “skip” results in the production of two discrete proteins [92, 93].  The schematic 











Figure 7: Illustration of F2A-peptide strategy in concatenating ORFs. Pax1 is 
used as an example for this illustration. E – exon; Neo – neomycin.  
 
While performing this study, the efficiency of the 2A-peptides and IRES 
elements in co-expressing concatenated proteins at equal levels were also being 
investigated, in an in vivo system, using other transgenic mouse lines (co-first 
authored publication; the findings have been published in [94]). Since the IRES 
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elements were the conventional choice in making the bi- or poly-cistronic vectors, the 
initial strategy was to use the IRES elements to concatenate the Pax1 and EGFP 
cistrons (Pax1IE/IE) to generate the Pax1 WT allele tagged with EGFP. Subsequently, 
through the extensive analysis of the other mouse lines, it was discovered that both 
IRES element and the F2A peptide reliably co-expressed the linked proteins. 
However, the F2A peptide was more efficient at producing stoichiometric (equal) 
levels of the linked proteins compared to the IRES element. The IRES element gave 
a consistently lower level of EGFP expression compared to the upstream protein 
[94]. Since Pax1 and Pax9 are expressed at moderate levels, and only in a limited 
number of cells, the strategy that will express EGFP at sufficiently detectable levels 
was opted for to ensure that the Pax1 and Pax9-specific cells could be efficiently 
enriched by FACS. Hence, for all the subsequent constructs to knock-out the Pax1 or 
Pax9 (Pax1 KO and Pax9 KO), the F2A peptide strategy was utilized. Notably, the 
use of F2A strategy will ensure the inhibition of Pax1 or Pax9 protein synthesis 
without disrupting any of the intronic regions in the genome, which may contain 
essential cis-regulatory elements. Also, to keep the study consistent, construct with 
the WT (Pax1) allele tagged with EGFP using the F2A peptide strategy (Pax1E/E) was 
generated.  
 
3.2  Generation of Pax1 and Pax9 tagged and knock-out mouse lines 
To perform cell-type specific gene expression profiling analyses, several 
mouse lines were generated with the Pax1 WT allele tagged with the EGFP reporter 
or knocked-out Pax1/ Pax9 using the EGFP reporter. 
BAC recombineering technology was employed to generate all the Pax1 and 
Pax9 constructs (listed in Table 4). The details of the construct(s) synthesis are 
described in the Materials & Methods section. The construct design, Southern 
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blotting confirmation strategy and the PCR primer pairs used for genotyping the mice 
are shown in Figures 8-12. Since the Pax9 heterozygotes did not show any vertebral 
column defects, an analysis of Pax9 WT vs Pax9-/- was not performed.  
For all the constructs, successfully modified BACs were screened carefully for 
potential mutations / deletions before being subcloned into a minimal vector, 
linearized and electroporated into mESCs (R1 or V6.4 cells). The modified and 
subcloned BACs were electroporated into mouse ES cells and were selected in G418 
medium for 8-10 days. Correctly targeted ES cell clones were identified by Southern 
blotting and/or PCR screening. External Southern probes were used to identify the 
clones that were correctly targeted, while internal probes were used to detect the 
clones which also had random integration of the cassettes (Figures 8-12). The ES 
clones were karyotyped and microinjected into 8-cell stage mouse embryos, which 
were then implanted into pseudo-pregnant mice. Chimeras were obtained and 
confirmed either by coat colour or PCR screening and mated with C57BL/6J (WT) to 
obtain the heterozygotes and subsequently the homozygotes by mating the 
heterozygotes. All the genotyping of the mice was first carried out by Southern 
blotting and subsequently confirmed by PCR screening. 
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3.2.1 Pax1IE/IE and Pax1E/E  - WT mice tagged with EGFP 
 
To tag the WT allele with EGFP, either the F2A-EGFP-FRT-PGKgb2-Neo-
FRT cassette or the IRES-EGFP-FRT-PGKgb2-Neo-FRT cassette was inserted by 
homologous recombination in the respective BAC clones. In both the cassettes, the 
Neomycin (Neo) resistance (selection marker) gene was expressed under the PGK-
gb2 promoters (a dual eukaryotic-prokaryotic promoter) to enable the selection of 
correctly targeted clones in both the bacterial system (for BAC modification) as well 
as the mammalian system (ES cell colonies). FRT sequences flanked the PGKgb2-
Neo sequence to enable the removal of the Neo through FLPe-mediated 
recombination.  
For the F2A-construct (Pax1E/E – Figure 8), the cassette was inserted 
immediately before the stop codon (in frame) in the Exon 5 of Pax1. As for the IRES 
constructs (Pax1IE/IE - Figure 9), the cassette was inserted at the 3ʼUTR (untranslated 
region) of the Pax1. 
 In the F2A-based cassettes (F2A-EGFP-FRT-PGKgb2-Neo-FRT), a RAKR-
GSG sequence was appended before the F2A peptide sequence (i.e. RAKR-GSG-
F2A-EGFP-FRT-PGKgb2-Neo-FRT). Since the “skipping” mechanism in the F2A 
peptide causes a 23 amino acid sequence to be fused to the C-terminal end of the 
upstream-concatenated protein, a furin protease recognition sequence (RAKR) was 
included immediately before the F2A peptide sequence. This RAKR sequence was 
used to trim the residual 2A peptide from the upstream protein, thus leaving only two 
additional amino acids (arginine and alanine) at the C-terminus of the Pax1 protein 
[95].  Moreover, a Gly-Ser-Gly (GSG) spacer was added after this RAKR sequence 
(just before the F2A sequence) in order to enhance the translational “skipping” [96]. 
 
 













Figure 8: Construct design and confirmation strategy for Pax1E/E. (A) The 
construct design whereby the F2A-EGFP-FRT-PGKgb2-Neo-FRT cassette was 
inserted at the 3ʼ end immediately before the translational stop codon of Pax1. Short 
and long homology arms of 2,344 bp and 8,499 bp were used for subcloning. The 
Southern probes (external – outside the homology arm and internal – within the 
homology arm) were designed in a repeat-free region. The expected band sizes (with 
a SacI restriction enzyme digestion) were 4,646 bp for a mutant band (correctly 
targeted) and 7,321 bp for a WT band. Restriction enzyme digestion sites are shown 
in red; location of the PCR primer pairs used for genotyping are indicated with black 
arrows; homology arms are represented as grey boxes. The legend on the right 
indicates the color coding for the external and internal Southern probes and the detail 
of the EGFP cassette. (B) Southern blotting result of genomic DNA extracted from ES 
cell colonies and digested with SacI restriction enzyme. Top - the blot probed with the 
external Southern probe; bottom - the blot probed with the internal Southern probe. 
(C) The primer pairs used and the corresponding PCR product sizes for genotyping 
of the genomic DNA extracted from the mouse tail tips or the yolk sac. Targeting 
efficiency of the construct in R1 cells was 10.9%. WT – wild-type; Mut – mutant; E5 – 


































Figure 9: Construct design and confirmation strategy for Pax1IE/IE. (A) The 
construct design whereby the IRES-EGFP-FRT-PGKgb2-Neo-FRT cassette was 
inserted at the 3ʼ UTR of Pax1. Short and long homology arms of 2,344 bp and 8,475 
bp were used for subcloning. The Southern probes (external – outside the homology 
arm and internal – within the homology arm) were designed in a repeat-free region. 
The expected band sizes (with a StuI restriction enzyme digestion) were 7,810 bp for 
a mutant band (correctly targeted) and 10,407 bp for a WT band. Restriction enzyme 
digestion sites are shown in red; location of the PCR primer pairs used for 
genotyping are indicated with black arrows; homology arms are represented as grey 
boxes. The legend on the right indicates the color coding for the external and internal 
Southern probes and the detail of the EGFP cassette. (B) Southern blotting result of 
genomic DNA extracted from ES cell colonies and digested with StuI restriction 
enzyme. Top - the blot probed with the external Southern probe; bottom - the blot 
probed with the internal Southern probe. (C) The primer pairs used and the 
corresponding PCR product sizes for genotyping of the genomic DNA extracted from 
the mouse tail tips or the yolk sac. Targeting efficiency of the construct in R1 cells 
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3.2.2 Pax1KO and Pax9 KO mice  
 
To knock-out the Pax1 and Pax9 genes, the F2A-EGFP-FRT-PgKgb2-Neo-FRT 
cassette was inserted in Exon 2 of Pax1 and Pax9, 3 amino acids after the start of 
the second exon, by homologous recombination in the respective BAC clones 
(Figures 10 and 11). The Exon 2 of both Pax1 and Pax9 contain the conserved 
paired-box (DNA-binding domain) that is crucial for the function of these TFs. Also, 
targeting the Exon 2 will disrupt all the transcripts of Pax1 and Pax9 to give a full 













Figure 10: Construct design and confirmation strategy for Pax1 KO (Pax1-/-). (A) 
The construct design whereby the F2A-EGFP-FRT-PGKgb2-Neo-FRT cassette was 
inserted in the second exon of Pax1, 3 amino acids after the start of the second 
exon. Short and long homology arms of 2,322 bp and 13,334 bp were used for 
subcloning. The Southern probes (external – outside the homology arm and internal 
– within the homology arm) were designed in a repeat-free region. The expected 
band sizes (with EcoRI restriction enzyme digestion) were 5,138 bp for a mutant 
band (correctly targeted) and 6,918 bp for a WT band. Restriction enzyme digestion 
sites are shown in red; location of the PCR primer pairs used for genotyping are 
indicated with black arrows; homology arms are represented as grey boxes. The 
legend on the right indicates the color coding for the external and internal Southern 
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probes and the detail of the EGFP cassette. (B) Southern blotting result of genomic 
DNA extracted from ES cell colonies and digested with EcoRI restriction enzyme. 
Top - the blot probed with the external Southern probe; bottom - the blot probed with 
the internal Southern probe. (C) The primer pairs used and the corresponding PCR 
product sizes for genotyping of the genomic DNA extracted from the mouse tail tips 
or the yolk sac. Targeting efficiency of the construct in R1 cells was 13.0%. WT – 
























Figure 11: Construct design and confirmation strategy for Pax9 KO (Pax9-/-). (A) 
The construct design whereby the F2A-EGFP-FRT-PGKgb2-Neo-FRT cassette was 
inserted in the second exon of Pax9, 3 amino acids after the start of the second 
exon. Short and long homology arms of 2,378 bp and 15,341 bp were used for 
subcloning. The Southern probes (external – outside the homology arm and internal 
– within the homology arm) were designed in a repeat-free region. The expected 
band sizes (with EcoRI restriction enzyme digestion) were 4,595 bp for a mutant 
band (correctly targeted) and 6,743 bp for a WT band. Restriction enzyme digestion 
sites are shown in red; location of the PCR primer pairs used for genotyping are 
indicated with black arrows; homology arms are represented as grey boxes. The 
legend on the right indicates the color coding for the external and internal Southern 
probes and the detail of the EGFP cassette. (B) Southern blotting result of genomic 
DNA extracted from ES cell colonies and digested with EcoRI restriction enzyme. 
Top - the blot probed with the external Southern probe; bottom - the blot probed with 
the internal Southern probe. (C) The primer pairs used and the corresponding PCR 
product sizes for genotyping of the genomic DNA extracted from the mouse tail tips 
or the yolk sac. Targeting efficiency of the construct in V6.4 cells was 5.2%. WT – 
wild-type; Mut – mutant; E2 – exon 2. 
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3.2.3 Pax1HA3 and Pax9HA3 - WT mice tagged with triple HA epitope 
 
For in vivo ChIP-seq studies, endogenous tagging of the WT Pax1 and Pax9 
alleles was required. The HA epitope (YPYDVPDYA) is from the hemagglutinin 
protein which is a surface glycoprotein of the influenza virus [97, 98]. It was chosen 
for to its small size (9 amino acids) and the availability of good commercial HA 
antibodies for ChIP. Triple tandem repeats of the HA epitope were used so as to 
increase the sensitivity of detection.  
The 3xHA-loxP-Neo-loxP cassette was inserted just before the stop codon in 
Exon 5 of Pax1 and Exon 4 of Pax9 by homologous recombination in the respective 
BAC clones (Figures 13 and 14). The C-terminal end was chosen for this epitope 
tagging so as to minimize potential interference of the epitope with the protein 
folding. This way, the multiple protein-coding transcripts of the Pax1/Pax9 can also 
be successfully tagged. For Pax9, both the protein-coding transcripts (Pax9-001 and 
Pax9-201) were tagged this way, whereas for Pax1, only one of the two transcripts 
(Pax1-001) could be tagged. Pax1-002 transcript could not be tagged owing to its 
inherent nature whereby it differs from the other transcript at both the N-terminal and 
C-terminal ends (Figure 12) (Ref: Ensembl genome browser). Moreover, the C-
terminal was preferred over the N-terminal end since a successful detection of the 
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Figure 12: Pax1 and Pax9 transcripts targeted for triple HA epitope tagging. 
Pax1-001 and Pax1-002 transcripts differ at the N-terminal and C-terminal ends. 
Pax9-001 and Pax9-201 transcripts are identical in terms of their translational start 
and stop sites. Only the protein-coding transcripts for each gene are shown. Ref: 










































Figure 13: Construct design and confirmation strategy for Pax1HA3. (A) The 
construct design whereby the HA3-loxP-PGKgb2-Neo-loxP cassette was inserted 
at the 3ʼ end of Pax1, immediately before the translational stop codon. Short and 
long homology arms of 2,344 bp and 8,499 bp were used for subcloning. The 
Southern probes (external – outside the homology arm and internal – within the 
homology arm) were designed in a repeat-free region. The expected band sizes 
(with StuI restriction enzyme digestion) were 6,544 bp for a mutant band 
(correctly targeted) and 10,407 bp for a WT band. Restriction enzyme digestion 
sites are shown in red; location of the PCR primer pairs used for genotyping are 
indicated with black arrows; homology arms are represented as grey boxes. The 
legend on the right indicates the color coding for the external and internal 
Southern probes and the detail of the HA3 cassette. (B) Southern blotting result 
of genomic DNA extracted from ES cell colonies and digested with StuI 
restriction enzyme. Top - the blot probed with the external Southern probe; 
bottom - the blot probed with the internal Southern probe. (C) The primer pairs 
used and the corresponding PCR product sizes for genotyping of the genomic 
DNA extracted from the mouse tail tips or the yolk sac. Targeting efficiency of the 
































Figure 14: Construct design and confirmation strategy for Pax9HA3. (A) The 
construct design whereby the HA3-loxP-PGKgb2-Neo-loxP cassette was inserted at 
the 3ʼ end of Pax9, immediately before the translational stop codon. Short and long 
homology arms of 1,499 bp and 10,762 bp were used for subcloning. The Southern 
probes (external – outside the homology arm and internal – within the homology 
arm) were designed in a repeat-free region. The expected band sizes (with a StuI 
restriction enzyme digestion) were 3,735 bp for a mutant band (correctly targeted) 
and 9,488 bp for a WT band. Restriction enzyme digestion sites are shown in red; 
location of the PCR primer pairs used for genotyping is indicated with black arrows; 
homology arms are represented as grey boxes. The legend on the right indicates the 
color coding for the external and internal Southern probes and the detail of the HA3 
cassette. (B) Southern blotting result of genomic DNA extracted from ES cell 
colonies and digested with StuI restriction enzyme. Top - the blot probed with the 
external Southern probe; bottom - the blot probed with the internal Southern probe. 
(C) The primer pairs used and the corresponding PCR product sizes for PCR 
genotyping of the genomic DNA extracted from the mouse tail tips or the yolk sac. 
Targeting efficiency of the construct in V6.4 cells was 8%. WT – wild-type; Mut – 
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3.3 Assessment of Pax1 and Pax9 mouse lines  
Pax1 mice 
3.3.1 Phenotypes of the Pax1E/E and Pax1IE/IE adult mice 
The phenotypes of the adult mice for Pax1E/E and Pax1IE/IE were assessed. 
The adult mice were of normal size and resembled the WT mice, with no observable 
abnormalities (Figure 15). The Pax1E/E and Pax1IE/IE mice were also viable and fertile. 
To flox out the Neo, the F1 mice were crossed to homozygous Rosa26RFlpe mice.  
 
Figure 15: Pax1 WT mouse 
lines tagged with EGFP. (A) 
Picture of the adult Pax1E/E 
heterozygous and homozygous 
mice compared to the WT B6 
mouse; mice did not exhibit any 
abnormalities and were viable 
and fertile. (B) Picture of the 
Pax1IE/IE homozygous mouse 
compared to the WT mouse; 
mice were phenotypically normal, 
viable and fertile as expected. N 




3.3.2 Fluorescence expression pattern in the Pax1E/E and Pax1IE/IE embryos 
Next, the EGFP fluorescence expression pattern was assessed at various 
developmental stages for the heterozygote and homozygote Pax1E/E and Pax1IE/IE 
embryos, with or without Neo (Figure 17 and Figure 18). This was to ensure that the 
EGFP fluorescence expression pattern recapitulated endogenous Pax1 expression 
(Figure 16) and that the presence of Neo did not adversely affect it. As expected, all 
the heterozygote and homozygote embryos of Pax1E/E and Pax1IE/IE mouse lines 
exhibited fluorescence expression in the Pax1-specific domains. In general, 
expression was seen in pharyngeal arches, anterior proximal limb buds, sclerotome, 
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intervertebral disc of the vertebral column, craniofacial region, eyelid mesenchyme 
and thymus glands. Presence of Neo also did not affect the fluorescence expression 
patterns in the Pax1E/E embryos. All the embryos showed no defects in the vertebral 
column or the length of the tail. 
 
Figure 16: Pax1 mRNA 
expression pattern during 
different developmental stages. 
Whole-mount in situ hybridization of 
E11.5 to E13.5 embryos using Pax1 
anti-sense DIG-labelled RNA probe. 
Top panel – embryos at E11.5 
showed expression in the fore- and 
hind-limb buds, pharyngeal arch, the 
forebrain and the sclerotome. Fontal 
and dorsal views of the embryos are 
shown. Middle panel – embryos at 
E12.5 still exhibited expression in 
the fore- and hind-limb buds and the 
vertebral column. Expression in the 
craniofacial regions was also seen 
at this stage. Lower panel – 
embryos at E13.5 showed Pax1 
expression in the facial region and 
the vertebral column. Expression in 
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Figure 17: EGFP fluorescence expression of Pax1 in the Pax1+/E and Pax1E/E 
embryos of different developmental stages, with or without Neomycin. Row 1: 
Pax1+/E, Neo+ embryos: E9.5 embryo (white light image on the left; fluorescence 
image on the right) showed expression in the pharyngeal arches and the sclerotomal 
cells of the somites; E11.5 embryo showed expression in the sclerotome and the 
fore- and hind-limb buds. Expression in the hind limb bud appears obscured owing to 
the angle at which the embryo was positioned.  Row 2: in the E11.5 embryos, 
expression in the facial region was seen only in the Pax1E/E, Neo+ embryos, albeit 
weakly. E12.0 embryo showed expression in the facial mesenchyme, limb buds and 
the sclerotome. E13.5 embryos exhibited fluorescence expression likewise in the 
facial mesenchyme and the vertebral column. Expression in the limbs was seen in 
the Pax1E/E, Neo+ embryo. Rows 3 and 4: E16.5 Pax1E/E, Neo- embryo showed 
expression in the eye lid mesenchyme, nasal region and the tail. Corresponding 
white light image is shown on the right. The vertebral column still expressed Pax1 at 
E16.5 as shown in the dissected vertebral column. N – Neomycin; VC – vertebral 
column.  
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Figure 18: EGFP fluorescence 
expression of Pax1 in the 
Pax1+/IE and Pax1IE/IE, Neo+ 
embryos of various 
developmental stages. (A) 
E11.5 and E12.5 Pax1IE/IE 
fluorescing embryos with white 
light image of E12.5 embryo on 
the right. Expression was 
observed in the facial 
mesenchyme, the fore- and 
hind-limb buds and the vertebral 
column. (B) E13.5 Pax1IE/IE and 
Pax1+/IE fluorescing embryos 
with dorsal view on the right. (C) 
Frontal view of E13.5 Pax1IE/IE 
embryo on the left; ventral view 
of dissected vertebral column of 
the cervical region on the right. 
(D) Top panel – transverse 
section of vertebral column; 
bottom panel – thymus glands 
showed strong fluorescence. (E) 
Frontal view of E15.5 Pax1IE/IE 
embryo on the left, showed a 
tail of normal length; the entire 
dissected vertebral column of 
E15.5 and E13.5 Pax1IE/IE on 
the right. (F) Thymus glands of 
E15.5 Pax1IE/IE embryo showed 
Pax1 expression. Thymus 
glands appeared more rounded 
instead of the elongated 
appearance seen at E13.5. R – 
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3.3.3 Pax1 and Pax9 protein expression in the Pax1E/E embryos 
Besides the fluorescence expression pattern, the Pax1 and Pax9 protein 
expression was also assessed by immunohistochemistry in the E13.5 Pax1+/E 
embryos to further confirm that the mouse line resembled the WT (Figures 19 and 
20). Pax1 protein was detected in the IVD anlagen (Figure 19) and Pax9 protein was 
also detected in the tooth and facial mesenchyme which are Pax9-specific regions 













Figure 19: Pax1 protein expression in the E13.5 Pax1+/E embryos compared to 
the WT. (A) Pax1 mRNA expression detected by sectioned in situ hybridization using 
anti-sense Pax1 DIG-labelled RNA probe. Pax1 expression was seen in the 
intervertebral disc anlagen; magnified image of the vertebral column is shown below 
the top panel. (B) Pax1 protein expression in the Pax1+/E embryo resembled 
expression pattern seen in the littermate WT (C). All the paraffin sections were of 










E13.5 Pax1+/E embryo – anti-Pax1 ab 






























Figure 20: Pax9 protein expression in the E13.5 Pax1+/E embryos compared to 
the WT. (A) Pax9 protein was detected in the intervertebral disc anlagen, tooth and 
facial mesenchyme in the Pax1+/E embryo, which recapitulated endogenous Pax9 
expression in the littermate WT shown in B; (B) Pax9 mRNA expression detected by 
sectioned in situ hybridization using anti-sense Pax9 DIG-labelled RNA probe shown 
on the side; expression was seen in the facial mesenchyme. All the paraffin sections 
were of 10 um thickness. SISH – sectioned in situ hybridization; ab – antibody.  
 
Even though no change in the EGFP fluorescence expression was detected 
in the presence of Neo, it was further ensured that there were no adverse effects in 
the Pax1 and Pax9 protein expression. Therefore, Pax1 and Pax9 protein expression 
was also evaluated in the E13.5 Pax1E/E Neo+ and Neo- embryos. All the Pax1 
expression domains, such as the IVD anlagen and tail, and the Pax9-specific tooth 
and craniofacial mesenchyme, were expressing Pax1 and Pax9 respectively, in both 
the Neo+ and Neo- E13.5 embryos (Figure 21). Since the presence of Neo did not 
E13.5 Pax1+/E embryo – anti-Pax9 ab 
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affect the fluorescence expression pattern, subsequent studies were all performed 
with the Neo+ embryos. 
 
Figure 21: Pax1 and 
Pax9 protein 
expression in the E13.5 
Pax1E/E Neo- and Neo+ 
embryos. Pax1 
expression was observed 
in the intervertebral disc 
anlagen and tail. Pax9 
expression was seen in 
the tooth mesenchyme 
and facial mesenchyme. 
A: Neo- and B: Neo+. All 
the paraffin sections 
were of 10um thickness. 












3.3.4 Phenotype of the Pax1-/- adult mice 
The Pax1-/-  adult mutant mice were viable and fertile, but slightly smaller and 
had short, kinked-tails compared to the WT mice, which correlated with what has 
been reported by Wilm et al (1998) (Figure 22) [73]. In all our litters, the Pax1+/- mice, 
however, did not show any vertebral abnormalities and appeared normal (not 
shown). This is in contrary to what was reported by Wilm et al. The authors had 
T	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reported an 88% penetrance of defects in the lumbar and sternum skeletal elements 
in the Pax1+/-. They attributed the lack of 100% penetrance to a potential genetic 
background effect [73]. Another reason for this discrepancy could be the fact that 
Wilm et al had deleted the first two exons of Pax1 including the first intron. In this 
method, the 2nd exon of Pax1 was disrupted by the insertion of the EGFP cassette, 
without disrupting any intronic regions. There may be some regulatory elements 
present within the 1st intron which resulted in the mild skeletal phenotypes seen by 
the authors.  
To remove the floxed Neo the F1 mice were further mated to homozygous 
Rosa26RFlpe mice.  
 
Figure 22: Pax1-/- and WT adult mice. 
Pax1-/- mouse was smaller, with a 
shortened and kinked tail (left) compared 






3.3.5 EGFP expression pattern 
The EGFP fluorescence expression pattern was assessed at various 
developmental stages for the Pax1-/- embryos, with or without Neo. The fluorescence 
expression pattern recapitulated endogenous Pax1 expression (Figure 16) and the 
presence of Neo did not adversely affect it (Figure 23). The Pax1-/- embryos showed 
shortened tail from E13.5 onwards, with the defect becoming progressively more 
severe at later developmental stages (Figure 23). Since the presence of Neo did not 
Pax1KO (Pax1-/-) 
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affect the fluorescence expression pattern, subsequent studies were all performed 
with the Neo+ embryos. 
 
Figure 23: EGFP fluorescence expression in 
the Pax1-/- Neo+ and Neo- embryos of various 
developmental stages. Top panel: Embryos 
with the Neo showed EGFP expression in the 
Pax1-domains (the facial mesenchyme, anterior 
proximal limb buds and the vertebral column); 
the tail appeared shorter in the E13.5 embryos 
compared to a WT (Figure 16 and 17D). Middle 
and lower panels: Embryos without the Neo 
also showed similar expression pattern to that 
of the Neo+ shown in the top panel. Embryos 
show progressively shorter tail with increasing 
developmental stages. Yellow arrows indicate 






3.3.6 Pax1 and Pax9 protein expression in the Pax1-/- embryos  
Loss of Pax1 protein expression in the Pax1-/- embryos was confirmed by 
immunohistochemistry in E13.5 Pax1-/- embryos using anti-Pax1 antibodies. The 
Pax1+/- embryos did not show any difference in the Pax1 protein expression 
compared to the littermate WT (Figure 24).  
Next, Pax9 protein expression was evaluated in the Pax1+/- and Pax1-/- 
embryos. In this study, no change was observed in the Pax9 domains of expression 
in both of the E13.5 Pax1+/- and Pax1-/- embryos. The expression in both the 
intervertebral disc anlagen and the tooth and facial mesenchyme resembled that of 
the WT (Figure 25). 



















Figure 24: Pax1 protein expression in the E13.5 Pax1+/- and Pax1-/- embryos 
compared to the littermate WT. (A and B) Pax1 protein expression was seen in the 
intervertebral disc anlagen; magnified image of the vertebral column is shown below 
the top panel. (C) Pax1 protein expression was not detected in the Pax1-/- embryo. All 
























Figure 25: Pax9 protein expression in the E13.5 Pax1+/- and Pax1-/- embryos 
compared to the littermate WT. (A) Pax9 protein expression was seen in the 
intervertebral disc anlagen (magnified image below the top panel) and the tooth and 
facial mesenchyme. Similar expression pattern was observed in the Pax1+/- and 
Pax1-/- embryos (B & C). All the paraffin sections were of 10 um thickness.  
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3.3.7 Pax1-/- vertebral defect  
Since the Pax1-/- embryos showed a shortening of the tail, the embryos were 
assessed by histology to investigate what caused such a vertebral defect. The E13.5 
Pax1+/- and Pax1-/- embryos were checked by immunohistochemistry using anti-GFP 
antibodies. While no vertebral defects were seen in the Pax1+/- embryo, the Pax1-/- 
embryo showed a clear loss of vertebral body and IVD cells in the lumbo-sacral 
region (Figure 26). Alcian blue staining of the transverse sections of these embryos 
in the lumbo-sacral region also showed a dorso-ventral reduction in the size of the 
vertebral bodies (Figure 27). 
This correlates with the known phenotype in the Pax1-/- newborn mice 
whereby, in the vertebral column, the split vertebrae defect occurred mainly in the 
lumbo-sacral segments. Moreover, it was reported that a decrease in proliferation 
and increase in apoptosis in the sclerotome of the E12.5 Pax1-/-Pax9-/- embryos in the 
tail region [62]. Hence, a significant loss of these sclerotome cells early in 
development appears to be responsible for the ventro-medial reduction of the 








































Figure 26: EGFP expression in the E13.5 Pax1KO embryos. (A) Littermate WT 
embryo did not show any EGFP expression as expected. (B) The Pax1+/- embryo 
showed EGFP expression in the intervertebral disc anlagen. No vertebral column 
defects were observed. (C) The Pax1-/- embryo showed EGFP expression in the 
intervertebral disc anlagen. A loss of vertebral bodies and intervertebral disc cells in 
lumbo-sacral region was also seen (red dotted box). All the paraffin sections were of 
10um thickness. Magnified image of the defective segment is shown on the right. ab 




































Figure 27: Histochemical analysis of E13.5 Pax1+/-, Pax1-/- embryos. Top panel: 
Transverse section of E13.5 embryos probed with anti-Pax1 antibody showed a 
complete loss of Pax1 protein expression in the Pax1-/- embryo. Expression of Pax1 
protein in the Pax1+/- recapitulates Pax1 mRNA expression shown by sectioned in 
situ hybridization on the WT embryo using Pax1 anti-sense RNA probe (right). Middle 
panel: Pax9 protein expression was still detected in the Pax1+/- and Pax1-/- embryos. 
Lower panel: Alcian blue staining (stains for the proteoglycans in the cartilage) of the 
Pax1+/- and Pax1-/- embryos clearly showed dorso-ventral reduction of the vertebral 
bodies only in the Pax1-/- embryo in the lumbo-sacral region. All the paraffin sections 
were of 10um thickness. Red arrows point to the notochord. ab – antibody. 
 
Pax9 Mice 
3.3.8 Fluorescence expression in the Pax9-/- embryos 
Pax9-/- mice exhibited cleft secondary palate and died shortly after birth, 
which correlated with the published report by Peters et al (1998 and 1999) [62, 74]. 
The embryos were harvested at different developmental stages and their EGFP 
expression pattern was assessed. The fluorescence expression pattern recapitulated 
endogenous Pax9 expression (Figure 28) – pharyngeal arches, facial 
mesenchyme,sclerotome and anterior proximal fore- and hind-limb buds [50]. The 
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expression domains in the facial and limb mesenchyme were all adjacent to the Pax1 


















Figure 28: Fluorescence expression pattern of the Pax9-/- embryos. Embryos 
showed expression in the pharyngeal arches at E9.5 (white light image on the left); 
expression in the somites was too weak to be detected; at E11.0 expression was 
seen in the facial mesenchyme, pharyngeal arches and the sclerotome; at E12.5 
expression was detected in the facial mesenchyme, anterior proximal fore- and hind-
limb buds (domains adjacent to what was observed for Pax1). Magnified images of 
the limb buds are shown on the right. FL – fore limb; HL – hind limb. 
 
 
3.3.9 Pax1 and Pax9 protein expression in the Pax9-/- embryos 
Loss of Pax9 protein expression in the Pax9-/- embryos was confirmed by 
immunohistochemistry in the E13.5 Pax9-/- embryos using anti-Pax9 antibodies. The 
Pax9-/- embryos did not show any difference in the Pax1 protein expression 
compared to the Pax9+/- embryo. No vertebral column abnormalities were observed in 
the E13.5 Pax9-/- embryos, unlike in the Pax1-/- where the vertebral column was 
defective in the lumbo-sacral segments (Figure 29). 
 
 























Figure 29: Immunohistochemistry of the E13.5 Pax9KO embryos. Left panel: 
Pax9 protein expression was detected in the facial and tooth mesenchyme and the 
intervertebral disc anlagen. Middle panel: the Pax9-/- embryo was devoid of any Pax9 
protein expression, while Pax1 protein was still expressed in the intervertebral disc 
(right panel). Pax1 protein was not detected in the facial and tooth mesenchyme - 
domains which are Pax9-specific. The vertebral column appeared to have no defects 
in both of the Pax9+/- and Pax9-/ embryos, including the lumbo-sacral region (all three 
panels). All the paraffin sections were of 10um thickness and were counter-stained 
with alcian blue. ab – antibody. 
 
 
3.3.10 Pax1/ Pax9 multiple allele knock-outs 
Once the Pax1KO and Pax9KO mouse lines were confirmed to be accurate, 
double heterozygotes (DH = Pax1+/-Pax9+/-) were generated by mating the Pax1-/- 
mice with the Pax9+/- mice. Different combinations of allele knock-out embryos were 
then generated from a DH x DH mating, since the DH mice were viable and fertile 
(Figure 30). The Pax1-/-Pax9+/- mice died post-natally (as reported in [62]), hence 
could not be used for mating to obtain the Pax1/Pax9 double null embryos for gene 
expression profiling analysis. The embryos were checked by fluorescence 
microscopy for their expression patterns (Figure 30), and the yolk sacs from the 
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corresponding embryos were genotyped by PCR.  Embryos of interest were FACS-
ed individually. 
 
Figure 30: Different 
combinations of knock-out 
allele embryos obtained from 
DH x DH matings. (A-G) 
Genotype of each embryo is 
shown, and fluorescence 
expression sites are indicated 
with white arrows. The Pax1+/- 
and Pax9+/- embryos exhibited 
very weak fluorescence 
expression (not shown). (B) In 
the Pax1-/- embryo, 
fluorescence expression was 
observed in the facial 
mesenchyme, fore- and hind-
limb buds and the vertebral 
column. (C) In the Pax9-/- 
embryo fluorescence 
expression was seen in the 
facial mesenchyme, but 
adjacent to the Pax1 domain. 
Similarly, expression in the 
anterior proximal fore- and hind-
limb buds was seen, including a 
much weaker expression in the 
vertebral column.  (G) 
Expression in the double null 
(Pax1-/-Pax9-/-) embryo was a 
combination of both the Pax1 
and Pax9 expression sites. The 
tail was significantly shortened 
as indicated by the yellow arrow. 
DH – double heterozygote 
(Pax1+/-Pax9+/-). 
 
The Pax1/Pax9 double-null embryos showed fluorescence expression in both 
the Pax1 and Pax9 expression domains (Figure 30). The tail was significantly shorter 
than the WT embryos which could be attributed to the prevalent loss of sclerotomal 
cells in these embryos [62].  The shortening of tail was more severe at older stages 
(Figure 31). Also, at E14.5, the double-null embryos showed mis-localization of the 
fluorescing cells. Instead of forming IVD structures medially, the cells were localized 
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on the lateral regions. The notochord, which is normally enclosed within the vertebral 
column, was exposed owing to the lack of normal vertebral body and IVD cells in the 
middle to surround it. Polydactyly was also observed in the hind limbs of the double-
null embryos by E14.5 (Figure 31).  
Figure 31: Pax1/Pax9 double-null embryos. (A) Double-null embryos at E12.5 and 
E14.5. Tail tip is indicated with orange arrow. Tail was progressively shorter at older 
stage. (B) In the E14.5 Pax1+/-Pax9+/- (double-heterozygote) embryo, fluorescence 
was seen in the IVD in a regular metameric fashion. In the double-null embryo, the 
fluorescing cells were mis-localized on the sides of the embryo with the notochord 
totally exposed in the middle (blue arrow). Bottom: dorsal view after the neural tube 
was removed. (C) Ventral view of hind limbs; In the Pax9+/- embryo, the anterior 
portion was normal; in the double-null embryo, signs of polydactyly could be seen in 





	   87	  
3.4 Assessment of Pax1 and Pax9 mouse lines for TF mapping studies 
 
The availability of inexpensive sequencing services and vast improvements in 
sequencing depth has led to the transition of technology from ChIP-Chip to ChIP-
Sequencing (ChIP-Seq). ChIP-Seq has enabled a more biologically meaningful 
detection of TF binding sites in the DNA. While ChIP-Seq performed on cells with 
over-expressed TFs (cell culture) provide accurate information on the binding sites, 
they are not necessarily always biologically relevant and have to be assessed with 
several caveats in mind. For instance, critical binding sites may be missed in the 
absence of the appropriate co-factors in the cell culture-based assays, which is not a 
problem in an in vivo assay. Also, different co-factors may be required in a different 
biological context in vivo (eg. cell-type specific co-factors), which cannot be easily 
reproduced in vitro. Moreover, developmental-stage specific information is often lost 
in such cell culture experiments [5, 99].  
Nonetheless, performing ChIP-Seq in vivo using embryonic tissues comes 
with limitations. In an over-expression cell culture system, one can easily use a 
construct whereby the TF-of-interest is tagged with a commonly used epitope, for 
which numerous antibodies are easily available. For an in vivo ChIP-Seq 
experiment, availability of a TF-specific ChIP-grade antibody, preferably 
commercially, is a pre-requisite. Raising antibodies against the TF-of-interest is time 
consuming and need not necessarily work in actual analytical experiments. The 
specificity of the antibody is also imperative. For example, since both the Pax1 and 
Pax9 TFs belong to the same subfamily, lack of cross-reactivity of the antibodies has 
to be verified. More importantly, even if specific antibodies are available, they may 
not be sensitive enough to immunoprecipitate a TF which is often expressed at 
moderate to low levels in vivo [100].  
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A simpler solution to these numerous impediments in studying protein 
function in vivo is to endogenously tag the protein-of-interest with a commonly used 
epitope. Commercial antibodies are readily available for various epitopes, such as 
HA, c-myc, VSV-G, FLAG, His, and also for an assortment of applications like 
Western  blotting, immunoprecipitation, immunofluorescence/ immunohistochemistry 
and affinity purification [100, 101].   
Such endogenous epitope-tagging of proteins by gene targeting has been 
widely implemented in the yeast for protein-DNA and protein-protein interaction 
studies [102-104]. However, it is much more challenging to perform this in the 
mammalian system owing to their unpredictable targeting efficiency. Use of BAC 
transgenes to express biotin-tagged proteins at close to endogenous levels in 
mouse ES cells has been carried out but it still does not enable the study of a protein 
function in a developmental stage-specific fashion [105].   
 In this study, mouse lines that stably express endogenously HA epitope 
tagged Pax1 and Pax9 proteins have been successfully generated (section 3.2.3). 
The Pax1+/HA3 (heterozygote) and Pax9HA3 (chimeric) embryos were assessed by 
immunohistochemistry using anti-HA, anti-Pax1 and anti-Pax9 antibodies (Figure 33 
and 34). The HA antibodies successfully detected expression in the IVD region in 
both the Pax1+/HA3 and Pax9HA3 (chimeric) embryos and no expression was detected 
in the littermate WT embryos indicating the specificity of the HA antibody (Figure 33 
and 34). The Pax1+/HA mice were also phenotypically normal, viable and fertile 
(Figure 32), and expressed the endogenous Pax1 and Pax9 in the correct domains 
as detected by the anti-Pax1 and anti-Pax9 antibodies (Figure 33). Thus, the triple 
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Figure 32: Pax1HA3 mouse. Picture of the adult 
Pax1+/HA3 mouse compared to the WT B6 mouse; mice 
did not exhibit any abnormalities and were viable and 











Likewise, the HA-epitope was detectable in the Pax9HA3 embryos. Since the 
Pax9HA3  mice are still at the chimeric stage, only the high-percentage chimeric 
embryos were investigated. The expression of the HA epitope was patchy but in the 
Pax9-specific domains like the facial mesenchyme and the IVD anlagen. This was 
because of the chimeric nature of the embryo. Nonetheless, these embryos showed 
a homogenous expression of the endogenous Pax1 and Pax9 proteins as observed 
with the anti-Pax1 and anti-Pax9 antibodies (Figure 34). Moreover no defects were 
observed in the vertebral column or the facial mesenchyme. This verified the 
embryos to be normal.  
Thus ascertained to be successfully tagged, these Pax1HA3 and Pax9HA3 mice 
will be profoundly useful in a myriad of proteomic experiments. For instance, this 
epitope tagging technique circumvents the potential cross-reactivity issue between 
the Pax1 and Pax9 proteins. Hence, they can be confidently used for ChIP-seq or 
immunoprecipitation experiments. More importantly, these proteins can now be 
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studied in vivo in a tissue-specific manner. In addition, the subcellular localization of 
these proteins can be studied in vivo through immunofluorescence coupled with 
confocal microscopy analyses [106, 107]. Potential changes in the protein 
localization or post-translational modifications in response to different treatments of 
the mice can also be determined [108, 109]. Besides, these mice are invaluable tools 
for protein-protein interaction studies. For example, the Pax1 and Pax9 proteins can 
be purified by affinity purification and subsequently used for mass spectrometry 
analysis to assess their protein partners in the different tissues (eg. vertebral column, 
thymus, tooth or facial mesenchyme etc) and at various developmental stages, which 
might assist in resolving their pleiotrophic mechanism of action.  
Figure 33: Immunohistochemistry of E13.5 Pax1HA3 embryo. Left: The Pax1+/HA3 
embryo paraffin sections of 10um thickness probed with the anti-HA antibody showed 
expression in the intervertebral disc anlagen, similar to the expression pattern seen 
with anti-Pax1 and anti-Pax9 antibodies. Right: the littermate WT was used as a 
negative control to the anti-HA antibody and showed Pax1 expression when probed 
with the anti-Pax1 antibody. ab – antibody. 
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Figure 34: Immunohistochemistry of the E13.5 Pax9HA3 chimeric embryo. Left: 
The Pax9HA3 chimeric embryo paraffin sections of 10 um thickness probed with the 
anti-HA antibody showed expression in the facial mesenchyme and the intervertebral 
disc anlagen, similar to the expression pattern seen with anti-Pax9 antibody. Only the 
HA epitope expression appeared patchy owing to the chimeric nature of the embryo. 
Pax1 protein was seen in the intervertebral disc anlagen but not the facial 
mesenchyme which are Pax9-specifc regions. Right: the littermate WT was used as 
a negative control to the anti-HA antibody and showed Pax9 expression when probed 
with the anti-Pax9 antibody. ab – antibody. 
 
 
3.5 Gene expression profiling - Pax1 and Pax9  targets in the vertebral 
column 
Identification of the target genes of Pax1 and Pax9 in a cell-type specific 
manner necessitated the isolation of specific cell types (IVD analgen cells) from the 
embryonic stages. As discussed in section 3.4, mouse lines expressing EGFP under 
the control of Pax1 or Pax9 promoter were generated. From these mouse lines, 
fluorescing mouse embryos were harvested at the required stages.  
For all the microarray gene expression profiling, fluorescing mouse embryos 
(Pax1+/E, Pax1+/-, Pax1-/-, Pax1-/-Pax9+/- and Pax1-/-Pax9-/-) were staged, dissected 
and dissociated into single-cells for sorting by fluorescence activated cell sorting 
(FACS). Only the dissected vertebral column tissue, including the tail (all the internal 
organs, limbs and head were discarded) was used for FACS and subsequent gene 
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expression analyses (microarray). Wild-type embryos of the same developmental 
stage, dissected and dissociated the same way as the fluorescing embryos, were 
used for gating during each FACS sorting experiment. Method of dissociation is 
described in detail in the Materials and Methods section. From the FACS-enriched 
pool of EGFP positive cells, RNA was extracted and converted to cDNA before a 
single-round of linear amplification was performed to obtain sufficient cDNA for 
biotinylation and hybridization on Illumina MouseWG-6 Expression BeadChips 
(Figure 35 for schematic diagram, Table 5 for RNA Integrity Number (RIN) values). 
For each array at least 3 (minimum) to 5 (maximum) biological replicates were used. 
Each biological replicate is comprised of cells pooled from multiple embryos (an 
average of 2 embryos), as very few fluorescing cells could be obtained from a single 
vertebral column (~ 2,000 – 4,000 cells), which are insufficient for even the 
downstream cDNA conversion and amplification. The Illumina bead chip was chosen 
for the gene expression profiling since it allows 6 samples to be assessed in parallel 
and it includes internal technical replicates. It also contains over 45,200 transcripts 














Figure 35: Schematic of FACS sorted cells used for microarray. For each 
biological replicate cells from an average of 2 embryosʼ vertebral column were used. 
From the extracted pool of total RNA, 2 ng was used for cDNA conversion and 
single-round amplification using NUGEN Ovation kit. The amplified single-stranded 
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DNA was then biotinylated, purified and used for hybridization on the Illumina 
MouseWG-6 Expression BeadChips according to the manufacturerʼs protocol. Bead 
chips were scanned by BeadScanner. B1-B5: biological replicates; ss – single-
stranded. 
 
Table 5: Quality of RNA extracted from E12.5 and E13.5 embryos for 
microarray 
  E12.5 





B1 34,269 7.4 
B2 17,051 8.2 
B3 31,628 8.4 






B1 15,716 7 
B2 8,949 8.2 
B3 16,447 7.3 
B4 15,788 8.1 






B1 4,614 8.7 
B2 32,892 9.4 
B3 11,738 9 
B4 Technical replicate of B2 






B1 8,350 8.5 
B2 11,732 9.1 
B3 41,487 9.4 
B4 8,479 8.9 
B5 10,479 9.2 
Pax1-/-Pax9-/- 
(Double-null)  
B1 18,882 8.2 
B2  16,030 8 
B3 12,598 8.8 
Pax1-/-Pax9+/- 
3 allele KO 
B1 55,659 8.7 
B2 27,177 8.3 
B3 54,615 8.8 
  E13.5 
Pax1+/E 
GFP(-) Control 
B1 191,610 9.1 




B1 8,173 7.7 
B2 11,228 7.3 
B3 15,554 8.2 




B1 7,794 8.1 
B2 6,913 7.7 
B3 6,424 8.1 
B4 7,474 8 
Pax1-/- 
Null  
B1 14,008 9.6 
B2 13,968 8.7 
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  B3 10,763 8.2 
B4 13,643 8.2 
# Multiple embryos were pooled to obtain sufficient number of cells for each 
biological replicate; RIN – RNA Integrity Number. 
 
3.5.1 Gene expression profile of Pax1-specific (GFP(+) cells) WT cells 
To ensure that the FACS sorted cells were of the correct population i.e. Pax1-
positive cells, and to further assess the set of genes that were enriched in Pax1-
specific cells of the IVD anlagen, an expression profile on GFP(+) versus GFP(-) 
population was performed. Cells collected from the vertebral column of E12.5 and 
E13.5 Pax1+/E (WT), Pax1+/-, Pax1-/-  embryos were compared with the GFP(-) fraction 
of cells from the FACS sort of the corresponding developmental stages.  
Using the GeneSpring software, one-way ANOVA and Benjamini-Hochberg 
multiple testing correction, with a fold-change cut-off of ≥1.5 fold and p-value < 0.05, 
was applied to the gene expression data (Materials & Methods). As expected, Pax1 
was the most enriched gene in the Pax1+/E, Pax1+/-, Pax1-/-  cells compared to the 
GFP(-) fraction of E12.5 and E13.5 stages (Table 6), indicating the success in 
enriching for the correct population of cells from these embryos. The Pax1 transcripts 
will be detected in the microarray even in the Pax1-/- embryos since the method of 
disruption of Pax1 function is at at the translational level using the F2A peptide 
strategy (section 3.1). Hence, the probes on the microarray would still be able to 
hybridize to the undisrupted regions of Pax1 transcript which includes any region 3 
amino acids after the start of the second exon. 
Table 6: Pax1 fold enrichment compared to GFP(-) fraction of cells 




In the E12.5 embryos GFP(+) cells compared to GFP(-) cells from Pax1+/E 
(WT) embryos, a total of 744 genes were up-regulated and 1,052 genes were down-
 Pax1 Fold enrichment 
  Stage  WT vs. GFP(-) Pax1+/- vs. GFP(-) Pax1-/- vs. GFP(-) 
E12.5 15.27 15.30 11.39 
E13.5 13.64 15.83 9.52 
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regulated. Similarly in E13.5  embryos, GFP(+) cells compared to GFP(-) cells from 
the Pax1+/E (WT) embryos, a total of 412 genes were up-regulated and 630 genes 
were down-regulated. 
Besides Pax1, several other TFs were also enriched in these cells which are 
listed in Table 7. Of these, notable TFs are Meox1, Meox2, Twist1, Sox5 and Foxc2 
(Mfh1) – genes which are either expressed in the IVD anlagen or known to be 
involved in the sclerotome and/or IVD development. In the E12.5 GFP(+) cells Pax9 
was also co-expressed with a 2.50-fold enrichment (lower than Pax1) and is also 
expressed in the IVD anlagen at E13.5 (Figure 36). Since Foxc2 is known to 
genetically interact with Pax1 in regulating the sclerotome cell proliferation, and both 
are co-expressed in the sclerotome up to E11.5,  Foxc2 expression pattern was 
checked at a later developmental stage of E13.5 (Figure 36). 
Table 7: Transcription factors enriched in GFP(+) versus GFP(-) E12.5 Pax1+/E 
cells. 
 
* - enrichment scores were derived from DAVID gene ontology analysis (ref: 










Transcription factors enriched in GFP(+) Pax1+/E vs GFP(-) 
Transcription factor activity 
E12.5 
Enrichment score: 2.31* 
p-value: 0.00741 
E2f6, Sox5, Elk3, Gli2, Pax1, Wt1, Pax9, 
Foxf2, Etv1, Nfatc4, Tcf3, Etv5, Foxd1, 
Twist1, Sim2, Nfatc1, Egr1, Mafb, Foxa1, 
Creb5, Tbx1, Tead2, Six5, Six4, Foxp4, 
Foxp1, Meox2, Meox1, Trps1, Gtf2ird1, 
Foxc2, Foxc1, Tbx18, Nfia, Nfib 
 
Transcription factor activity 
E13.5 
Enrichment score: 2.75* 
p-value: 0.00573 
Tshz2, Thra, E2f6, Nfix, Pax1, Gli1, 
Nkx6-2, Hlx, Foxf2, Nfatc4, Foxd1, 
Nfatc1, Mafb, Tead2, Bmyc, Creb5, 
Foxp4, Foxp1, Hoxd9, Hoxc10, Meox2, 
Meox1, Foxc2, Nfic, Nfia, Nfib, Sox5 






















Figure 36: Expression patterns of Pax1, Pax9, Foxc2, Foxf2 and Sox9 in E13.5 
vertebral column sections. Paraffin sections of 10uM thickness were probed with 
the respective anti-sense RNA probes. Adjacent sections of the same region were 
used for expression analysis in A-C & E. (A-B) Pax1 and Pax9 expressions were 
seen in the IVD anlagen. (C) Foxc2 (Mfh1) was expressed mainly in the 
perichondrium of the vertebral bodies and diffusely in the tissues surrounding the 
vertebral column. (D) Foxf2 expression was seen in the IVD anlagen. (E) Sox9 was 
expressed in the VB and slightly more intensely in the perichondrium. VB- vertebral 
body; IVD – intervertebral disc anlagen; P- perichondrium. 200x magnification. 
 
At E13.5, Pax1 and Pax9 were strongly expressed in the IVD anlagen, to a 
lesser degree in some of the vertebral body cells and in the mesenchymal cells 
surrounding the vertebral column. Pax9 expression, however, was significantly 
weaker than Pax1. Likewise, Foxf2 was also intensely expressed in the IVD anlagen. 
Foxc2 (Mfh1) was expressed in the perichondrium and in the mesenchymal cells 
surrounding the vertebral column. It appeared as if Foxc2 was outlining the borders 
of the vertebral bodies and the IVD. Sox9 was expressed in the vertebral bodies, and 
slightly more intensely in their perichondrium. Foxc2 and Sox9 expression 
overlapped with that of Pax1 and Pax9 expression mainly in the perichondrium. Sox9 
did not appear to be enriched in the GFP(+) compared to the GFP(-) fraction because 
the vertebral body cells would have appeared in the GFP(-) fraction, which would 
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have expressed almost equally high levels of Sox9 transcripts as the perichondrial 
cells which would be in the GFP(+) fraction. Hence, the slight difference in the 
expression levels between the vertebral body cells and the perichondrial cells may be 
below 1.5-fold and so missed by the fold-change cut-off. 
In 2010, a gene expression profiling study was performed by Sohn et al 
(2010), whereby gene expression of mouse tissues from E13.5 laser-microdissected 
WT IVD anlagen was compared with the WT vertebral body tissues to identify IVD-
enriched genes [60]. Their list of IVD-enriched genes was compared with the list of 
genes enriched in the GFP(+) cells. 46 genes and 23 genes were found to be 
overlapping with the E12.5 and E13.5 lists respectively. Some of those genes verified 
to be expressed in the IVD anlagen based on literature search/ gene expression 
database in the study by Sohn et al (2010) are shown in Table 8.  
 
Table 8. List of some of the genes enriched in the E12.5 and E13.5 Pax1+/E 
GFP(+) cells and known to be expressed in the IVD anlagen. 
Genes known to be expressed in the IVD anlagen & enriched in GFP(+) cells 
Stages  Symbol Name 
E12.5 Col14a1 Collagen, type XIV, alpha 1 
E12.5 Col6a1 Collagen, type VI, alpha 1 
E12.5 Lrig1 Leucine-rich repeats and immunoglobulin-like domains 1 
E12.5 Pax9 Paired box gene9 
E12.5 Tgfb3 Transforming growth factor, beta 3 
E12.5 Trps1 Trichorhinophalangeal syndrome I (human); similar to Trps1 
protein 
E12.5 Wisp1 WNT1 inducible signalling pathway protein 1 
E13.5 Fgf18 Fibroblast growth factor 18 
E12.5 & E13.5 Col6a2 Collagen, type VI, alpha 2 
E12.5 & E13.5 Col6a3 Collagen, type VI, alpha 3 
E12.5 & E13.5 Emilin3 Elastin microfibril interfacer 3 
E12.5 & E13.5 Fmod Fibromodulin 
E12.5 & E13.5 Foxf2 Forkhead box F2 
E12.5 & E13.5 Nfatc1 Nuclear factor of activated T cells, cytoplasmic, calcineurin 
dependent 1 
E12.5 & E13.5 Pax1 Paired box gene1 
E12.5 & E13.5 Vcan Versican 
 
Besides this verified list of IVD-expressed genes, the entire list of Pax1-
enriched genes clearly serves as a resource of genes that are co-expressed with 
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Pax1 in the IVD anlagen, and are probably involved in IVD development. 
Gene Ontology analysis was performed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) web-based gene ontology 
enrichment analysis tool, to identify the set of TFs, biological processes, signalling 
pathways and molecular functions that were enriched in these Pax1-specific cells at 
E12.5 (only the genes up-regulated in Pax1-cells). A myriad of GO annotation terms 
were enriched and selected GO enrichment terms are shown in Figure 37. Genes 
were enriched for expected biological processes such as ECM, glycoprotein, 
somitogenesis, skeletal system development (cartilage development and osteoblast 
differentiation), pattern specification process, segmentation, regionalization, 
somitogenesis, anterior/posterior pattern formation, cell adhesion, collagen, cell 
migration, regulation of cell proliferation, regulation of cell size and regulation of cell-
substrate adhesion among several others (Figure 37). Notably, GO terms were also 
enriched for face development, odontogenesis and inner ear morphogenesis, which 
are all associated with Pax9 rather than Pax1. This could be because Pax9 is co-
expressed with Pax1 in these cells (highlighted in red in the chart, Figure 37). At the 
same time, it was surprising to observe terms such as appendage development and 
inner ear morphogenesis to be enriched in these cells since they were obtained only 
from dissected vertebral column tissue. One possibility is that these genes have 
pleiotrophic roles, like Pax1/Pax9, and so are expressed in the vertebral column cells 
as well, potentially having a function in the axial skeleton. Evidently, not all the 
functions of all of the genes in the mouse genome have been completely studied 
and/or annotated yet, hence these genes may not yet have been discovered to play a 
role in the vertebral column.  
The genes were also enriched for numerous intracellular signalling pathway 
components (receptors and ligands), such as TGF-beta signalling pathway, 
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Hedgehog signalling pathway, G protein coupled receptor and Wnt signalling 
pathway, all of which are involved in a number of cellular processes relevant to the 
formation of mesenchymal condensations and chondrogenesis/ osteogenesis. For 
instance, TGF-beta signalling pathway is mediated by secreted proteins (TGF-beta 
ligands, BMPs, activins, growth differentiation factors etc) and is involved in the 
regulation of cell differentiation, cell proliferation, cell migration, ECM production/ 
degradation, as well as endochondral and intramembranous ossification [110-112]. 
Moreover it has been shown to be critical in IVD development at the early embryonic 
stages [60, 61]. Hedgehog signalling components Ptch1 (Patched receptor which 
represses the signalling component, Smo, by binding to it) and Gli2 (downstream bi-
potential TF, i.e. context-dependent activator or repressor) were also expressed in 
these Pax1/Pax9-positive cells indicating that they are still competent to mediate Hh 
signals at E12.5 [44, 113]. Similarly, Wnt signalling is also known to be vital in 
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Figure 37: Gene Ontology term enrichment of E12.5 GFP(+) Pax1+/E cells. GO 
terms relevant to Pax1 were enriched, including those relevant to Pax9 (highlighted 
in red) since it was also co-expressed in the Pax1-specific cells. The -log10(p-value) 
are shown at the end of the bars; a value of more than 1.3 is deemed significant (-
log10 transformation of a p value of 0.05 is equal to 1.3).   
 
3.5.2 Genes regulated by Pax1 – a temporal study 
Confirming that the correct population of cells were enriched from the E12.5 
and E13.5 embryos, Pax1 regulated targets were then identified. First, a temporal 
study was performed by analysing the Pax1 WT (Pax1+/E) with the Pax1-/- for E12.5 
and E13.5 stages. These stages were chosen since that is when IVD anlagen are 
first formed.  
Only the WT and Pax1-/- (null) samples were compared using Studentʼs 
unpaired T-test, p-value < 0.05 and a FC	 ≥ 1.5, for E12.5 and E13.5. Since the 
Pax1+/- embryos did not show any defect in the vertebral column and the adult mice 
were reported to have very mild defects only (Table 3), they were excluded from 
further analysis [73]. A total of 130 genes (50 down-regulated and 80 up-regulated in 
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null) and 122 genes (47 down-regulated and 75 up-regulated in null) were 
differentially expressed at E12.5 and E13.5 respectively (Figure 38). Some of the 
down-regulated targets were randomly chosen and validated by sectioned in situ 
hybridization (Figure 39). Up-regulation is harder to show by sectioned in situ 




Figure 38: Total number of 
differentially expressed 
genes in E12.5 and E13.5 
embryos (WT vs Pax1-/-). 
The numbers of differentially 
expressed genes are shown 
for both the developmental 
stages – E12.5 & E13.5. Up 
refers to up-regulation in 
Pax1-null; Down refers to 
down-regulation in Pax1-null 


































Figure 39: Gene expression 
profiling target validation 
for E12.5 and E13.5 by 
sectioned in situ 
hybridization. Sagital 
paraffin sections of E12.5 and 
E13.5 Pax1+/E (WT) and Pax1-
/- embryos, at 10 uM 
thickness, were probed with 
Sorbs2, Hnt and Sdc4 to 
validate their down-regulation 
seen in the (microarray) gene 
expression profiling.  Pairs of 
sections for comparison were 
probed at the same time with 
the same concentration of 
probe and signals were 
developed for the same 
amount of time in the same 
regions of the embryos. FC – 
fold change. Dorsal region 
facing the top of the page; 




Gene Ontology analysis was then performed on the set of differentially 
expressed genes at E12.5 and E13.5 using DAVID. At E12.5, GO terms relevant to 
Pax1 function were enriched (p-value < 0.05) such as cell adhesion, cell junction, 
transcriptional regulation, transcription factor activity and macromolecule 
biosynthesis process (selected GO terms shown in Figure 40). At E13.5, the up- and 
down-regulated genes were enriched for several more GO terms like skeletal system 
development, collagen (triple helix), ECM, glycoprotein, regulation of apoptosis, 
ECM-receptor interaction, focal adhesion, cell-cell signalling, transcriptional 
regulation and transcription factor activity (selected GO terms shown in Figure 41). 
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TFs, cell adhesion and apoptosis related genes that were differentially expressed at 
both the stages are shown in Table 10.	   
 
Figure 40: Gene Ontology term enrichment of E12.5 Pax1 differentially 
expressed genes. GO terms relevant to Pax1 were enriched like cell adhesion, 
macromolecule biosynthesis and transcriptional regulation. The -log10(p-value) are 
shown at the end of the bars; a value of more than 1.3 is deemed significant (-log10 











































Positive regulation of macromolecule biosynthetic process!
cell junction!
GO:0045941~positive regulation of transcription!
GO:0033043~regulation of organelle organization!
GO:0007155~cell adhesion!
GO:0010817~regulation of hormone levels!
GO:0060284~regulation of cell development!
()*+%!#,-(./)012#
GO enrichment of E12.5 Pax1 regulated genes!
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Figure 41: Gene Ontology term enrichment of E13.5 Pax1 differentially 
expressed genes. GO terms relevant to Pax1 were enriched such as cartilage 
development, skeletal system development, focal adhesion, ECM, glycoproteins and 
transcriptional regulation among several others. The -log10 (p-value) are shown at 
the end of the bars; a value of more than 1.3 is deemed significant (-log10 
transformation of a p-value of 0.05 is equal to 1.3).  
 
The differentially expressed genes of both stages were then overlapped. 
Surprisingly, only 7 genes (~ 5.56%) were common at both stages. They showed a 
consistent directionality and an increasing down-regulation or up-regulation (based 
on fold-change) with increasing developmental stage as expected (Table 9).  
 
        Table 9: Common genes differentially expressed in 
E12.5 & E13.5 embryos (Pax1+/E vs Pax1-/-) 
Common genes E12.5* E13.5* 
Tbx3 (a TF) Down (1.78) Down (1.89) 
Mela Down (1.57) Down (1.54) 
Igfbp3 Down (1.51) Down (1.77) 
Trpc4ap Down (1.54) Down (1.59) 
Crh Up (2.51) Up (2.85) 
Foxa1 (a TF) Up (1.56) Up (1.83) 
2010011I20Rik (Fam210b) Up (1.50) Up (2.99) 
*Directionality - down in null; up in null; Fold change values are shown in parenthesis; 





































positive regulation of macromolecule biosynthetic process!
GO:0001502~cartilage condensation!
GO:0001503~ossification!
GO:0006357~regulation of transcription from RNA polymerase II 
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GO:0010605~negative regulation of macromolecule metabolic 
GO:0051216~cartilage development!
GO enrichment of E13.5 Pax1 regulated genes!
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Table 10: TFs, cell adhesion, apoptosis, migration, proliferation & ECM genes 
differentially expressed in Pax1-/- 
Genes differentially expressed 




Egr1, Maf, Tbx3, Irx2, 
Foxa1, Emx2, Foxo1, 
Lef1, Olig1 
Tbx3, Jun, Foxa1, Tbx20, 
Foxf2, Sox5, Klf16, Foxc2, 
Rarb, Sox9, Grhl2, Foxp2 
Cell adhesion  
(GO:0007155) 
Igsf11, Lama4, 
Pcdhb6, Lpp, Tek, 
Nlgn1, Pcdh12, Lef1, 
Col11a1 
Col9a1, Ctgf, Tnc, Hspg2, 




Tbx3, Myocd, Tek, 
Foxo1, Igfbp3 





Xrcc2, Tbx3, Foxo1, 
Igfbp3 
 
Tbx3, Grid2, Foxc2, Col2a1, 
Cdh1, Ngfr, Rarb, Sox9, 
Igfbp3, Card10 










Gpc4, Col9a1, Ctgf, Tnc, 




(I) Pax1 plays a role in the mesenchymal condensation process 
Based on these results, it appears that Pax1 regulates genes involved in 
processes essential for condensation processes – cell adhesion (focal adhesion, 
adherens/ cell junctions), cell-cell signalling, ECM (glycoproteins) components and 
cartilage condensation. Condensation of mesenchymal cells is a pre-requisite for the 
formation of skeletal elements via endochondral ossification [116]. This in essence, 
requires sufficient number of cells to aggregate, form adhesions between each other 
to prevent them from migrating away, and to communicate information through 
intercellular signalling. Cell-matrix interactions are also vital in this communication 
between cells. The ECM (composed of glycoproteins and glycosaminoglycans, 
GAGs) acts as a medium for soluble factors and conveys signals from the 
surrounding region to the cells (or vice versa), which in turn activates intracellular 
signalling pathways. They also provide an attachment surface for cells during 
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migration. Furthermore, components of ECM like collagen and aggrecan enable 
water retention, and this osmotic swelling pressure in turn confers resistance to 
compressive forces. Boundaries also need to be established in condensations. 
Tenascin, an extracellular glycoprotein and its cell-surface receptor, syndecan, are 
known to help define the boundaries of condensations, potentially through cell-cell 
and cell-ECM interactions [116-118]. Both Sdc4 (Syndecan 4) (1.62-fold down in 
Pax1-/-) and Tnc (Tenascin C) (1.63-fold up in Pax1-/-) were found to be differentially 
expressed in the E13.5 Pax1-/- embryos.   
Pax1, along with Pax9, is known to promote sclerotome proliferation [62]. In 
the analysis of Pax1-null cells, genes involved in proliferation were found, but not 
enriched. This could be because the prior study was performed in Pax1-/-Pax9-/- 
double-null mutants which have a more severe phenotype, compared to this analysis 
whereby only the Pax1-/- embryos were analyzed. The analysis of double-null 
mutants may reveal an enrichment for genes involved in proliferation.  
In the study of Pax1/Pax9 double-null embryos, the authors also observed an 
increase in apoptosis. However, the authors claimed apoptosis might not be a true 
function of these two Pax genes, and the increase in apoptosis might be a causative 
effect of drastically reduced cell numbers in the mesenchymal condensations. In the 
Pax1-/-, genes involved in apoptosis were also found to be differentially expressed but 
not enriched. Identification of the direct targets of Pax1 and Pax9 might help to reveal 
if these Pax genes truly regulate apoptotic processes or if it just a secondary effect 
as the authors had predicted [62]. The direct targets of Pax1 and Pax9 are discussed 
in later sections (section 3.6.4). 
Thus, the hypothesis that Pax1 regulates processes involved in mesenchymal 
condensation formation and differentiation appears valid and some of the genes 
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involved in these processes have been identified in this study through a genome-
wide approach  [62, 76].  
 
(II) Different sets of genes are regulated at different time-points 
Although some of the processes regulated by Pax1 at both stages are similar, 
the genes involved are quite different. For instance, genes involved in transcriptional 
regulation, cell adhesion, proliferation, apoptosis, migration and ECM were found at 
both stages, but the genes corresponding to each of these functions were different 
(Table 10).  One reason for the lack of a large overlap could be because of the 
inherent differences and dynamic changes in the developmental processes itself. It is 
between E12.5 and E13.5 that the IVD anlagen is formed and those cells are in the 
process of further differentiation to give rise to a hyaline cartilage for the inner 
annulus and a fibrous outer annulus by E14.5 [63] (See [119] for histological sections 
of mouse IVD from E12.5 to E15.5 & Figure 64). Another possibility is that besides 
Pax9, other TFs involved in the same or parallel pathway were also compensating for 
the loss of Pax1. For example, Foxc2 and Sox9 were up-regulated at E13.5 in the 
Pax1-/- mutants. Foxc2 (Mfh1) and Pax1 are known to cooperatively regulate the 
mitotic activity of sclerotome cells [41]. Likewise, Sox9 is essential for chondrocyte 
differentiation and production of cartilage-specific ECM proteins like collagen and 
aggrecan, which are major components of ECM [52, 120-123]. Indeed, several of the 
known targets of Sox9 like Col2a1 [121], Wwp2 [124] and Sox5 [125] were up-
regulated in the E13.5 Pax1-/- as well (Table 12). At E12.5, the IVD anlagen are first 
formed. Hence, in response to the cells sensing the dysregulation of some of the 
genes in E12.5 Pax1-/-, compensation may have been kick-started slightly later, the 
effects of which are observed only at E13.5. Then again, it is not clear at this stage if 
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Pax1 was instead repressing Foxc2 and Sox9 (in WT embryos). Analysis of E13.5 
Pax1/Pax9 double-null mutants may reveal their true regulation. 
 
(III) A small number of genes are differentially expressed in the Pax1-/- mutants 
It appears that the knock-out of Pax1 alone affects only a small population of 
genes. The total number of genes changing at each stage (E12.5 and E13.5) was 
also about the same. This was not too surprising since at these developmental 
stages, the only morphological defects seen in the Pax1-/- embryos were a loss of 
vertebral body and IVD cells, mainly in the lumbo-sacral region (Figures 26 & 27; 
similar to what has been reported before [73, 76]). It is well known that a critical 
number of cells are needed to form a condensation, and that the size of the 
condensation in turn determines the size of the skeletal element formed later [116, 
118]. Thus, the loss of cells from particular vertebral segments probably translates to 
the absence of or small-sized vertebrae in the lumbo-sacral region of the adults, 
which in turn leads to a misaligned vertebral column giving rise to a kinked-tail 
phenotype.  
Another reason for the small number of differentially expressed genes could 
be compensation by Pax9, thus masking most of the genes regulated by Pax1 in an 
analysis of just Pax1-/- with WT. Indeed, the paralogous genes Pax1 and Pax9 are 
known to synergistically regulate axial skeleton development [62]. Therefore, to 
uncover these masked genes (genes compensated by Pax1/Pax9), it is essential to 
analyze the double KO embryos.  
 
3.5.4 Genes regulated by both Pax1 and Pax9  
As it was evident that majority of the genes regulated by Pax1 was masked 
by Pax9, and a gene-dosage effect of Pax1 and Pax9 on axial skeleton formation has 
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been reported before, multiple allele KO embryos were collected for gene expression 
analysis. This included the Pax1-/-Pax9+/- (3 allele KO) and Pax1-/-Pax9-/- (4 allele KO, 
i.e. double-null) mutants. A rate-limiting step for this analysis was obtaining sufficient 
number of cells for gene expression profiling as the chances of getting a 3 allele KO 
and 4 allele KO mutants from mating the double heterozygotes (Pax1+/-Pax9+/-) are 2 
in 16 and 1 in 16 respectively (based on Mendellian ratio of inheritance). Also, the 3 
allele KO mutants do not survive (Pax1-/-Pax9+/- and Pax1+/-Pax9-/- undergo postnatal 
lethality), which precluded them for use in mating. Hence, from mating a pair of 
double heterozygotes, each of the embryos had to be sorted separately and 
subsequently their genotypes were determined by PCR genotyping. Therefore, 
considering the cost-, time- and labour-intensiveness of this study, the analysis was 
restricted to just Pax1-/-Pax9+/- and Pax1-/-Pax9-/-, and the Pax1+/-Pax9-/- could not be 
analyzed. In the double-null embryos, the first signs of abnormalities in cell 
proliferation and apoptosis of sclerotomal cells and an arrest of chondrogenesis was 
observed at E12.5, so the gene expression profiling was performed for embryos at 
E12.5 [62].  
In total, 3 biological replicates (2 embryos each) worth of cells were collected 
for each of the Pax1-/-Pax9+/- and Pax1-/-Pax9-/- genotypes (Table 4 for RIN values). 
Owing to time and fiscal constraints new Pax1+/E (WT) and Pax1-/- samples could not 
be collected. Hence, cDNA from the Pax1+/E (WT) and Pax1-/- embryos, left-over from 
the biological replicates used in the prior analysis (E12.5 Pax1-/- vs WT), were biotin-
labelled and used in the new microarray chips alongside the multiple-allele KOs (3 
biological replicates each). Since the Pax1+/E (WT) and Pax1-/- samples were stored 
in the cDNA form at -20oC, degradation ought to be minimal. Nevertheless, to 
improve the accuracy and statistical strength of the results, the new gene expression 
data set was combined with the old data set. That is, the raw intensity data from 
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these new multiple allele KO gene expression results and the old gene expression 
results (E12.5 Pax1+/E (WT), Pax1+/- and Pax1-/-) were loaded on to GeneSpring GX™ 
11.0 software and quantile normalized. Any differences between both batches of data 
were successfully mitigated by quantile normalization. This allowed the data to be 
comparable across all of the new and old samples. A gene-level analysis and a more 
stringent statistical testing (one-way, Welch ANOVA; i.e. unequal variance) was 
performed with Benjamini-Hochberg multiple testing correction (protects against 
false-positives) and Student Newman-Keuls (SNK) post-hoc test. Only genes with p-
value < 0.05 and FC > 1.5 were deemed differentially expressed. 
 
3.5.4.1 Differential gene expression analysis of multiple allele knock-out 
The various comparisons made in the multiple-allele KO analysis are shown 
schematically in Figure 42. The assumptions for these comparisons are as follows: 
the comparison of Pax1-/- with WT would reveal targets uniquely regulated by Pax1, 
direct or indirect. Likewise, the targets regulated by both Pax1 and Pax9 can be 
revealed by a comparison of WT with the 3 allele KO and 4 allele KO. The 
comparison of Pax1-/- with a 4 allele KO would give the targets regulated by 2 copies 
of Pax9 in the absence of Pax1, while the comparison of the 3-allele KO with the 4 
allele KO would reveal the targets regulated by a single copy of Pax9 in the absence 
of Pax1. By default, these targets are assumed to be Pax1 targets as well since in 
the Pax9+/- and Pax9-/- embryos, no vertebral column defect is observed, and Pax1 is 













Figure 42: Schematic of multiple allele knock-out comparisons and the 
potential targets they would reveal. WT – wild-type; KO – knock-out. 
 
In the double-null vs WT analysis, a total of 599 genes were differentially 
expressed (326 genes down- and 273 genes up-regulated in the double-null 
embryos). This is about six times more than what was seen in the E12.5 Pax1-/- vs 
WT (130 genes). With the Pax1-/-Pax9+/- (3 allele KO) vs WT, a total of 467 genes 
were differentially expressed. Also, in the comparison of Pax1-/- vs double-null (genes 
regulated by 2 copies of Pax9), 844 genes were differentially expressed. Whereas 
the comparison of Pax1-/-Pax9+/- (3 allele KO) vs Pax1-/-Pax9-/- (4 allele KO) (genes 
regulated by 1 copy of Pax9) showed only 120 genes to be differentially expressed. It 
was quite unexpected that 2 copies of Pax9 could be regulating many more genes 
than Pax1 and Pax9 combined (844 genes vs 599 genes), when Pax1 is believed to 
play a bigger role in axial skeletogenesis. However, the actual gene regulation might 
be more complex and not necessarily have a linear change in terms of number of 
genes that are differentially expressed. Nevertheless, these results indicate that the 
comparison of the Pax1-/- with the 3 alleles or 4 allele KO can reveal genes regulated 
by Pax9 in the absence of Pax1 (genes masked by redundancy) (Figure 43). 
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Gene Ontology enrichment analysis was performed on the set of differentially 
expressed genes in the E12.5 WT vs double-null comparison (599 genes) using 
DAVID.  As expected, several more GO terms were enriched compared to what was 
seen in the E12.5 Pax1-/-, such as ECM, cartilage development, skeletal system 
development, cell adhesion and apoptosis. Interestingly, these terms were also 
enriched in the E13.5 Pax1-/-. GO terms that were not found in either of the E12.5 or 
E13.5 Pax1-/-, but were only enriched in the double-null were collagen fibril 
organization, pattern binding, thyroid metabolic process, blood vessel development, 
cell motion, TGF-beta binding, platelet derived growth factor binding, appendage 
development and epithelial cell proliferation (highlighted in red in Figure 43 B; details 
of the genes involved are shown in Table 11). Validation of some of the targets was 
performed by sectioned in situ hybridization on the Pax1-/-Pax9+/- embryos as more of 
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Table 11: Genes enriched for selected GO terms in the Pax1-/-Pax9-/- mutants 
 
Genes in bold are known to be expressed in the IVD anlagen (inner or outer annulus 
fibrosus) or somites; genes which are down-regulated in the Pax1-/-Pax9-/- mutants 

























































Figure 43: Number of differentially expressed genes in multiple allele KO 
comparisons and the GO enrichment. (A) Bar graph of all the differentially 
expressed genes. (B) GO enrichment of differentially expressed genes from the 
Pax1-/-Pax9-/- vs WT comparison (Pax1 and Pax9 targets). New GO terms that were 
not found in the E12.5 or E13.5 Pax1-/- vs WT comparisons are highlighted in red. 
The -log10 (p-value) are shown at the end of the bars; a value of more than 1.3 is 
deemed significant (-log10 transformation of a p-value of 0.05 is equal to 1.3).The 
directionality is always in relation to the genotype shown first. i.e. in Pax1-/-Pax9-/- vs 
WT, Up refers to genes up-regulated in Pax1-/-Pax9-/- compared to WT. WT – wild-

































































































Figure 44: Validation of selected targets by sectioned in situ hybridization. 
Respective anti-sense probes were hybridized on 10 uM thick paraffin sections of 
E12.5 WT and Pax1-/-Pax9+/- embryos. Adjacent transverse sections from lumbo-
sacral regions were used. For Col2a1 and Wwp2, the expression in the notochord is 
unaffected since Pax1 and Pax9 are not expressed there. Red arrows point to the 
notochord. All the pictures were taken at a magnification of 100x. NT – neural tube; 
FC – fold change. 
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Figure 45: Venn diagram of overlap of genes from the different genotype 
comparisons. 4-allele KO – Pax1-/-Pax9-/- ; 3-allele KO – Pax1-/-Pax9+/- ; 2-allele KO 
– Pax1-/-. WT – wild-type; KO – knock-out. 
 
 
The differentially expressed genes were then overlapped for the different 
microarray gene expression comparisons to elucidate the trend in the regulation of 
genes. The various degrees of overlaps can be seen from the Venn diagram in 
Figure 45. The biggest overlap was between blue and yellow segments - genes 
regulated by both Pax1 and Pax9 (4 allele KO vs WT - blue) and genes regulated by 
2 copies of Pax9 in the absence of Pax1 (4 allele KO vs 2 allele KO - yellow). These 
overlapping set of genes (448 genes) are probably those Pax9 was regulating to 
compensate for the loss of Pax1. Likewise, 79 of the genes regulated by a single 
copy of Pax9 in the absence of Pax1 (green), overlapped with the 4 allele KO vs WT 
(blue). These are the genes which change when the last copy of Pax9 is also 
removed in the absence of Pax1. Besides these, a total of 28 genes (21.5%) from 
E12.5 Pax1-/- and 17 genes (13.9%) from E13.5 Pax1-/- were overlapping with the 
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genes regulated in the 4 allele KO (blue overlap red). Of the 28 genes from E12.5 
Pax1-/-, 27 of them showed the same directionality with the 4 allele KO. On the 
contrary, from the 17 genes in the E13.5 Pax1-/- only 4 showed the same 
directionality, while 13 of them showed opposite directionality. 11 of the 13 genes 
were up-regulated in the E13.5 Pax1-/- but down-regulated in the E12.5 Pax1-/-Pax9-/- 
(Table 12). Also, those set of genes were not differentially expressed in the E12.5 
Pax1-/-. The fold change values and direct binding sites of these genes are provided 
in section 3.6.4, Table 13. 
Table 12: Genes with opposite or same directionality in double-null and Pax1-/- 
Gene symbol E12.5 Pax1-/-Pax9-/- vs. WT E13.5 Pax1-/-  vs. WT 
Col2a1 Down (3.12) Up (2.21) 
Wwp2 Down (2.46) Up (1.60) 
Sox5 / A730017D01Rik  Down (2.23) Up (1.63) 
Extl1 Down (1.78) Up (3.08) 
Ctgf Down (1.57) Up (1.74) 
Nnat Down (2.62) Up (1.78) 
Greb1 Down (1.85) Up (1.54) 
Cdc25c Down (1.79) Up (1.95) 
Csrp2 Down (1.75) Up (1.52) 
Tle1 Down (1.68) Up (1.63) 
Sorl1 Down (1.54) Up (1.57) 
Anxa11 Up (1.87) Down (1.55) 
Plagl1 Up (1.54) Down (2.16) 
4833440I11Rik Down (2.23) Down (1.95) 
Mgst2 Down (2.39) Down (2.39) 
Hspg2 Down (2.37) Down (1.66) 
Crh Up (6.04) Up (2.85) 
Gene symbol E12.5 Pax1-/-Pax9-/- vs. WT E12.5 Pax1-/-  vs. WT 
Crh Up (6.04) Up (2.51) 
Cxcl13 Up (4.07) Up (1.91) 
C030002B11Rik/ 
Ppm1h Up (2.39) Up (1.66) 
AI593442 Up (3.34) Up (2.08) 
Tek Up (3.29) Up (1.65) 
Cbln2 Up (2.97) Up (1.86) 
Myocd Up (3.95) Up (1.86) 
Tcfec Up (2.88) Up (1.79) 
Vstm2 Up (1.77) Up (1.59) 
	   118	  
Maf Up (2.76) Up (2.17) 
Plekhd1/ 
3830431G21Rik Up (2.12) Up (1.65) 
Luzp2 Up (2.10) Up (1.95) 
Mid1 Up (2.01) Up (1.75) 
Tmem87a Up (1.96) Up (2.17) 
Tmem106c/D15Ertd40
5e Up (1.89) Up (1.56) 
Kdt1 Up (1.69) Up (1.72) 
Pdzrn4/1110017D07Ri
k Up (1.68) Up (2.05) 
Nlgn1 Up (1.58) Up (1.64) 
6820402O20Rik/ Phf20 Down (2.14) Down (1.52) 
Kcnrg Down (2.11) Down (1.59) 
Crym Up (1.68) Down (1.56) 
Sorbs2/ 
9430041O17Rik Down (2.08) Down (1.87) 
Kcna1 Down (2.33) Down (1.76) 
Col11a1 Down (1.85) Down (2.07) 
D330048F12Rik Down (1.79) Down (1.58) 
Fibin/ 1110018M03Rik Down (1.76) Down (1.91) 
Mmp24 Down (1.53) Down (1.72) 
C130072C03Rik Down (1.53) Down (2.07) 
 
 
3.5.4.2 Discussion  
 
The analysis of Pax1/Pax9 double-null embryos has clearly revealed several 
more genes regulated by both Pax genes. These genes were also enriched for 
relevant processes like collagen fibril organization, cartilage development, skeletal 
system morphogenesis, cell motion and proliferation, ECM proteins and cell 
adhesion. How these processes are relevant to Pax1 and Pax9 function in IVD 
development are discussed in this section. 
 
(I) Collagen fibril organization 
 
Collagen fibril organization refers to processes that order the collagen fibrils 
within the ECM and so is vital to maintain the structural integrity of the IVD [126]. 
Several genes involved in this process were dysregulated in the double-null embryos 
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(Figure 43; Tables 11 and 12). Disorganization of collagen fibres is known to impede 
their ability to resist the osmotic swelling pressure generated by the water retention of 
the proteoglycans (eg. aggrecan) in the cartilage ECM. This often results in abnormal 
vertebral bodies and IVDs that lead to misalignments and even degeneration [127]. 
Targeted knock-out or mutations in several of the genes involved in this process, 
such as Acan [128], Col2a1 [127, 129] and Col11a1 [130], are associated with 
various skeletal defects. More importantly, they were all down-regulated in the 
Pax1/Pax9 double-null mutants.   
Mouse mutants of Acan, Col2a1 and Col11a1 exhibit remarkably similar 
phenotypes such as craniofacial defects (cleft palate, short snout), shortened limbs, 
abnormal/ misaligned vertebral bodies which give rise to kyphosis, dwarfism and disc 
degeneration/ herniation at post-natal stages [127, 128, 130]. The highly similar 
phenotypes may be because they are all integral components of the cartilage ECM 
and play a collaborative structural function. Importantly, cleft palate and vertebral 
abnormalities are characteristic features of the Pax1/Pax9 double-null mutants as 
well [62]. Moreover, certain forms of kyphoscoliosis in humans have been linked to 
the PAX1 gene [84-86].  
The Acan gene encodes for the large proteoglycan - aggrecan, which is a 
major component of the cartilage ECM [128]. Mutations in the human ACAN gene 
have been linked to spondyloepiphyseal dysplasia (SEMD) and osteoarthritis [131, 
132].  
Similarly, collagen II also forms a key component of the ECM. It is a 
homotrimer composed of αI (II) chains which are encoded by Col2a1 gene. In 
Col2a1-null mice, the IVDs fail to form owing to disorganized collagen fibrils which 
results in a failure of notochord dismantling in the vertebral bodies as well as its 
expansion into the IVD regions [127]. In humans, mutations of COL2A1 gene are 
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responsible for various type II collagenopathies, certain forms of SEMD and rare 
skeletal dysplasia like dysspondyloenchondromatosis (DSC) [129]. Besides, Col3a1 
and Col5a1 were up-regulated in the double-null mutants. This was not surprising 
since ectopic expression of other types of collagens is known to occur in the mutant 
cartilage lacking collagen II. For instance, in the Col2a1-null mice, collagen I and III 
were found to be ectopically expressed in the cartilage. Hence, a similar mechanism 
might be involved in the double-null mutants, which may be forming abnormal 
heterotypic collagen fibrils owing to the reduction in the expression of αI (II) collagen 
chains [127].  
 Col11a1 also encodes fibrillar collagen (type XI), but unlike collagen II, it is 
only a minor component of the ECM. It copolymerizes with collagen type II molecules 
and is postulated to regulate collagen fibril diameter [130]. Similar to ACAN, 
polymorphisms in human COL11A1 have been associated with susceptibility to 
lumbar disc herniation (LDH) [133-135]. It is noteworthy that the biochemical 
hallmarks of IVD degeneration are altered proteoglycan and collagen content of the 
IVD ECM. The loss of structural integrity of the IVD components (annulus fibrosus 
and nucleus pulposus) is responsible for the reduced load-bearing ability of the disc, 
which leads to progressive degeneration [29, 136, 137]. Thus, Acan, Col2a1, 
Col11a1, as well as the other genes like Dpt, Col3a1 etc (Tables 10 and 11) which 
have essential roles in collagen fibril organization, all play important structural 
functions in the IVD anlagen.  
Thus, these observations reiterate that Pax1 and Pax9 have essential roles in 
IVD morphogenesis. More importantly, the identification of Pax1 and Pax9 to be 
regulators of these genes in the IVD is a novel finding.  
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(II) Cartilage and skeletal system morphogenesis 
In the Pax1/Pax9 double-null mutants, numerous genes involved in cartilage 
development and skeletal system morphogenesis were enriched (Figure 43; Tables 
10 and 11). Besides Col2a1 and Acan, Sox5 and BMP4 were also differentially 
expressed, which are well known for their importance in cartilage development.  
Sox5 (SRY-box containing gene 5) encodes a HMG-domain containing TF. 
Sox5 and Sox6 play redundant but important roles in the regulating the proliferation 
of chondroblasts and up-regulating the cartilage matrix genes like Acan [138] and 
Col2a1 [139] for the timely maturation of chondroblasts. While Sox5 and Sox6 single-
null mutants possess very mild skeletal defects, the Sox5/Sox6 double-null mutants 
are characterized by chondrodysplasia owing to defect in the differentiation of the 
chondroblasts [140]. Moreover, their ability to regulate Fmod, an IVD anlagen 
marker, and the impairment of IVD formation in the Sox5/Sox6 double-null mutant, 
suggest they have essential roles in IVD development [119]. It is also noteworthy that 
Sox5 was down-regulated along with Acan and Col2a1 in the Pax1/Pax9 double-null 
mutants [119, 140]. This indicates that the down-regulation of Acan and Col2a1 might 
potentially be because of Sox5 down-regulation rather than a direct effect of the 
Paxes. The ChIP-Seq analysis of Pax1 and Pax9 would confirm if they are direct or 
indirect targets (discussed in section 3.6.4, Table 13).  
Bone morphogenetic protein 4 (encoded by Bmp4) belongs to the TGF-beta 
superfamily of secreted signalling proteins. As the name suggests, BMPs are growth 
factors important in endochondral bone formation [111]. During the very early stages 
of patterning and compartmentalization of the somites, antagonism of BMP signal is 
necessary for sclerotome specification [42]. But in vivo rescue experiments [141] and 
in vitro experiments [142] on cultured explants showed that at later stages, BMP 
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signalling promotes ECM production and chondrocyte proliferation which are 
essential functions in cartilage development. 
 
(III) Growth factor binding ECM proteins  
Hspg2 encodes the large heparan sulfate proteoglycan, perlecan, which 
accumulates significantly in the ECM during cartilage development. It has important 
roles in cell adhesion and growth factor binding (eg. FGFs and PDGF-B), whereby 
the latter function modulates growth factor bioavailability [143]. Moreover, the 
targeted null mutants showed decreased chondrocyte proliferation, decreased 
glysosaminoglycan content and abnormal collagen fibril organization in the ECM, 
which resulted in chondrodysplasia, thus emphasizing the importance of perlecan 
[144, 145]. 
Similarly, Cspg2 (versican) encodes a larger chondroitin sulfate proteoglycan 
of the ECM. It is important in localizing the TGF-beta molecules, thus regulating its 
signals for joint development. Considering that TGF-beta signals have been shown to 
be important in the IVD development (a form of joint in the vertebral column), and 
versican is also expressed in the IVD anlagen, it might be playing similar roles in 
tethering TGF-beta (expression database: www.eurexpress.org) [146].  
Ctgf, connective tissue growth factor, encodes a secretory protein that is 
associated with the ECM. It is a well known for its multiple properties and functions 
like mitogen, cell adhesion, migration, ECM remodelling, ECM production and 
chondrogenic differentiation [147]. It mediates TGF-beta and BMP signals by directly 
interacting with them [148]. Upon induction by TGF-beta it promotes mesenchymal 
cell condensation and ECM production [149, 150].  It also binds BMP7 and prevents 
its inhibition of TGF-beta signalling [151]. Also, in the Ctgf-/- mice, endochondral 
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ossification is delayed and they show cleft palate and enlarged vertebral bodies in 
the axial skeleton [152].  
Thus, Pax1 and Pax9 activate genes which encode ECM proteins that are 
essential components of cell signalling as they interact with the growth factors to 
stimulate the cells to grow or proliferate (Figure 43; Tables 10 and 11). 
 
(IV) Cell motion 
Genes involved in cell motion were also enriched in the Pax1/Pax9 double-
null mutants (Figure 43). During the early stages of paraxial mesoderm formation, 
Pax1 expressing cells from the ventro-medial somites are known to migrate toward 
the notochord and surround it [153]. Also, Pax9 is expressed in neural crest-derived 
tissue, whereby neural crest cells are known to have migratory properties [74]. 
Moreover, in the double-null mutants, the fluorescing cells were found to be mis-
localized in the lateral regions and failed to surround the notochord medially (Figure 
31). Hence, cell motion is likely an essential property of these Pax1- and Pax9-
expressing cells. Although these genes are often associated with axon guidance, 
they also show regionally restricted expression in the somites at E9.5 and/or IVD at 
E14.5 (eg. Alcam, Sema6a, App, Psen1, Ctgf, Etv1, Reln, Nr2f2, Boc and Foxd1; ref 
- Expression databases: eurexpress.org, MGI and EMAGE). Of these, Psen1 and 
Ctgf are known to have skeleton defects in the targeted null mutants, with Psen1 
mutants exhibiting a phenotype strikingly similar to Pax1/Pax9 double-null mutants 
(Tables 10 and 11). 
Psen1 encodes a transmembrane protein, presenilin 1, which is involved in 
regulating cell motion and cell proliferation, mainly identified through neuronal studies 
[154]. While it has been strongly related to the Alzheimerʼs disease, the targeted null 
mutants of Psen1 also show a dramatic axial skeleton defect characterized by fused 
	   124	  
vertebrae throughout the entire vertebral column, lack of sacral elements and floating 
ribs. The mice exhibit very short, curled tails [154]. Some of these skeletal defects 
are similar to the Pax1/Pax9 double-null mutants which also exhibit a strong skeletal 
phenotype with absent sacral elements and the proximal parts of ribs [62]. Also, 
somitogenesis and sclerotome formation are unaffected in both Pax1/Pax9 double-
null mutants and the Psen1 mutants [62, 154]. The lack of sufficient studies on the 
skeleton phenotype in the Psen1-/- mutants hinders the identification of the actual 
roles of Psen1 in axial skeletogenesis. Nonetheless, their migratory, proliferation and 
cell-adhesion roles in the neurons can probably be extrapolated to the skeletal cells 
as well. 
 
(V) Cell proliferation 
Likewise, genes involved in proliferation were also differentially expressed 
(Bmp4, Psen1, Col8a1 and Col8a2). While the GO term is referred to as “epithelial 
cell proliferation”, these genes are also expressed in the IVD anlagen, hence 
probably have similar functions in IVD development (Expression databases: 
eurexpress.org, MGI and EMAGE) (Figure 43 and Table 11). Besides these, others 
like Ctgf, Sox5 and Hspg2 which were discussed above, are also known to promote 
proliferation.  
 
(VI) Pax1 and Pax9 expression levels 
Intriguingly, Pax1 was down-regulated in the Pax1/Pax9 double-null mutants. 
The decrease was evident with multiple copies of Pax9 being lost in the Pax1-/- 
background (i.e. double-null vs Pax1-/-: 1.50-fold down; and double-null vs WT: 2.35-
fold down). It is not clear if Pax1 or Pax9 or both are regulating it directly, or if the 
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down-regulation is an indirect consequence.  ChIP-seq experiments on Pax1 and 
Pax9 TFs may illuminate the regulation of Pax1 (section 3.6.4). 
It is notable that with the strategy employed in this study to knock-out Pax1 or 
Pax9, the full length transcript would be produced. It is during translation the protein 
product is not made. Hence, the decrease seen in Pax1 transcript level is not 
because of truncation of the transcript, but a true down-regulation.   
Peters et al (1999) reported that the Pax9 domain of expression was spatially 
expanded and up-regulated in the anterior segment of the sclerotome in the Pax1-/-
Pax9+/- and Pax1-/-Pax9-/- embryos at E10.5 [62]. This was proposed by the authors 
as a potential mechanism by which Pax9 partially rescues Pax1-deficiency. Contrary 
to what has been reported before, in this gene expression profiling study, Pax9 was 
not differentially expressed in any of the knock-out mutants (i.e. 4 allele KO, 3 allele 
KO or 2 allele KOs). The Pax9 protein expression resembled that of the WT in both 
heterozygote and homozygote Pax1 mutants (Figure 25). In the study by Peters et al, 
1999, the authors had knocked-out Pax9 by the insertion of a lacZ cassette in the 
exon of Pax9 [107]. Hence, the mode by which the authors had investigated Pax9 
expression levels was through X-gal staining, which is not an accurate method of 
assessment of the actual Pax9 protein levels. Prolonged X-gal staining is known to 
give rise to spurious background staining [107]. With our current method of 
assessment using immunohistochemistry, neither a change in Pax9 expression level 
nor a spatial expansion was observed in the E13.5 Pax1+/- and Pax1-/- embryos.  
Then again, it is possible that such spatial expansion might occur only at 
E10.5, the stage which the authors had investigated. The Pax9 expressing cells may 
have moved into Pax1 regions to compensate. Pax1 expression is found in all the 
sclerotomal cells initially, and later it becomes restricted to posterior ventro-medial 
regions. Pax9 is expressed in the posterior regions [62]. Hence, in the absence of 
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Pax1, Pax9-expressing cells may have occupied the anterior regions to compensate, 
and once the patterning was complete, they may have been subjected to the same 
regulatory controls from the neighbouring tissues as Pax1-cells normally would have 
and become restricted to the posterior regions. Hence, such a spatial expansion may 
have been missed by our investigation in E13.5 embryos. Therefore, while the 
increase in transcript level does not explain the compensation, spatial expansion 
theory still remains a possibility. Investigation of the Pax1-/- and Pax1-/-Pax9+/- 
embryos at E10.5 might help clarify this doubt. 
 
(VII) Genes with opposite directionality – a consequence of compensation? 
The set of genes exhibiting opposite directionality in regulation were 
particularly interesting since they were up-regulated only at E13.5 in the Pax1-/- 
(unchanged in E12.5 Pax1-/-), but down-regulated once both copies of Pax9 were 
lost. Sox5, Col2a1, Wwp2, and Ctgf were among those set of genes (Table 12). The 
basis for this trend might be because Pax9 was compensating for the loss of Pax1. 
Also, as mentioned earlier (section 3.5.3), Sox5, Col2a1, Wwp2 and Ctgf are known 
to be down-stream targets of Sox9 [125]. Hence, Sox9, which was concomitantly up-
regulated in E13.5 Pax1-/-, may be cooperating with Pax9 in activating these targets 
in the absence of Pax1, resulting in an up-regulation of these targets beyond normal 
levels. The time delay might be because sufficient time was needed for the 
transcripts to be up-regulated to significant levels.  
Then again, one might argue that a similar trend would be observed if Pax1 
was repressing while Pax9 was activating these genes. However, if Pax1 and Pax9 
were functioning antagonistically, one would expect the transcript levels of these 
genes to return to normal once both the activator and repressor were removed. On 
the contrary, a significant down-regulation is observed. Moreover, Sox9 was not 
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differentially expressed in the E12.5 Pax1/Pax9 double-null mutants. This precludes 
Sox9 from being responsible for the observed down-regulation. Furthermore, Pax1 
and Pax9 are paralogous genes and are known to function synergistically [62]. Thus, 
it is highly possible that Pax1 and Pax9 were not functioning antagonistically. Only 
through further experimentation can we determine which hypothesis holds true.  
One way to assess the validity of these postulations is to similarly investigate 
the differential gene expression pattern in the Pax9-/- and Pax1+/-Pax9-/- mutants (with 
respect to WT). Taking Col2a1 as an example, if a similar spike in expression level is 
seen in the Pax9-/- and a subsequent down-regulation in the Pax1+/-Pax9-/- mutants, 
the second hypothesis would be valid, i.e. both Pax1 and Pax9 are activators. 
Performing an in vitro assay is complicated because there are no sclerotomal cell 
lines available. Chondrogenic cell lines may be used instead, like differentiated 
ATDC5 cells or C3H10T1/2 (multipotent murine mesenchymal stem cell-line), but the 
differentiation process must be optimized since Pax1 and Pax9 are known to be 
down-regulated upon chondrogenesis and are not expressed in the fully 
differentiated mature cartilage of the vertebral bodies [62, 71]. Assuming that the 
differentiation conditions are optimized, the cells can then be transfected with over-
expression vectors of Pax1 and/or Pax9. The endogenous Col2a1 transcript levels 
can be assessed at different concentrations of the Pax1 and/or Pax9. If Pax1 was a 
repressor and Pax9 an activator, Col2a1 level should go up with decreasing 
concentrations of Pax1 or increasing concentrations of Pax9. One caveat of this 
method is that it is not clear if endogenous Sox9 might complicate the results. 
However, considering that it is an over-expression assay, the effects of endogenous 
Sox9 may be minimal. 
In conclusion, all the target genes discussed here exhibit phenotypes or 
defects of the axial skeleton some of which are strikingly similar to that of the 
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Pax1/Pax9 double-null mutants. It has to be noted though that the expression of 
these genes are not totally abrogated in the double-null mutants. Therefore, no one 
gene could be responsible for the phenotype observed in the Pax1/Pax9 double-null 
mutants. Instead, they prove the point that they are all linked in a common pathway 
and it must be a collective effect of the dysregulation of these genes which results in 
the skeletal defect seen in the Pax1 and Pax9 mutants. Moreover, the analysis of the 
single-null mutant and double-null mutant revealed genes with opposite directionality 
in regulation, indicating potential compensation effects. It is not clear if the 
compensation is caused by Pax9 or in conjunction with other genes like Sox9.  
 
3.6 Genome-wide binding site mapping of Pax1 and Pax9  
Genome-wide mapping of TF binding site is essential to complement the 
differential gene expression data derived for Pax1 and Pax9. The differential gene 
expression analyses reveal the genes regulated directly by Pax1/ Pax9 as well as 
those that are affected indirectly owing to the altered cascade of events triggered by 
the loss of Pax1/Pax9. Hence, the direct binding targets of Pax1 and Pax9 in the WT 
tissue identified through TF mapping and overlapping this data with their 
corresponding differential gene expression data, would reveal which genes are 
directly regulated (differentially expressed as well as have Pax1/Pax9 binding sites) 
and indirectly regulated (differentially expressed but lack corresponding Pax1/Pax9 
binding site). This would add another dimension to comprehending Pax1/Pax9 
transcriptional regulation of these genes. Chromatin immunoprecipitation coupled 
with high-throughput sequencing allows the identification of binding sites of TFs on a 
genome scale, and with a high resolution. 
While the HA-tagged mouse lines were being generated for the ChIP-Seq 
studies, in the meantime, TF mapping was performed using gene-specific antibodies 
on WT embryos. At the time this study was performed, there were only two 
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commercially available ChIP-grade antibodies each for Pax1 and Pax9. Even though 
Pax1 and Pax9 belonged to the same subfamily their proteins were highly divergent 
at their C-terminal ends. Hence, to avoid cross-reactivity, these commercial 
antibodies were raised against the C-terminal fragments of the proteins (amino acids 
246-361 of mouse Pax1 and amino acids 247-341 of human PAX9). To ensure that 
these antibodies indeed did not cross-react, their specificity was first checked by 




Figure 46: Pax1 and Pax9 ChIP-grade commercial antibodies were specific. (A 
& D) E13.5 WT embryos probed with anti-Pax1 and anti-Pax9 antibodies 
respectively. Only anti-Pax9 antibody detected expression in the tooth and nasal 
mesenchyme, which are Pax9-specific regions. (B & E) Transverse sections of E13.5 
Pax1-null embryos probed with anti-Pax1 and anti-Pax9 antibodies respectively. Anti-
Pax1 antibody did not detect the Pax9 protein (B) which was still expressed in the 
Pax1-null embryos (E). (C & F) E13.5 Pax9-null embryos probed with anti-Pax1 and 
anti-Pax9 antibodies respectively. Anti-Pax9 antibody did not detect Pax1 protein (F) 
which was still expressed in the Pax9-null embryos (C). Paraffin sections of 10 uM 
thickness were used for immunohistochemistry. Anti-Pax1 ab – Santa Cruz M116X; 
anti-Pax9 ab - Santa Cruz H95X. ab – antibody. 
 
The ChIP-grade antibodies Santa Cruz Pax1 M-116X (sc-25407x) and Santa 
Cruz Pax9 H-95X (sc-25410x) were tested on E13.5 mouse embryo sections by 
immunohistochemistry for sensitivity and specificity. Anti-Pax1 antibody was 
sensitive enough to detect endogenous Pax1 protein (Figure 46C).  It also did not 
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cross-react with Pax9 evident from the lack of signal in the tooth and nasal 
mesenchyme which are Pax9-specific regions (Figure 45A). In addition, the anti-Pax1 
antibody did not show any signal in the Pax1-null embryo, despite the presence of 
endogenous Pax9 protein (Figure 46B). Likewise, anti-Pax9 antibody was able to 
detect the Pax9 protein specifically in the tooth and nasal mesenchyme in the WT 
embryo (Figure 46D), as well as the vertebral column in the Pax1-null embryo (Figure 
46E). It did not detect any signal in the Pax9-null embryos which still expressed Pax1 
protein (Figure 46F). Thus, both antibodies proved to be sensitive and specific in 
detecting the right proteins. Therefore, I proceeded to perform the ChIP on the CD1 
WT, embryonic vertebral column-enriched tissues using these antibodies. 
For immunoprecipitation, only the dissected vertebral column tissues 
(discarded were head, limbs and internal organs) were used. After 
immunoprecipitation according to the procedure mentioned in the Materials & 
Methods section, the library was prepared from the ChIP-DNA (Illumina ChIP-Seq 
DNA Prep kit) and was subsequently size-selected (200-300bp), purified, quantitated 
by Agilent Bioanalyzer (DNA chip) and sent for sequencing by Illuminaʼs Solexa 
sequencing platform (Figure 47). The input chromatin was used to prepare the 
control library, which was used as the background control. Any region bound by the 
Pax1 or Pax9 proteins solely due to the open chromatin state (i.e. background) can 
be identified using this input library and accordingly subtracted from the signals 
detected in the Pax1- and Pax9-libraries. The ChIP-Seq was performed on E13.5 
and E12.5 embryonic tissues for Pax1 and Pax9 respectively. While E12.5 Pax1 
ChIP-Seq and E13.5 Pax9 ChIP-Seq were meant to be performed subsequently, 
owing to unforeseen fiscal constraints, those experiments could not be performed. 
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Figure 47: ChIP-Seq libraries for sequencing. (A) Pax1 ChIP-Seq library analyzed 
by Agilent Bioanalyzer; (B) Pax9 ChIP-Seq library; (C) input library prepared from 
sonicated chromatin. (D) Representative picture of sonicated chromatin resolved on 
1% agarose gel. 
 
3.6.1 Binding site distribution of Pax1 and Pax9 
After high-throughput sequencing of the short tags of DNA in the libraries, the 
sequence reads were mapped to the mouse genome (NCBI build 37/mm9) to identify 
the genomic binding sites of Pax1 and Pax9. The peaks were called using Model-
based Analysis of ChIP-Seq (MACS) algorithm [155]. Binding sites can be 
considered biologically relevant only if the tag density reads (peaks) in those regions 
are significantly enriched above the background levels (input control). In this study, a 
stringent fold-enrichment p-value cut off of a minimum 1.00e-5 was applied to identify 
significant peaks. 
For Pax1 and Pax9 libraries, after background subtraction and statistical 
analysis, a total of 10,203 peaks (p-value ≤ 1.00e-5)	 and 11,333 peaks (p-value ≤ 
1.00e-10)	 were identified for Pax1 and Pax9 respectively. The binding site 
distribution for the number of peaks within the TSS, promoter, intragenic, proximal, 
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distal and beyond 100 kb of a gene was assessed for Pax1 and Pax9. The 
percentage of binding site distribution is shown as a pie-chart in Figure 48, including 
the criteria set for defining the TSS/ promoter/ intragenic/ proximal/ distal/ others 
regions.  
 
Figure 48: Binding site distribution for Pax1 and Pax9. Left: Pax1 had total 
MACS peaks of 10,203, whereby 37% fell in distal, 34% in intragenic, 19% at > 
100kb, 6% in proximal, 3% in promoter and 1% at TSS. Right: Pax9 had a total 
MACS peaks of 11,333, where 29% fell in distal, 25% in intragenic, 21% in TSS, 17% 
at >100kb, 5% in proximal and 3% in promoter. The p-value cut off was 1.00e-5 and 
1.00e-10 for Pax1 and Pax9 respectively. 
 
 From the binding site distribution, it was evident that majority of the binding 
sites fell in a distal region, followed by intragenic sites for both Pax1 and Pax9. This 
indicates that Pax1 and Pax9 were regulating most of their target genes from distal or 
intragenic sites. In fact, gene regulation from distal cis-regulatory elements of > 50 
kb, up to even few hundred kilobases, are not uncommon. For example expression of 
Shh in the Zone of Polarizing Activity (ZPA) in the limbs is driven by an enhancer 
element that resides 1 MB away from Shh locus, in the intron of a neighbouring gene, 
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Lmbr1 [156]. Likewise, enhancers that drive Sox9 expression in the mandible, 
second branchial arch, paraxial mesoderm of ribs and cervical vertebrae all lie in a 
350 kb - 600 kb segment upstream of Sox9 locus [157]. Furthermore, multiple 
independent enhancers may be involved in regulating the expression of a particular 
gene in a specific tissue and time [158]. Chromatin looping brings the TFs bound to 
distal enhancer regions close to the promoter where it interacts with the rest of the 
transcriptional machinery poised for transcription. These distal cis-regulatory 
elements could be enhancer or repressor elements, that control spatio-temporal and 
even the level of expression of a particular gene [159].  
In general, both Pax1 and Pax9 showed a similar distribution within proximal 
(5-6%) and promoter (3%) regions. Remarkably, a striking difference was seen in the 
proportion of peaks within the TSS, whereby it was 21% for Pax9 but only 1% for 
Pax1. Clearly, at E12.5-E13.5, Pax1 was regulating most of its genes from distal or 
intragenic sites whereas Pax9 was regulating a significant proportion from the TSS 
as well.  
 
3.6.2 Motif discovery in Pax1 and Pax9 binding sites 
Pax proteins are known to execute their transcriptional regulation function by 
binding to the DNA via their paired domain and/or homeodomain. Pax1 and Pax9 
belong to subfamily 1, both of which possess only the paired domain and an 
octapeptide motif but not the homeodomain. Hence, their entire binding specificity is 
largely reliant upon the paired box. The Pax proteins are also known to bind the DNA 
as monomers [68]. The paired domain is bipartite in nature, with the N-terminal and 
C-terminal sub domains, each possessing a helix-turn-helix motif (HTH) and DNA-
binding ability [67, 160]. However, the two subdomains are interdependent and 
cannot bind the DNA autonomously [160]. The two subdomains of the paired box 
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recognize two half-sites positioned on adjacent major grooves of the DNA. The 5ʼ half 
site and 3ʼ half sites were identified using Pax5. The 3ʼ half site is recognized by the 
N-terminal subdomain while the 5ʼ half site is recognized by the C-terminal 
subdomain. Moreover, the Pax1 proteins bound to Pax5 recognition sequences, 
albeit with lower affinity than Pax5. Binding to both half sites are needed to confer 
greater affinity and stability in DNA-binding in vitro. Yet base changes in one can be 
compensated by a perfect match on the other. It is believed that such modular 
properties of the HTH motifs may generate diversity in the binding specificities of the 
Pax proteins [67, 160].  
The paired domain of Pax1 is known to recognize a 24 bp sequence. 
Chalepakis et al 1991 [68], through in vitro assays, had identified two 
pentanucleotide core motifs instrumental in the DNA-binding affinity of Pax1: GTTCC 
and TAGAT. The known motifs for Pax1 and Pax9 (verified in vitro / predicted) are 
shown in Figure 49. 
 
 
Figure 49. Pax1 and Pax9 motifs found in motif databases. Motifs for Pax1 and 
Pax9 found in Transfac, Matrix and MEME are shown. For Pax1, both GTTCC and 
TAGAT pentanucleotide core motifs mentioned in the literature are underlined. For 
Pax9, the 3ʼ half site of the paired domain (GTGACC), also identified in our Pax9 TF 
mapping, is underlined. 
 
From the binding sites obtained for Pax1 and Pax9, binding sequence motif 
was identified using Weeder, a motif-finding program (Figure 50). The motif identified 
to be enriched in the Pax1 library did not show the Pax1 motif found in the 
TRANSFAC database. Instead, it showed a motif for Zscan4c, which did not contain 
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either of the pentanucleotide core motif sequences. However, it resembles more of 
the “GTG” based 3ʼ half site of Pax5 subfamily proteins. It  However, when probed for 
motifs enriched up to 250 bp surrounding the binding sites using Centrimo, Pax5 
motif was found. It is noteworthy that Centrimo uses JASPAR motif database which 
does not contain the motifs for Pax1 or Pax9. Hence, any Pax motif the program 
finds, it would not be able to label it as “Pax1” or “Pax9” specifically.  
For Pax9, the 3ʼ half site identified in the Pax5 subfamily (also present in the 
predicted motif for Pax9), was found to be enriched (Figures 49 and 50). Just like 
Pax1, when the 250 bp surrounding the Pax9 binding sites were checked for 









Figure 50: Motif discovery results for Pax1 and Pax9. Weeder motif-discovery 
program was used to assess if Pax motifs were enriched in the Pax1 and Pax9 
libraries. (A) Table of Pax libraries and the corresponding most significant motif, and 
motifs enriched within 250 bp of the binding sites. Pax1 library was enriched for 
Zscan4c motif, while Pax9 showed a Pax2 paired box 3ʼ half-site motif (boxed in red). 
(B) Known consensus 3ʼ half-site motif (boxed in red) for paired domain in the Pax5 
subfamily that also encompasses Pax2 and Pax8. 
 
Even though the expected MGI expression, mouse phenotype and biological 
processes were enriched in the Pax1 ChIP-seq library (discussed in section 3.6.3), it 
was surprising that the known consensus motif was not enriched (Figures 51 and 52 
in the next section). It is possible that such in vitro assay-derived motifs may not be 
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the only sequences Pax1 truly bound to in vivo. In fact, the known Pax1 motif was 
derived solely based on various mutant oligonucleotide sequences derived from a 
single target sequence - the e5 site from Drosophila even skipped promoter. Even in 
vitro, Pax1 protein bound to the native e5 sequence only weakly [68]. Hence, for 
Pax1, there is a possibility that it may have alternative motifs in an actual in vivo 
scenario.  
Besides, even though only a half site, the expected motif was enriched in the Pax9 
ChIP-Seq library which provides confidence in the dataset. 
3.6.3 Gene Ontology analysis of Pax1 and Pax9 binding sites 
Gene Ontology (GO) enrichment analysis is often performed on the binding 
sites to assess the quality of the ChIP-Seq and also to obtain a broader 
understanding of the functions of the genes involved. Hence, the set of GO terms 
enriched (in the Pax1 and Pax9 binding sites) for MGI expression, mouse phenotype, 
biological processes and signalling pathways were assessed using the Genomic 
Regions Enrichment of Annotations Tool (GREAT) web-based tool. In brief, the BED 
file of chromosome regions with peaks (identified by MACS) for Pax1 or Pax9 is 
uploaded to GREAT tool. For each gene GREAT assigns a regulatory domain based 
on user-defined criteria. The genomic regions (binding sites) are then associated with 
the genes whose regulatory domains overlap with that of the binding sites. The 
criteria assigned to define the regulatory domain for this analysis was 5.0 kb 
upstream and 1.0 kb downstream of the TSS and a 1000 kb (1MB) extension in both 
directions to the next closest geneʼs TSS but a maximum extension in only one 
direction (Figure 51). This is also the recommended settings by GREAT [161]. 
 
 





Figure 51. Genomic regulatory domain assignment criteria in GREAT. Arrows 
represent the TSS of a gene. Regulatory domain for each gene was defined as 5.0 
kb upstream and 1.0 kb downstream of the TSS and a 1 MB extension in both 
directions to the next closest geneʼs TSS but a maximum extension in only one 




Figure 52: GO enrichment for MGI expression pattern in Pax1 TF mapping. 
Binding sites were enriched for genes expressed in known Pax1 expression sites like 
embryo skeleton, foregut, cranium, scapula, thymus primordium, tail and paraxial 
mesenchyme and limb. The -log10 (binomial p value) are shown at the end of the 
bars; a value of more than 1.3 is deemed significant (-log10 transformation of a p 
value of 0.05 is equal to 1.3).   
 
In the GREAT analysis expected Pax1-expression sites were significantly 
enriched (log transformed p-value > 1.3) in the Pax1 ChIP-Seq library. Genes 
expressed in the embryo skeleton, foregut, thymus, pectoral girdle, axial skeleton, 
scapula, pre-cartilage mesenchyme, branchial arch, limbs and tail and paraxial 
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2 for Pax1 expression sites). Although the ChIP was performed only on dissected 
vertebral column tissues, expression sites like limbs, thymus, scapula were also 
enriched. This is possibly because the set of genes involved in axial skeleton are 


























Figure 53: GO enrichment for Mouse phenotype for Pax1 binding sites. Pax1 
binding sites were enriched for genes associated with mouse phenotypes like 
abnormal bone, dorsal-ventral axis patterning, thymus development, caudal 
vertebrae etc. which are all relevant to Pax1 function. The -log10 (binomial p value) 
are shown at the end of the bars; a value of more than 1.3 is deemed significant (-
log10 transformation of a p value of 0.05 is equal to 1.3).   
 
As expected, the Pax1 binding sites were also associated with genes involved 
in numerous mouse phenotypes relevant to Pax1 function. The genes associated 
with small/ abnormal bone morphology, abnormal thymus development, abnormal 
thoracic cavity and small caudal vertebrae were enriched, all of which are defects 
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Figure 54: GO enrichment for MGI expression pattern in Pax9 TF mapping. 
Binding sites were enriched for genes expressed in known Pax9 expression sites like 
branchial pouch, forelimb mesenchyme, paraxial and tail mesenchyme, cartilage 
condensations, tooth mesenchyme, mandible and maxilla, chondrocranium and axial 
skeleton. The -log10 (binomial p value) are shown at the end of the bars; a value of 
more than 1.3 is deemed significant (-log10 transformation of a p value of 0.05 is 
equal to 1.3).   
 
Similar to Pax1, Pax9 ChIP-Seq binding sites were also assessed by GREAT 
to assess if relevant genes were associated with the binding sites. As expected, the 
Pax9 binding sites were associated with genes expressed in the Pax9-specific 
regions like forelimb mesenchyme, branchial pouch, paraxial and tail mesenchyme, 
maxilla and mandible, vertebral cartilage condensations, chondrocranium and tooth 
mesenchyme (Figure 54; Table 2 for Pax9 expression sites). Moreover, the genes 
were associated with known Pax9-null mouse mutant phenotypes like abnormality of 
dentin, pterygoid process, thyroid cartilage, Reichertʼs cartilage morphology; absent 
ultimobranchial arch, abnormal development of thymus, palate shelf elevation and 
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Figure 55: GO enrichment for Mouse phenotype for Pax9 binding sites. Pax9 
binding sites were enriched for genes associated with mouse phenotypes like 
abnormal craniofacial bones (Reichertʼs & thyroid cartilage), dentin morphology, 
thymus development, absent ultimobranchial body, polysyndactyly etc, which are all 
hallmarks of  Pax9-/- mutant mice. The -log10 (binomial p value) are shown at the end 
of the bars; a value of more than 1.3 is deemed significant (-log10 transformation of a 
p value of 0.05 is equal to 1.3).   
 
In conclusion, both Pax1 and Pax9 binding sites were associated with the 
relevant genes based on the MGI expression and mouse phenotype GO analysis, 
thus providing greater confidence in the dataset for further analyses.  
3.6.4 Pax1 and Pax9 direct targets 
 The Pax1 and Pax9 binding sites were further analyzed to understand their 
biological significance. A total of 8,263 genes (10,203 peaks) and 8,221 (11,333 
peaks) genes were associated with Pax1 and Pax9 binding sites respectively based 
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The Pax1 TF mapping data was overlapped with the differentially expressed 
genes from E12.5 and E13.5 Pax1-/- and double-null mutants. This would reveal the 
direct targets of Pax1 and Pax9. Of these, 50 genes (38.5% of E12.5 gene 
expression profiling targets) and 62 genes (50.8% of E13.5 gene expression profiling 
targets) from E12.5 and E13.5 stages respectively, were direct targets of Pax1 
(Figure 56). Notably, Sox5, Col2a1, Acan and Ctgf were some of the targets with 
direct binding site for Pax1 (Table 13 for entire list). Gene ontology of the direct 
targets of Pax1 at E12.5 an E13.5 showed enrichment of the same set of processes 
that were observed earlier (Figures 40 and 41) with the list of differentially expressed 
genes: transcriptional regulation, cell adhesion, cell proliferation, apoptosis, cartilage 
and skeletal system development, ECM proteins, cell migration and growth factor 
binding (Figure 56).  
When overlapped with the double-null differentially expressed genes, a total 
of 27.2% (162 genes) of the differentially expressed genes in the double-null 
overlapped with both Pax1 and Pax9 ChIP-Seq TF mapping targets, 37.3% (222 
genes) overlapped with Pax1 ChIP-Seq TF mapping targets and 39.8% (237 genes) 
with Pax9 ChIP-Seq TF mapping targets. The remaining ChIP-Seq TF mapping 
targets which did not overlap with the differentially expressed gene lists could 
represent TF binding regions where Pax1 or Pax9 were poised, but not functional. 
They could be waiting for the appropriate partners/ co-factors which are probably 
available only at specific time-points or tissues. The entire 296 genes that overlapped 
with Pax1 and Pax9 ChIP-Seq were therefore the direct targets of Pax1 and/ or Pax9 
and were further analyzed for GO term enrichment. Besides the terms that were seen 
enriched in the direct targets of Pax1 (single-null, Figure 56), new terms like TGF-
beta binding, PDGF binding, thyroid metabolic process, Notch signalling and 
enzyme-linked receptor signalling pathway, somitogenesis, disease mutation and 
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chromatin organization were enriched (Figure 57). The genes in “disease mutation” 
were Gnas, Col2a1, Col11a1, Pax1, Papss2 and Lpin1. Not all of the genes actually 
known to have disease causing mutations were picked up in the DAVID GO analysis. 
Some of the interesting targets with their Pax1 and Pax9 binding sites are shown in 
Table 13, and the list of genes with their associated skeletal defects are shown in 
Table 15.  
The targets which had shown opposite directionality (13 genes) in E12.5 
double-null and E13.5 Pax1-/- were checked for the presence of Pax1 and Pax9 
binding sites (Table 13). 9 out of the 13 genes had a direct binding site for Pax9, 
indicating a potential regulation by Pax9 at E13.5 Pax1-/- (Table 13). Interestingly, 
Sox5, Col2a1, Wwp2, Ctgf and Acan were among those targets. Several other 
targets known to be essential for collagen fibril organization happened to be direct 
targets of Pax1 or Pax9, such as Hspg2, Acan and Col11a1, all of which were also 
positively regulated by these TFs. Some of the binding sites (mapped to the mouse 
genome reference sequence using the UCSC genome browser) are shown as 
examples in Figures 59 – 61. Besides, both Pax1 and Pax9 had binding site for 
themselves and for each other. Pax1 had a distal binding site from itself and Pax9 
had binding sites in the intragenic, distal and beyond 100 kb regions from its TSS. 
Moreover, Pax9 was seen bound to the TSS, intragenic and beyond 100kb region of 
Pax1, while Pax1 had a binding site >300 kb away from the TSS of Pax9.  
Having identified the direct and indirect targets of Pax1 and Pax9, the data 
from the double-null vs WT gene expression profiling and the individual TF binding 
sites for Pax1 and Pax9 were combined, and some of the selected targets are shown 
as a network in Figure 58.  Selected genes include TFs, genes involved in cell 
proliferation, cell motion, ECM and cartilage development.  



























Figure 56: GO enrichment of Pax1 direct targets. (A) Venn diagram of genes 
overlapping between Pax1 binding sites and E12.5 and E13.5 Pax1 microarray 
differential gene expression targets. (B & C) GO terms enriched for Pax1 direct 
targets at E12.5 and E13.5. The -log10 (p-value) are shown at the end of the bars; a 
value of more than 1.3 is deemed significant (-log10 transformation of a p-value of 
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Figure 57: GO enrichment of Pax1 and Pax9 direct binding targets. (A) Venn 
diagram of genes overlapping between genes differentially expressed in the double-
null and the Pax1 and Pax9 binding targets. (B) GO terms enriched for Pax1 and 
Pax9 direct targets. Only relevant terms are shown. Terms highlighted in red were 
not found enriched in Pax1 direct targets and were found enriched in the double-null 
gene expression profiling. Terms in blue were not enriched in the double-null gene 
expression profiling targets (direct and indirect targets). The -log10 (p-value) are 
shown at the end of the bars; a value of more than 1.3 is deemed significant (-log10 
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/-  vs. WT 
Strand Pax1  
binding site & 
association 
Pax9  
binding site & 
association 
Col2a1 Down (3.12) Up (2.21) (-) Distal (-37420) TSS (+142) 
Intragenic (-11709)  
Distal (+22076) 
Wwp2 Down (2.46) Up (1.60) (+) Others (+119082) TSS (-42) 
Intragenic (+36571, 
+47089) 
Sox5 /  
A730017
D01Rik  










Extl1 Down (1.78) Up (3.08) NIL None None 





Others (-112141)  
Nnat Down (2.62) Up (1.78) NIL None Others (-102387, -
97245, -96403, -
95841, -85698) 
Greb1 Down (1.85) Up (1.54) (-) Intragenic (-27723) None 
Cdc25c Down (1.79) Up (1.95) (-) None TSS (+160) 




Tle1 Down (1.68 Up (1.63) (-) Others (-168337) Intragenic (-1706) 
Others (-771651, -
361646, -263771) 
Sorl1 Down (1.54) Up (1.57) (-) Distal (+39660) Others (-263565, -
263361,-173813, 
173447, -172853) 
Mgst2 Down (2.39) Down (2.39) (+) Promoter (-1969)  Distal (+65657, 
+88790) 
Others (+211192) 
Hspg2 Down (2.37) Down (1.66) (+) None Intragenic (+17479, 
+20390)  




(-) Others (+45513) Distal (+44422) 
Trpc4ap Down (1.72) E12.5 
(Down, 1.54) 
E13.5 
(Down, 1.59)  






E12.5   










Down (2.09) Down (1.87) (+) None Intragenic 
(+180350)  
Mmp24 Down (1.53) Down (1.72) (+) Distal 
(+32671,+37478) 
None 
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Acan Down (2.60) (+) Intragenic (+20455, +37855) 
 
Others (-126874) 
Col3a1 Up (1.53) (+) None Others (-175921) 
Col5a2 Up (1.61) (-) Distal (+84613) Others (-262665,-172549) 
Dpt Down (2.42 NIL None None 
Atp7a Down (1.52) NIL None None 
Cell motion genes 
Psen1 Down (1.58) (+) Intragenic (+35387) None 
Etv1 Down (1.61) (+) None Others (-225544) 
Sema6a Down (1.62) (-) Others (+324074) Intragenic (-2499) 
Others (-189029) 
Rpl24 Down (1.58 NIL None None 
Growth factor binding 
Fbn1 Up (1.53) (-) Intragenic (-6096, -119119) Others (+150155, 
+174241,+223932) 
Col4a1 Down (1.50) (-) Intragenic (-89590, -91485) 
Others (-130183, -150727) 
Intragenic (-29532) 
Other interesting targets with associated skeletal defects 
BMP4 Down (2.00) (-) None Others (-328284, -214745) 
Cspg2/ 
Versican 




Down (1.81) (+) Intragenic (+10172) Intragenic (+10133)  




Col19a1 Down (2.57) (-) Intragenic (-180946)  Promoter (+3866) 
Intragenic (-116063, -
126269) 
Sim2 Down (2.31) (+) Others (+339750, +408467) Others (-128077, -127751,-





Up (1.97) (+) None TSS (-88, -137, -328) 
Intragenic (+9644) 
Distal (+17113, -95156) 
Pax1 Down (2.35) (+) Distal (+66304) TSS (+126) 
Intragenic (+7442, +8789) 
Others (+206782, +325684) 
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Figure 58: Network representation of selected Pax1 and Pax9 targets. Only 
selected targets like TFs, key cell proliferation, cell motion and ECM genes were 
used to construct this network for easier visualization. Directionality was based on 
the results from double-null vs WT gene expression profiling. TFs are shown in 
green. Blue solid arrows indicate direct and positive regulation; red solid bars indicate 
direct and negative regulation; dotted lines indicate indirect regulation. 
 











Col2a1 Down (3.12) Down (2.80) Down (2.38) Up (2.21) 
Wwp2 Down (2.46) Down (1.95) Down (1.81) Up (1.60) 
Sox5 / 
A730017D01Rik Down (2.23) Down (2.35) Down (1.92) Up (1.63) 
 
 








Figure 59: UCSC track for Pax9 binding site at Wwp2. The true peaks are boxed 
in red. The binding peak at the TSS corresponds to CpG islands shown below. Black 























Figure 60: UCSC track for Pax1 and Pax9 binding sites for Col2a1. The true 
peaks are boxed in red. Top: Pax1 binds at a distal region (-37420 bp from the TSS) 
and its potential looping mechanism to contact the TSS region is shown with a dotted 
red arrow. Bottom: the peak for Pax9 binding at the TSS (+142 bp from TSS) is 
shown. The location of known Sox9 binding site in the intronic enhancer region is 




















Figure 61: UCSC tracks of Pax1 and/or Pax9 binding sites for selected targets. 
The true peaks are boxed in red. (A) Pax1 binding site for Acan. (B) Pax1 binding site 
for itself. The potential looping mechanism for Pax1 to contact the TSS region is 
shown with a dotted red arrow. (C) Pax1 and Pax9 binding sites for Papss2. Red 
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Table 15: Genes with associated skeletal defects 
Gene Function Mutant phenotype/ associated defects Ref 
Col2a1 
(Collagen, type 






tethering in ECM 
to modulate its 
signaling 
- Col2a1-null mice show alterations in collagen fibril 
formation. Mutant cartilage was replaced with 
collagen III and collagen I. This gives rise to 
abnormal collagen fibres, which are structurally 
unstable. 
- show defective IVD formation & abnormal 
endochondral ossification 
- Heterozygous mutations in humans give rise to 
type II collagenopathies, and rare dysplasia like 
dysspondyloenchondromatosis (DSC). 














- Col11a1 null mice exhibit short limbs, cleft palate, 
short snout, flared ribs, shortened vertebral column 
- Mutations in Col11a1-  polymorphisms are 
associated with lumbar disc herniation (LDH) 
- Mutations in Col11a1 are also associated with 
connective tissue diseases like Stickler syndrome, 
characterized by eye/vision (vitreous phenotype) 




Acan / Agc1 
(Aggrecan) 









- Mutation in mice leads to vertebral misalignments, 
cleft palate, dwarfism, short tail and limbs, 
progressive disc degeneration.  
- Mutations are associated with spondyloepiphyseal 

















-Sox5-null mice exhibit cleft secondary palate, 
defects of sternum, narrow thoracic cage, and 
delayed bone mineralization.  
- in conjunction with Sox6-null, shows abnormal IVD 
(inner annulus and nucleus pulposus) and impaired 











- ECM synthesis 
and organization 
- Ctgf-null mice show axial skeletal defects, 
shortened sternum, kinked ribs, cleft palate, 
impaired osteogenesis, chondrogenesis (delayed 
endochondral ossification) and growth plate 









- Null mutants exhibit kyphosis, malformed/ 
overgrowth of ribs 
- associated with Marfan syndrome (a connective 
[164, 
165] 

















- null mice show defects of axial skeletons, short 
tail, impaired brain growth, cerebral hemorrhages, 
inhibited cleavage of amyloid precursor protein, 
reduction in Notch signaling, and perinatal death. 











- Mutant mice are runted and exhibit cleft palate, 











- Null mice show numerous skeletal dysplasias: 
dwarfism, cleft palate, short snout, defective 
vertebral bodies with multiple ossification centres, 









- sulfation of 
proteoglycans 
- Null mice display dome-shaped skull, short thick 
tail, overall shortening of axial length, shortened 
limbs, delayed growth and defective bone formation. 
- Mutations in human PAPSS2 are associated with 
Brachyolmia, a type of skeletal dysplasia mainly 









- Null mutants possess cleft palate defect and 
malformed pterygoid processes.  













- Heterozygotes show short kinked tail, defects of 
the spine, eyes and possess ventral white spots, 
and exhibit malocclusion 




-Mutants show homeotic transformations of 2nd 
cervical vertebrae (C2 à C1); malformed neural 
[172] 














axial skeleton  
- Homozygotes show slow growth; transformation of 
lumbar to thoracic vertebrae (L1 à T10); defects of 
sternum and ribs and mutants have hunched backs. 
[173, 
174] 






















- ENU-induced heterozygous mutants show 





V, alpha 2) 
-collagen fibril 
organization 
- Homozygous mutants exhibit kyphosis and 
lordosis to varying extent, defects of skin and 





The identification of the Pax1 and Pax9 direct binding targets has helped to 
distinguish the direct and indirect targets of Pax1 and Pax9. Almost one-third of the 
targets (27.2%) differentially expressed in the Pax1/Pax9 double-null mutants are 
direct targets of both Pax1 and Pax9. Certainly not all of the distal/ intragenic binding 
sites identified via TF mapping represent enhancers. They could also be silencers, 
assisting in the repression of the gene associated with the binding site. By comparing 
both differential gene expression trend and the TF mapping (ChIP-Seq) data, we can 
postulate if they ought to be enhancers or silencers. Moreover, not all of the binding 
sites overlap with the gene expression profiling data. These binding sites, as 
mentioned earlier, could be non-functional at the particular developmental time-point, 
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or in that particular tissue, and are probably simply poised, waiting for the co-factors 
or partners to be available.  
Moreover, coupling the gene expression profiling data with the TF mapping 
(ChIP-Seq) data reiterates that Pax1 and Pax9 are indeed true regulators of cartilage 
development genes, some of which are discussed in further detail below. 
(I) Pax1 and Pax9 are regulators of key cartilage development genes  
§ Regulation of Wwp2, Col2a1 and Sox5  by Pax1 and Pax9 
Interestingly, Pax1 and Pax9 had binding sites near Col2a1, Wwp2 and Sox5. 
As mentioned in section 3.5.4.2, owing to the opposite directionality that was 
observed in the E13.5 Pax1-/- and the double-null, one of the hypothesis was that 
Pax1 might be repressing while Pax9 might be activating it. The other hypothesis 
was that Pax9 was also regulating these targets to up-regulate them, in response to 
the loss of Pax1. Considering that these targets all possess a binding site for Pax9, 
some of them at the TSS itself (Wwp2 and Col2a1), the compensation hypothesis 
appears more plausible. Thus, Pax9 most likely did play a role in the up-regulation of 
these targets (Col2a1, Wwp2 and Sox5) as seen in E13.5 Pax1-/-, possibly in 
conjunction with Sox9.  
 
§ Sox9-Wwp2-Med25-Sox5-Sox6 complex in Col2a1 transcription 
Sox9, a master regulator of chondrogenesis, is well-known to function by up-
regulating key genes of the cartilage ECM component such as Col2a1 [120], Col11a1 
[124], Ctgf [124], Acan [138] and Wwp2 [124]. One of the well-studied targets of Sox9 
is Col2a1, whereby it binds to an intronic enhancer region of Col2a1 to regulate its 
transcription [120, 178]. Additionally, this regulation involves the formation of a 
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complex of Sox9 with co-factors like Wwp2 and Med25 [124]. Wwp2 is WW domain 
containing E3 ubiquitin protein ligase 2, required for ubiquitylation, while Med25 
(mediator of RNA polymerase II transcription, subunit 25 homolog (yeast) is a 
cofactor protein. It was shown in vitro that Sox9 also regulates Wwp2, by binding to 
its promoter region (luciferase assay with Wwp2 promoter which inherently contains 
the Sox9 motif). Wwp2 then mono-ubiquitylates Sox9 and enhances its 
transcriptional activity, while Sox9 mediates the translocation of Wwp2 into the 
nucleus, where the Sox9-Wwp2-Med25 complex drives Col2a1 expression. Unlike 
poly-ubiquitylation which results in proteasomal degradation of the protein, mono-
ubiquitylation is a form of post-translational modification [167]. Such mono-
ubiquitylation mediated enhancement of transcriptional activity of TFs was shown for 
Goosecoid (Gsc) as well [167].  Thus, Wwp2 was shown to be associated with Sox9 
in a complex with the co-factor protein Med25, which then bind to the intronic 
enhancer of Col2a1 to drive its expression [124]. Sox5 and Sox6 which are known to 
enhance the transcriptional activity of Sox9 were postulated to be bound to Sox9 in 
this complex as well [124, 139]. 
Pax1 and Pax9 may have a role in this complex. Firstly, Pax9 has a binding 
site at the TSS and intronic regions of Wwp2. An intronic region between the exon4 
and exon5 of Wwp2 has been reported to be bound by Sox9 (ChIP-PCR on ATDC5 
cells), which lies at around +38 kb from the TSS [167]. The intragenic regions 
identified in this Pax9 in in vivo TF mapping are +36,571 bp and +47,089 bp from the 
TSS.  The first intronic peak is in close proximity to the known Sox9 intronic binding 
site, while the second intragenic peak corresponds to the start site of another Wwp2 
transcript. Hence, Pax9 and Sox9 may be brought in close proximity to each other via 
chromatin looping, which brings Sox9 from the intronic region to the promoter. This 
also shows that the multiple binding regions identified for each gene in the TF 
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mapping probably correspond to the multiple points of contact involved in the 
chromatin looping. Similarly, Pax1 has a binding site > 100 kb away from Wwp2 
(+119,082 bp), and might also be involved in the regulation of Wwp2. 
  A simplified diagram of this postulated looping mechanism is shown in 
Figure 62 for Pax9 and Sox9. Also, Pax9 positively regulates Wwp2 owing to the 
decrease in transcript levels by 2.46-fold in the double-null. There is also a gradual 
decrease seen with increasing loss of Pax9 (1.95-fold down with 2 copies lost; 1.81-
fold down with 1 copy of Pax9 in the absence of Pax1; Table 14). Furthermore, 
Wwp2-null mice were runted and had craniofacial defects [167]. Similarly, knock-
down of wwp2 in zebrafish gave rise to a palatal phenotype. This phenotype in 
zebrafish was only partially rescued by the co-injection of sox9a and sox9b 
transcripts [124], indicating that other factors are involved in the control of Wwp2, 
which could be Pax9 and/or Pax1. Indeed, Pax9-/- mice are known to possess cleft 
palate too, similar to Sox9 mutants [179], proving that Pax9, Sox9 and Wwp2 are all 









Figure 62: Postulated model of Wwp2 regulation by Pax9 in co-operation with 
Sox9. Sox9 potentially contacts the promoter region which possesses the Sox9 
motif, and also the intronic region (+38 kb from TSS) identified through in vitro 
studies by others. Binding site for Pax9 has been identified in the in vivo TF mapping 
at the TSS (-42 bp) and intragenic region (+36571 bp).  
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Secondly, Pax9 and Pax1 have binding sites for Col2a1; Pax9 contacts the 
TSS (+142), intragenic (-11,709) and distal region (+22,076) and Pax1 binds at a 
single distal region (-37,420). As mentioned earlier, Sox9, Sox5 and Sox6 complex 
contact the intronic enhancer region (at around +2,113 to +2,343 bp from TSS, in the 
intron1) to drive Col2a1 expression [120, 139, 178]. In addition, the loss of Pax9 (in 
the absence of Pax1) leads to a decrease in Col2a1 transcript levels in a gene-
dosage dependent fashion, indicating an activating effect on Col2a1. In the 
comparison of double-null vs Pax1-/- and double-null vs Pax1-/-Pax9+/-, Col2a1 was 
decreased by 2.80-fold and 2.38-fold respectively. In the double-null vs WT, the 
decrease was 3.12-fold (Table 14). Thus, the dramatic decrease in Col2a1 levels in 
the double-null, coupled with presence of binding sites by both Pax1 and Pax9, 
reflect a potential mechanism of Col2a1 regulation by the Paxes with the Soxes. It is 
not yet known if Pax1 and Pax9 form a complex with the Sox9-Wwp2-Med25 proteins 
as well, and what other intermediary proteins may come into play. Similar to 
Pax1/Pax9 double-null mutants, loss of Col2a1 also gives rise to cleft palate and 
axial skeleton defect [127]. As mentioned earlier, COL2A1 defects in humans is 
known to give rise to kyphoscoliosis – a defect associated with PAX1 and PAX9 as 
well [83, 86, 129].  
On top of these, Sox5 was also down-regulated in the double-null and 
showed a similar decrease in transcript with progressive loss of Pax9 (Table 14). 
Pax1 and Pax9 also have binding sites in proximal, intragenic and > 100 kb from the 
TSS of Sox5.  
All of these observations indicate a high possibility for the Pax genes being 
directly involved in the regulation of Col2a1, Wwp2 and Sox5. While the shared 
craniofacial and axial defect phenotype of Sox5/Sox6 [140], Sox9 [179], Wwp2 [167], 
Col2a1 [127] and Pax1/Pax9 [62] mutants all clearly reflect the interplay of these 
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factors in vivo, further in vitro validations via luciferase assays, EMSA, co-IP and pull-
down assays could help to affirm these regulatory mechanisms. Moreover, through 
such assays, we can confirm if Pax1 and Pax9 are involved in these regulations at 
the same time and how these two TFs can compensate for each other. Most 
importantly, the regulation of all of these factors by Pax1 and Pax9 is novel and their 
association with the Sox genes has never before been shown. 
 
§ Acan is regulated by Pax1 and Pax9, possibly directly 
Aggrecan, an important ECM component was also positively regulated by 
Pax1 and Pax9 based on the double-null gene expression profiling results. While 
Pax1 had binding sites in the intragenic regions of Acan, Pax9 binding site was >100 
kb upstream of the TSS of Acan. 
Notably, mouse Pax1 was shown to induce aggrecan expression in the 
explants of chick presomitic mesoderm, independent of Shh [57]. This corroborates 
with the results of this study, whereby Pax1 positively regulates Acan at E12.5-E13.5, 
possibly directly via its intragenic binding sites.  
(II) Bapx1 was not regulated by Pax1 or Pax9 at E12.5 and E13.5 in the IVD anlagen 
As mentioned in the introduction, Bapx1 is an important TF for the transition 
of pre-chondrogenic cells to chondroblasts [53]. Bapx1 was identified as one of the 
direct binding targets of Pax1 and Pax9 through in vitro assays (-880 to -844 from 
the TSS) (Figure 63) [57]. It is indeed the only known direct binding target of Pax1 
and Pax9 in literature. Also, the authors had claimed a reduction in Bapx1 levels only 
in the sclerotome in the double-null embryos based on their E10.5 whole-mount in 
situ hybridization and E11.5 sectioned in situ hybridization data [57].  
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However, in our gene expression profiling analysis which was performed on 
highly pure population of Pax1/ Pax9-specific cells, Bapx1 was not differentially 
expressed in any of the single-null, Pax1-/-Pax9+/- or double-null comparisons. The 
loss of Bapx1 expression seen in the double-null embryos by the authors could 
indeed be due to the prevalent loss and mis-localization of sclerotomal cells in the 
double-null (refer: Figure 30). Moreover, in our in vivo TF mapping data, Bapx1 did 
not have a Pax1 binding site, but had a Pax9 binding site in the intragenic region (-
2445 bp from TSS, (-) strand).  
These observations were not too surprising as it was postulated by the 
authors [57] that Pax1 and Pax9 may only be required to initiate the expression of 
Bapx1 at E9.5 and not for its maintenance. In the wild-type, chondrocytes continue to 
express Bapx1 even when Pax1/Pax9 expression is reduced in the chondrocytes 
from E12.5 onwards [57]. The regulatory loop between Sox9 (a master-regulator of 
chondrogenesis) and Bapx1 is believed to maintain Bapx1 expression in the 
chondrocytes during chondrogenesis [55]. In addition, a Sox9 binding site was 
identified at -868 to -852 from the TSS of Bapx1, which largely overlaps with the 
Pax1/ Pax9 binding site identified in the in vitro study [54]. Similarly, Meox1/ Meox2 
(TFs also important in sclerotome differentiation) also possess binding sites within 
the Bapx1 promoter, immediately adjacent to the Pax1/ Pax9 binding site (-840 to -
810) [54-57]. Therefore it is highly likely that by E12.5 and E13.5, the stages at which 
the TF mapping was done, Bapx1 promoter is actually bound by a different set of 
proteins (Sox9/ Meox1/ Meox2) and hence not bound by Pax1 and/or Pax9 (Figure 
62 for illustration). Furthermore, Sox9 or Meox1/ Meox2 may compensate for the loss 
of Pax1/ Pax9 and thus help to initiate the expression of Bapx1 at E9.5. These 
hypotheses also correlate with the lack of differential expression of Bapx1 in the 
absence of Pax1 and/or Pax9. Importantly, they all the more reflect the need for in 
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vivo studies to complement the in vitro results, and together they greatly assist to 
comprehend such dynamic changes in binding sites as well as reveal the complex 






Figure 63: Illustration of binding sites identified for Bapx1 promoter in vitro by 
other studies. The positions of binding sites shown are in base pairs from the TSS 
of Bapx1. Refer to main text above for explanation. 
 
(III) Regulation of Pax1 and Pax9 
The Pax1 transcript levels decreased in the Pax1/Pax9 double-null and also 
when Pax9 was lost in the absence of Pax1 (double-null vs WT - 2.35-fold down, 
Pax1-/-Pax9+/- vs WT – 1.63-fold down and double-null vs Pax1-/- - 1.50-fold down). On 
top of that, Pax1 had a distal binding site associated with itself, indicating a potential 
self regulation. While the initiators of Pax1 are Shh and Nog, Pax1 might be partly 
required to maintain itself under normal circumstances. Considering that Pax1 itself 
was not differentially expressed in the Pax1-/-, it seems likely that there may be other 
regulators of Pax1 (eg. Shh or Nog) involved in the maintenance.  
Furthermore, since Pax9 also has binding sites for Pax1, it might also have a 
role in regulating Pax1. When Pax9 is also lost, the decrease in Pax1 levels becomes 
more prominent. Then again, validation of these binding sites are required to 
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ascertain if there is a true direct regulation of Pax1 by Pax1 and Pax9, or if the 
observed decline in Pax1 levels is an indirect consequence. 
On the other hand, Pax9 had binding sites in its own introns and several 
distal and >100 kb sites associated with itself, and a Pax1 binding site >300 kb from 
the TSS of Pax9. However, there was no differential expression of its transcripts in 
the double-null or any of the 3 allele KO or Pax1-/- mutants. A similar observation was 
made by Peters et al (1999), whereby Pax9 transcript expression did not decrease in 
the double-null embryos [62]. The authors proposed that neither Pax1 nor Pax9 are 
required for the transcription of Pax9 in the vertebral column [62]. Hence, it is likely 
that Pax9 does not self-regulate, nor regulated by Pax1 in the vertebral column cells. 
The observed binding sites maybe functional in some other tissue or regulates some 
other neighbouring gene since they are not found in the TSS or promoter region of 
Pax9.  
(IV) Connection to the chondro-osteogenic pathway 
Based on the genome-wide gene expression profiling and binding site of 
Pax1 and Pax9, Sox5 appears to be the key point of connection to the Pax genes in 
the chondro-osteogenic pathway.  
In our own labʼs analysis of Sox9 and Sox5/Sox6 double-null mutants, Pax1 
was negatively regulated by these Sox genes at E12.5 (2.71-fold up in Sox9-null) and 
E13.5 (1.71-fold up in Sox5/Sox6 double-null) respectively. In fact, Sox9 had a direct 
binding site for Pax1 in a distal region (+331,470 bp). This indicates a potential feed-
back loop, which could explain the initial co-expression of the Sox and Pax genes in 
the sclerotome and IVD anlagen and the eventual down-regulation of Pax1 in the 
differentiating chondrocytes of the cartilage (Figure 64 for illustration). Such negative 
feed-back loops in a network are known to diminish expression levels of the target 
gene [5, 180]. Figure 64 shows the expression of Pax1 in the IVD anlagen at E13.5. 
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Sox9 and Sox5 are also expressed in the Pax1-expressing cells (Figure 36 and 
Table 7) at this stage. Subsequently by E15.5, the IVD anlagen have differentiated 
into two morphologically distinct components, inner cartilaginous and outer fibrous 
annulus fibrosus. At this stage, Pax1 and Pax9 expression becomes restricted to the 
outer annulus fibrosus. The negative feed-back loop potentially explains how the 
Pax1 expression becomes down-regulated in the mature cartilage. Interestingly, at 
E12.5 and E13.5, none of these Sox genes regulated Pax9 (our labʼs analysis of the 
Sox mutants). What factors regulate Pax9 in the IVD is still unknown.  
Figure 64: Expression of Pax1 and Pax9 and morphology of IVD during E13.5 
and E15.5. (A) Left: Pax1 mRNA expression is in the IVD anlagen at E13.5. Right: 
the IVD anlagen develop into cartilaginous inner annulus and fibrous outer annulus 
fibrosus by E15.5. Pax1 and Pax9 protein expression could be seen restricted to the 
outer annulus cells at E15.5. Yellow dotted lines demarcate prospective boundaries 
between the vertebral body and the IVD. Sections were counter-stained with 
Malloryʼs tetrachrome staining (left) or alcian blue (right). (B) Regulatory connections 
between Sox5, Sox6, Sox9, Pax1 and Pax9 in the IVD anlagen based on the results 
from this study and our labʼs analyses of Sox5/Sox6 double-null and Sox9 mutants in 
chondrogenic cells. It is assumed that Pax1 and Pax9 are acting synergistically and 
not antagonistically in this model (refer to section 3.5.4.2 for explanation). VB – 
vertebral body; IVD – intervertebral disc; n – notochord; NP – nucleus pulposus; IAF 
– inner annulus fibrosus; OAF – outer annulus fibrosus; WT – wild-type. 
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3.7 Conclusion 
In conclusion, Pax1 and Pax9 clearly appear to have a role in regulating the 
early functions of IVD tissue morphogenesis, i.e. cell proliferation, cell adhesion, 
mesenchymal condensation, ECM organization and cartilage development. The 
annulus fibrosus of the IVD is derived from Pax1 and Pax9 expressing sclerotomal 
cells. Subsequently, by E15.5, the annulus fibrosus differentiates into inner 
cartilaginous and outer fibrous tissues. Since Pax1 and Pax9 are positively regulating 
cartilage development genes at E12.5, when the IVD anlagen is formed, Pax1 and 
Pax9 may be assisting the Sox genes to activate the early chondrogenic genes. As 
seen from the genome-wide data, some of the key cartilage development genes 
regulated by the Pax are well-known to be regulated by the Sox trio as well. Once the 
chondroblasts mature into chondrocytes in the inner annulus fibrosus, these Pax 
genes are down-regulated in the chondrocytes. Pax1- and Pax9-expressing cells 
then become restricted to the outer annulus fibrous cells where they may be involved 
in more patterning functions. While the lack of sufficient double-null embryos 
precluded further histological analysis of their vertebral column, studies in 
spontaneous Pax mutants provide support for this hypothesis. In the Uns/+ adult mice, 
the annulus fibrosus structures were malformed and had a fibrous appearance 
instead of forming a normal hyaline cartilage. Also, the normally bony acromion 
process of the scapulae was ligamentous in the mutants [71, 76].  
Notably, the presence of dorsal cartilage structures in the Pax1/Pax9 double-
null mutants indicate that Pax1 and Pax9 genes are not needed for overt 
chondrogenic differentiation [62]. They are not master regulators of chondrogenesis 
but probably perform essential accessorial functions in chondrogenesis. Their 
primary roles may still be in ensuring proper formation of mesenchymal 
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condensations in the right places by controlling cell proliferation, cell adhesion and 
migration.  
 Thus, based on the literature and the regulatory connections that have been 
deciphered in this study, I propose the following model to depict the involvement of 
the various TFs in the IVD development (Figure 65). As mentioned earlier, in terms of 
sclerotome-derived cells, the focus has largely been on the regulatory mechanisms 
involved in vertebral bodies. The regulatory pathways involved in IVD morphogenesis 
require equal attention. Shown here is just a small circuit of the larger network. In our 
lab, we have generated similar genome-wide data sets for the Sox5, Sox6, Sox9, 
Bapx1, Runx2 and Runx3. By connecting this Pax data with the Sox data, we can 
generate the bigger network and from there dissect out such smaller regulatory 
connections and possibly identify network motifs. That is indeed the essence of 
GRNs – to be able to represent the interplay of various TFs in a global scenario, as 





















Figure 65: Proposed model of regulatory connections between TFs involved in 
the sclerotome-derived components of the IVD development. The connections 
shown are based on literature search (see introduction) and this study. Blue arrows 
represent positive regulation; red bars represent negative regulation; dotted lines 
indicate indirect regulation and solid lines indicate direct regulation. Note: It is not yet 
known if Meox1/Meox2 regulation of Pax1/Pax9 is direct or indirect. For simplification 
purposes, self-regulatory connections are not shown. VB – vertebral body; AF – 
annulus fibrosus; MSC – mesenchymal stem cell; IVD – intervertebral disc. 
 
3.7.1 Future work  
The direct and indirect targets of Pax1 and Pax9 have thus been identified. 
The immediate future work would involve in vitro validations of the key regulatory 
connections that have been deciphered.  
This includes luciferase assays and EMSA (electrophoretic mobility shift 
assay) to confirm if Pax1 is an activator or repressor of Sox5 and Col2a1 genes 
which showed opposite directionality and had a binding site for these genes. 
Considering that Pax1 and Pax9 are paralogous genes and are known to function 
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synergistically, the current hypothesis is that Pax1 is an activator of Sox5 and 
Col2a1. Activation of these targets by Pax9 would also be validated in vitro similarly. 
The Col2a1 regulation by Pax1/Pax9 might potentially occur in conjunction with Sox9 
and its associated complex of proteins (Sox5, Sox6, Med25 and Wwp2). Therefore, it 
would be assessed if these proteins are associated with Pax9 and/or Pax1. For 
example, HA-tagged Pax9 or Pax1 can be over-expressed in vitro in chondrogenic 
cell lines (ATDC5 or C3H10T1/2 cells) and myc-tagged Med25 can be transfected 
into the same cells. After 24 – 48 hrs, total protein lysates can be immunoprecipitated 
using anti-HA antibodies and probed on Western blot with anti-myc antibody. Such 
co-immunoprecipitation assays can be performed for Pax1 or Pax9 with each of the 
proteins separately to assess their interactions at protein level as a protein complex. 
Moreover, the chromosome looping mechanism for Pax1 or Pax9 to contact 
the promoter regions of particular genes (eg. in the regulation of Wwp2) can be 
affirmed by Chromosome Conformation Capture (3C) or Chromosome Conformation 
Capture Carbon Copy (5C) assays.  
While the target genes of Pax1 and Pax9 in the IVD have been identified, the 
question of how Pax1 and Pax9 compensate for each other remains unanswered. 
Considering that the paired domains of Pax1 and Pax9 are highly similar (differing  
only at 3 amino acids within the paired box) [50], and the fact that in in vitro assays 
they could interact with similar sequences (e5 sequence [50], Bapx1 promoter [57]), it 
is possible that they have the ability to bind to each otherʼs binding sites in the 
absence of the other protein. That is, in the absence of Pax1, Pax9 might be able to 
bind to Pax1 binding sites and vice versa. Whether such dynamic changes in binding 
sites occur can be assessed in vivo. For instance, TF mapping can be performed 
using anti-Pax9 antibodies in the Pax1-/- embryos. Similarly, TF mapping on Pax9-/- 
embryos using anti-Pax1 antibodies can be performed. The results of such 
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experiments would provide unique perspectives on the compensation mechanisms at 
a molecular level. It would also be an evidence of the existence of alternate gene 
regulatory pathways in the event of abnormal conditions (in this case the loss of Pax1 
or Pax9) or diseased states.	  	  
	  
3.7.2 Challenges & Improvements 
 
The main challenge in this study was to work with small numbers of cells, 
which posed limitations on the amount of RNA that was available for gene expression 
profiling analysis. This also hampered the identification of Pax1 targets at E9.5 which 
would reveal the earliest functions of Pax1 in the sclerotome. Moreover, since Pax9 
transcripts are only beginning to be expressed at that stage, the targets identified at 
E9.5 could possibly be unique targets of Pax1. 
Furthermore, the regional differences in the severity of defects in the Pax1-/- 
mutants highlights the inherent differences in the regulatory mechanisms involved in 
the development of different vertebral segments. To capture such mechanisms, one 
has to look at individual vertebral segments or even at a single cell level. This was 
not possible before owing to the limitations of the technology. However, emerging 
technologies like RNA-sequencing and the availability of Illuminaʼs Clontech 
SMARTerTM Ultra Low RNA Kit for Illumina Sequencing (for RNA-Seq library 
construction) are promising and such intricate studies could be possible in the future.  
Besides these, since this study was focused on the E12.5 - E13.5 embryos, a 
few days after the initiation of Pax1 and Pax9 expression, one may argue that we are 
looking at gene expression changes caused by the phenotype rather than the actual 
functions of the gene. Here, this issue has been circumvented by comparing the 
differentially expressed genes with the TF mapping performed on WT tissues. If the 
genes do have a binding site for Pax1 and Pax9 in the WT at the same stage and 
also are differentially expressed, then they are most likely not an effect of the 
	   168	  
phenotype, but true targets of Pax1 and/or Pax9. Nevertheless, an alternative 
approach would be to make inducible conditional knock-out mice whereby the gene-
of-interest can be flanked by loxP sites and then mated to mice with inducible-Cre 
alleles. The construct can be designed in such a way that only upon floxing the gene-
of-interest, the EGFP reporter will be expressed. This way, Cre expression can be 
induced at specific time-points, which will result in the deletion of the gene only at 
those specific time-points, and the cells with the deleted gene can be isolated using 
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CHAPTER 4 - CONCLUSION 
The main aim of this study was to identify the direct and indirect targets of 
Pax1 and Pax9, in a cell-type specific manner, during IVD development. This has 
been achieved using a traditional transgenic approach and two of the currently widely 
used genome-wide technologies - microarray and ChIP-Seq. Importantly, this is the 
very first study in which the target genes of Pax1 and Pax9 have been identified, in 
vivo, in a specific cell type.  
Using the strategies mentioned in section 1.6.2, 130 genes and 122 genes 
were differentially expressed in Pax1-/- at E12.5 and E13.5. In general, these genes 
were enriched for cell adhesion, transcriptional regulation, macromolecule 
biosynthesis, skeletal system development and regulation of apoptosis, all of which 
are relevant to mesenchymal condensation process. Only a small number of genes 
were differentially expressed at these early stages in the Pax1-/-, exposing the 
influence of compensation by Pax9, which obscured the true targets of Pax1 and 
Pax9. Through the use of 3-allele (Pax1-/-Pax9+/-) and 4-allele KO (Pax1-/-Pax9-/-) 
embryos, targets genes that had been masked by the redundant roles of Pax9 have 
been uncovered in this study. By extension, these would also be the common set of 
target genes of Pax1 and Pax9. There were six times more genes differentially 
expressed (599 genes) in the double-null embryos compared to Pax1-/-. Moreover, 
through different combinations of comparisons of the multiple allele KOs, genes 
regulated by 2 copies of Pax9 and 1 copy of Pax9 in the absence of Pax1 were 
identified, which in turn represent the target genes regulated by Pax9 to compensate 
for the loss of Pax1. Thus, the various hypotheses proposed by prior groups 
regarding the functions of Pax1 and Pax9 were validated by utliziing the differential 
gene expression data – i.e. Pax1 and Pax9 regulate genes involved in cell 
proliferation, cell motion, cell adhesion and ECM genes involved in cartilage 
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development or mesenchymal condensation process. Furthermore, processes such 
as collagen fibril organization and blood vessel development, which were not 
anticipated by other reseachers in prior publications, were revealed in this study. 
Notably, 17 of the genes regulated by Pax1/Pax9 are also associated with skeletal 
developmental abnormalities, some of which phenocopy Pax1/Pax9-deficient 
mutants. 
 In addition, it is through the temporal analysis of Pax1 regulated targets in 
Pax1-/- mutants that interesting trends could be observed – the genes with opposite 
directionality, which could potentially be a consequence of compensation. That is, 
genes identified to be down-regulated in the E12.5 double-null were unchanged at 
E12.5 Pax1-/- but up-regulated in the E13.5 Pax1-/-. Such observations reveal that 
gene regulation is dynamic and temporal analyses can unveil such intricate 
mechanisms of regulation.  
 Importantly, by the means of ChIP-Seq, the direct binding sites of Pax1 and 
Pax9 were identified in the WT vertebral column tissues. Overlapping of the TF 
mapping data with the differential gene expression data distinguished the direct and 
indirect targets of Pax1 and Pax9. The direct targets of both Pax1 and Pax9 were 
also enriched for ECM, cartilage development, cell adhesion, cell motion, 
proliferation, ECM-receptor interaction and blood vessel development, indicating that 
these are the true molecular functions of Pax1/Pax9.  
 Interestingly, Col2a1, Wwp2, Acan and Sox5 were among the direct targets of 
Pax1 and Pax9. Mutations/ knock-out in any one of these four key ECM genes result 
in vertebral column and facial abnormalities similar to the Pax1/Pax9-deficient mice. 
Notably, Sox9 is also known to regulate Wwp2 and Col2a1 directly, whereby the 
regulation of the latter involves the binding of the Sox9-Wwp2-Med25 complex at the 
intronic enhancer of Col2a1. Therefore, it is hypothesized from this study that Pax1 
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and Pax9 could be regulating Col2a1 together with Sox9, potentially interacting with 
the Sox9-Wwp2-Med25 complex and several other intermediary proteins may be 
involved in this complex formation.  
Also, Sox5 is one of the crucial genes involved in the chondro-osteogenic 
pathway and serves as a key link between these Pax genes and osteo-chondrogenic 
pathway. Mining of the Sox5/Sox6 and Sox9 differential gene expression and TF 
mapping data generated by other researchers in the lab (unpublished data) showed 
that these Sox genes also regulate Pax1 in return, but negatively, thus forming a 
negative feedback loop. It is known that Pax1 and Pax9 expression becomes down-
regulated in the mature cartilage (i.e. upon chondrogenesis) while the Sox trio are 
essential for and are up-regulated during chondrogenesis. Based on these 
observations, it could be hypothesized that this negative feedback loop mechanism is 
how the Pax1/Pax9, which are initially uniformly expressed in the IVD analgen, 
subsequently become down-regulated in the cartilaginous inner annulus and are 
restricted to the fibrous outer annulus of the IVD. While only a hypothesis currently, it 
is an important point that warrants further investigation in the future. 
Thus, the four specific aims that were put forth at the beginning of this study 
have been addressed. The enormous amount of data that has been generated in this 
study is a valuable resource that can be used to build the GRN of embryonic skeletal 
development. Constructing the bigger network from the various datasets is a time-
consuming and a bioinformatics-intensive task. Hence, in this study, the focus has 
only been on the connections within a small circuit (Sox and the Pax genes). More 
importantly, the connection between the Sox genes and Pax genes identified in this 
study is novel. Indeed, this reiterates that there is still much to be learnt about the 
regulatory mechanisms involved in chondrogenesis and IVD development, and by 
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combining and mining such genome-wide data sets, more of such surprising 
connections could be delineated.  
Moreover, the numerous mouse lines and the identification of genes enriched 
in Pax1- and Pax9- specific cells are all important resources for the scientific 
community. The endogenously tagged Pax1HA3 and Pax9HA3 mouse lines are 
invaluable for in vivo protein-protein interaction studies, TF mapping etc. These 
various mouse lines can also be used to study the other functions of the Pax genes 
such as in odontogenesis or thymus development. 
It is imperative to understand though, that the identification of Pax1 and Pax9 
targets in the IVD is only the beginning. How they compensate for each other at DNA 
binding level, who are their interacting partners, how they execute their pleiotrophic 
roles in different tissues are all important questions that deserve answers. Resolving 
those questions also requires a variety of other approaches to be undertaken. This 
study nevertheless serves as the starting point and certainly brings us closer to 
achieving our ultimate goal of constructing the gene regulatory network of embryonic 
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